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ABSTRACT OF DISSERTATION 
 
 
 
STEROID-DEPENDENT REGULATION OF THE OVIDUCT:  
A CROSS-SPECIES TRANSCRIPTOMAL ANALYSIS 
 
Reproductive success depends on a functional oviduct for gamete storage, 
maturation, fertilization, and early-conceptus development.  The ovarian-derived 
sex steroids estradiol and progesterone are known to affect functionality of the 
oviduct.  Advances in microarray and NanoString technology allow for gene 
expression analysis to increase understanding of processes critical for fertility.  
Studies were conducted to investigate mechanisms regulating oviductal function in 
cattle and mice by using the Bovine Gene 1.0 ST array and the Mouse Gene 430-2.0 
arrays (Affymetrix Inc., CA), respectively.   
For the first study, oviducts were collected from heifers assigned to luteal or 
follicular phase groups.  In the second study oviducts were collected from immature 
mice with a global deletion of estrogen receptor-1 (ESR1) and their wild-type 
littermates at 23 days of age or 48 hr after treatment with 5 IU of PMSG.  Following 
microarray hybridization, the resulting datasets were analyzed using Partek 
Genomics Suite 6.6 (Partek Inc., MO).   
The results of the first two studies illustrated a dynamic hormonal regulation 
of the oviductal epithelium and revealed the identity of novel genes affecting 
fertility in cattle and gave us insights into the genes regulated by estrogen and ESR1 
in mice.  Many genes identified as differentially regulated are believed to play an 
integral role in the regulation of oviductal inflammation.  Therefore, the objective of 
the third study was to test the hypothesis that intraperitoneal administration of E. 
Coli-derived lipopolysaccharide induces the expression of inflammatory mRNAs in 
the mouse oviduct.  Mice were treated with 0, 2 μg or 10 μg of LPS from E. Coli. and 
killed 24 h later. 
 
 
Oviducts were collected for determination of inflammatory gene expression 
by a targeted NanoString approach using the nCounter GX Mouse Inflammation Kit 
(NanoString Technologies, Wa).  Results indicate that systemic treatment with LPS 
induces inflammation in the oviducts of mice and provides evidence of a repeatable 
animal model of oviductal inflammation.  Overall, data from these studies extends 
our knowledge of the mechanisms regulating oviductal functions and immune 
response, as well as identified target molecules and processes to improve 
production animal and human fertility. 
 
Keywords: Oviduct, Steroid hormones, LPS-induced inflammation, Tubal-factor 
infertility, immune response  
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CHAPTER 1. 
INTRODUCTION 
The female reproductive organs consist of the external genitalia, cervix, 
uterus, oviducts (uterine tubes or fallopian tubes in women), and ovaries.  A 
normally functioning female reproductive tract is essential for gamete production 
and transport, fertilization, conceptus development and fetal development leading 
to the birth of live offspring.  
The oviduct in particular can be considered an understudied organ as less 
intense investigation has been directed toward the oviduct compared to the uterus 
and ovaries, specifically at the transcriptional level.  In more recent decades, a 
paradigm shift has occurred and the oviduct is being increasingly recognized as a 
biologically active organ that undergoes significant physiological and morphological 
changes throughout the estrous cycle to facilitate early events in reproduction, 
rather than just a tube involved in gamete transport.   
Analysis of the causes for women to seek assisted reproductive technologies 
(ART) to establish a pregnancy highlights the importance of further understanding 
the function of the oviduct in fertility.  In women under 35 years of age, oviductal 
factors exceed both ovulatory dysfunction and endometriosis as the causal factors of 
these women to seek ART [1-3].  Observations using oviduct epithelial cell cultures 
have provided evidence of the complex interaction between gametes, conceptus, 
and the oviduct.  Co-culture of a conceptus with oviductal epithelial cells improves 
developmental potential when compared with culture in conventional media and 
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the incidence of persistent or recurrent inflammation, fibrosis, scarring in the 
oviduct as well as pelvic inflammatory disease (PID) and ectopic pregnancy are 
known to impact female fertility [1-4].   Targeted investigations of the oviduct have 
been completed; however, less extensive investigations have been done regarding 
the molecular mechanisms involved in oviduct function in humans. 
In cattle, the impact of tubal dysfunction is less clear.  First service 
conception rates range from 50 to 70% in beef cattle and as low as 30% in dairy 
cattle [5].  It is difficult to determine the role of the oviduct in the failure of cattle to 
establish successful pregnancies.  Since early embryonic death occurs within one 
estrous cycle, often producers are unaware that an embryo existed.  In addition, 
confounding factors such as oocyte viability, spermatozoa quality, and management 
practices influence conception and pregnancy rates.  Low conception and 
subsequent pregnancy rates represent lost economic opportunity for dairy and beef 
cattle producers warranting further investigation of oviduct function. 
The following review of literature will discuss the key findings related to 
oviduct structure and function as it pertains to the establishment of pregnancy. 
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CHAPTER 2.  
A REVIEW OF THE LITERATURE 
Structure of the Oviduct 
 The mammalian oviduct contains an epithelial mucosa called the 
endosalpinx comprised of ciliated and secretory simple columnar epithelial cells 
surrounded by a smooth muscle layer called the myosalpinx and the perisalpinx 
which contains connective tissue and blood vessels.  The oviduct is comprised of 
four distinct regions.  The infundibulum is located near the surface of the ovary and 
includes the fimbriae which are finger-like projections that aid in the capture of the 
cumulus-oocyte complex and the majority of cells in this segment are ciliated [6].  
The ampulla is located below the infundibulum and has a large diameter compared 
to the other regions of the oviduct.  Through ciliary beats and myosalpingeal 
contraction towards the uterus, the oocyte is transported to the ampulla where 
fertilization occurs.  The epithelial mucosa of the ampulla is elaborately folded and 
adjacent to a thin layer of smooth muscle.  Electron microscopy and histological 
evaluations have revealed that ciliated and secretory cells are equally abundant in 
the ampulla with ovarian steroid hormones influencing morphological changes in 
ciliated cells and hypertrophy of secretory cells [6-8].  
 The isthmus spans the interval from the ampulla to the utero-tubal junction 
and is adjacent to a prominent musculature.  The epithelial mucosa of the isthmus is 
well defined; however, less elaborate relative to the ampulla.  The isthmus in 
particular serves as a reservoir and functional filter for spermatozoa and entrance 
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of the conceptus into the uterus [9].  Similar to the isthmus, the muscle layer of the 
utero-tubal junction is well defined and is the segment of the oviduct that 
transitions the isthmus region to the uterus [6-8, 10].   
 
Steroidal Regulation of the Oviduct 
 Steroidal environment affects morphological and functional changes in the 
mammalian oviduct.  Ovarian steroids estradiol and progesterone are known 
regulators of oviductal function as receptors are abundant in the mucosal 
epithelium.  Prostaglandins are also major physiological regulators of oviductal 
function.  A counter-current vascular route between the ovarian vein and artery 
exists where steroids and prostaglandins can reach the oviduct via the utero-tubal 
artery.  For example, estradiol produced by a preovulatory follicle is transported 
through arterioles and can affect ipsilateral oviduct epithelial cell function in 
preparation for male gametes and ovulation.  In pigs, estradiol and progesterone 
concentrations are 10 fold higher in arteriolar samples compared to systemic 
circulation demonstrating the local delivery of ovarian steroids [11].   Peritoneal 
fluid is another source of concentrated ovarian steroids and other hormones.  
Cincinella et al, 2009, evaluated progesterone levels in peritoneal fluid near the 
corpus luteum and ipsilateral oviduct of women and found concentrations were 
higher compared to systemic blood samples [12].  Furthermore, Paracrine delivery 
also exists, for example the cumulus-ooctye complex and follicular fluid can deliver 
paracrine factors affecting oviduct function after ovulation.   
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 The physiological changes that occur within the oviducts’ mucosal epithelia 
can in part be attributed to estradiol and progesterone.  A number of authors have 
reported a difference in ratio of ciliated to secretory cells throughout the estrous 
cycle in primates [13], sheep [14], cattle [8, 15], and rodents [16].  In the bovine, a 
decrease in ciliated cells and increase in secretory cells is observed in the 
infundibulum and ampulla during the luteal phase (progestogenic environment), 
but not the other regions of the oviduct [8, 17].   Similar findings have been 
observed in primates with the number of ciliated cells increasing in the ampulla 
during the follicular phase (estrogen environment) [13].  Cyclic changes in the 
epithelial mucosa are related to function such as gamete transport through the 
oviduct as well as gene expression changes such as an increase in immune related 
genes during the luteal phase [18].   
 Estradiol exerts its effects through two receptor subtypes, estrogen receptor 
alpha (ESR1) and estrogen receptor beta (ESR2).  Ulbrich et al, 2003, described the 
region-specific and cycle-phase dependent changes in hormone receptors where 
ESR1 mRNA increased in the bovine isthmus during the follicular phase compared 
to the luteal phase, but remained unchanged in the ampulla [19].  Gamete storage 
and maturation as discussed below occur during an estrogen dominant 
environment and many molecules have been shown to be regulated in an estrogen 
dependent manner.  For example, interleukin-6 (IL-6), a proinflammatory cytokine 
has been reported to be regulated by estrogens in the oviduct and increases in 
women with tubal ectopic pregnancy [20-22].  Furthermore, ESR1 mutant mice lack 
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the expression of hematopoietic form of prostaglandin D synthase (HPGDS), a 
proposed regulator of oviductal inflammation [23]. 
 Progesterone produced by luteal cells from the corpus luteum is also a 
known regulator of oviductal function.  Progesterone exerts its effects through 
progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B) [24].  Okado et 
al., 2003, described the mRNA expression and protein localization of progesterone 
receptors in the rat oviduct during different stages of the estrous cycle and 
suggested effects of progesterone on ciliogenesis [25].  Expression profiles of mRNA 
have also been described in bovine oviductal epithelial cells during the luteal phase 
(progestogenic environment) with significant gene ontology classifications related 
to cell proliferation and transcriptional regulation supporting the phenotype of 
secretory cell differentiation during the progesterone dominant phase [4, 8, 17]. 
Estradiol and progesterone are also thought to act synergistically with 
prostaglandins to control reproductive functions in females [26].  Prostaglandins 
are synthesized through the liberation of arachidonic acid (AA) from phospholipids 
by phospholipase A2 (PLA2) and phospholipase C (PLC) whereby cyclooxygenases 
COX-1 or COX-2 convert AA to an intermediary form, prostaglandin H2.  Cell specific 
synthases convert the intermediate prostaglandin into distinct forms with differing 
functions [27, 28].  Certainly the role of prostaglandin F2alpha in luteolysis and 
smooth muscle contraction in the uterus is well known, however, prostaglandins are 
also implicated in the function of the oviduct as bovine oviductal epithelial cells 
secrete prostaglandins [29, 30].  For example, prostaglandin E2 (PGE2) 
concentrations in the bovine oviduct increase during the peri-ovulatory period and 
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luteinizing hormone (LH) has a stimulatory effect on PGE2 production which is 
thought to act as an immunosuppressive factor by down-regulating phagocytosis of 
sperm [31].  Other than immune-regulatory functions, prostaglandins also aid in 
oviduct contractility which facilitates gamete transport, fertilization, and zygote 
transport to the uterus [32, 33].   
 
Gamete Storage and Maturation 
 Gamete and oviduct interactions are well documented in the literature.  In 
order for fertilization to occur motile spermatozoa must first enter the oviduct 
through the utero-tubal junction.  Properties of the sperm membrane have been 
shown to influence the passage of spermatozoa through the utero-tubal junction. 
For example, there are several male mutant mouse models that appear to have 
normal sperm morphology but are infertile because they lack the necessary proteins 
or enzymes involved in sperm passage through the utero-tubal junction [34-36].  
After passage through the utero-tubal junction sperm enter the isthmus where a 
storage and maturation reservoir is formed.  As reviewed by Holt (2011), the 
formation of the sperm reservoir is essential for fertilization as it allows for sperm 
to survive until ovulation.  The sperm reservoir may also act to decrease the 
incidence of polyspermy by releasing sperm in intervals and impact sperm 
maturation processes [37, 38].  In the bovine, binding of sperm to epithelial cells in 
the isthmus is facilitated, in part, by seminal plasma proteins on the sperm 
membrane [9, 39].  Binder of sperm proteins (BSP 1, 3, and 5) are secreted by 
seminal vesicles and coat the sperm membrane.  Once in the isthmus, sperm can 
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then bind fucosylated molecules located on the epithelium of the oviduct [40, 41].   
Oviduct epithelial cell secretions and membrane proteins are also known to affect 
the sperm reservoir with heat shock proteins and glycoprotein secretion playing a 
role in prolonging sperm viability [42]. 
 Near to or immediately after ovulation various factors influenced by the 
contact of sperm with oviductal epithelial cells and steroid hormones enable 
capacitation, acrosome reaction, and hyperactivation.  Capacitation is a biochemical 
event in which sperm acquire the ability to fertilize the oocyte.  The acrosome 
reaction is the fusion of the acrosome with the plasma membrane of the sperm in 
order to release enzymes needed for sperm to penetrate the zona pellucida.  
Hyperactivation is an increase in sperm motility required for sperm penetration of 
the zona pellucida.  Calcium concentration in the lumen of the oviduct is one of the 
most well-known and studied factors affecting sperm motility and fertilization 
ability with increasing concentrations associated with the acrosome reaction [43]  
More recently, neurotensin has been localized in both the isthmus and ampulla 
epithelium of mice with receptors expressed on spermatozoa.  Hirdate et al., 2014, 
demonstrated that neurotensin induced tyrosine phosphorylation in sperm which is 
known to occur during sperm capacitation.  Furthermore, neurotensin was found to 
facilitate the acrosome reaction in vitro in a dose dependent manner [44].  As far as 
gamete storage and maturation is concerned the literature is well established with 
numerous targeted investigations illustrating evidence in support of a sperm 
reservoir and factors influencing sperm maturation.  Sperm maturation events have 
been linked to the release of sperm from the reservoir.  For example, the presence of 
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binder of sperm protein 1, 3, and 5 on the sperm membrane decrease after 
capacitation which may lead to the release of sperm from the reservoir [45].   
Although the presence of proteins such as BSP 1, 3, and 5 have been 
extensively investigated, less is understood about the role of thermotaxis and 
chemotaxis.  These two processes involve chemoattractants and thermal gradients 
which are thought to affect sperm motility and direct them toward the ampulla for 
fertilization.  In regards to thermotaxis, a temperature gradient has been observed 
in the mammalian oviduct since the 1970’s.  There is evidence that the sperm 
reservoir in the isthmus region is cooler in temperature than the ampulla and the 
described temperature difference between the isthmus and ampulla is a proposed 
mechanism for sperm release from the reservoir to the site of fertilization [46-48].  
As far as chemotaxis in concerned, Kaupp et al., 2008 and 2012 conclude that the 
oocyte cumulus complex releases chemical factors that attract sperm [49, 50].    The 
role of other factors such as steroid hormones and epithelial cell secretions in 
chemotaxis have yet to be clearly defined; increasing the importance of investigating 
gene expression changes during these critical events.  
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Fertilization and Conceptus Development 
  After ovulation the cumulus oocyte complex (COC) is captured in the 
fimbriae and transported through the infundibulum to the ampulla.  Contact with 
epithelial cells aids in the movement of the COC so that the oocyte may come in 
contact with sperm.  A number of studies have attributed oocyte transport through 
the oviduct to ciliated epithelial cells beating in the direction of the uterus as well as 
smooth muscle contraction.  The fertilization cascade initiated by oocyte-sperm 
contact will not be discussed here; however, the role of oviduct epithelial cells in 
facilitating fertilization will be included. 
 Recently in cattle, epithelial cadherin (E-cadherin) was localized to ampulla 
and isthmus epithelial cells in the follicular and luteal phases of the estrous cycle.  
Furthermore, E-cadherin and β-catenin expression was found in the cumulus oocyte 
complex, mature oocytes and spermatozoa.  When monoclonal anti-E-cadherin 
antibody was used, sperm interaction with oviduct epithelial cells and cumulus 
oocyte complex was impaired in vitro suggesting that oviduct epithelial expression 
of E-cadherin is involved in sperm-oocyte adhesion events [51].  Presence of 
glycosidases and glycoproteins such as oviductal glycoprotein 1 (OVG1) have also 
been implicated in aiding gamete transport and sperm-ooctye interaction therefore 
analyses of the oviduct epithelium transcriptome will assist in identifying specific 
molecules participating the fertilization process [52, 53].   
 Upon successful fertilization, several rounds of embryonic cleavage occur, a 
morula develops and travels the remaining length of the oviduct before reaching the 
uterus as a late morula or differentiated blastocyst at around day 5.5 (in cattle) after 
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ovulation.  A normally functioning oviduct is critical for conceptus growth and 
differentiation and movement towards the uterus.  Ciliary beats and smooth muscle 
contraction are involved in transport and epithelial cell secretions provide an 
optimal environment for conceptus survival.  Similar to gamete storage and 
maturation, many bioactive compounds are involved in conceptus development 
such as glutamate, bicarbonate, potassium, arginine, alanine, and glycoprotein 
specific to the oviduct.  Steroid environment as discussed above is also vital to 
successful development and transport of the conceptus.   
 
Oviduct Epithelial Cell Secretions 
As mentioned above, factors such as calcium concentration, thermal gradient, 
chemoattractants from the cumulus oocyte complex, and oviduct epithelial cell 
secretions influence the ability of spermatozoa to travel through the utero-tubal 
junction and isthmus before reaching the ampulla, the site of fertilization.  Although 
in vivo fertilization and early cleavage events in the oviduct are not completely 
understood, the oviduct epithelial cell layer is clearly an active site of biosynthesis 
and secretion.   
Reports on the structural characteristics of secretory cells within the oviduct 
identify differences in the size and amount of secretory granules between the 
phases of the estrous cycle and spatial location [54, 55].  During the follicular phase 
biosynthetic activity of the oviductal mucosa increases in an estrogen dependent 
manner in multiple species, as reviewed by Buhi et al., 2000 [56].  Epithelial cells 
within the infundibulum and ampulla also appear to have a greater biosynthetic 
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activity than the isthmus and utero-tubal junction [53, 56, 57].  Studies involving 
both in vitro [58] and in vivo [59, 60] systems distinguish the composition of 
oviductal fluid as clearly different from that of serum or uterine fluid, further 
supporting the importance of oviductal function on early reproductive events.  
Evaluations of oviductal fluid describe components such as amino acids and 
proteins, carbohydrates, ions, lipids, and metabolic substrates [51, 53, 59-62].  Of 
note is the identification of estrogen-dependent, oviduct-specific glycoproteins 
which have been described in many studies.  Oviduct-specific glycoproteins are 
thought to act by binding gametes and the developing conceptus and have been 
found to increase capacitation and fertilization capabilities in bovine sperm [63] and 
increase blastocyst cleavage rates pigs in vitro [64].  However reports on in vivo 
function are conflicting based on species.  
Although significant changes in the composition of oviductal fluid exist 
between the phases of the estrous cycle with ovarian steroids being a major 
regulator, the presence of gametes and the conceptus also affects cell secretions.  
Spermatozoa have been shown to modulate gene expression and protein synthesis.  
Ellington et al., 1993, described the de novo synthesis of proteins in bovine 
oviductal epithelial cells from the isthmus when co-cultured with bull spermatozoa 
[62].  In turn, oviduct secretions regulate sperm function and the process of 
fertilization [44, 51].  Reports on the presence and interaction of a conceptus with 
the oviduct describe changes in oviduct gene expression and cell secretions [57, 65, 
66].  For example, oviduct derived embryotrophic factors such as complement 
protein component-3 has been described to be synthesized and secreted in the 
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oviducts of mice when a conceptus is present compared to pseudo-pregnant females 
[67].  Together these studies indicate the important balance in oviduct biosynthesis 
and secretion regulating the microenvironment required for gamete and conceptus 
health.   
 
Inflammatory Response in the Oviduct 
 A key aspect of function is understanding both normal, cyclic and pathogen-
induced inflammatory responses within the oviduct.  Existing research recognizes 
the critical role played by the immune system in female reproduction with estradiol 
and progesterone being important regulators.  The inflammatory response within 
the oviduct can be considered a normal and necessary physiological occurrence in 
response to ovulation, post-ovulatory follicular debris, and presence of sperm; 
however, salpingitis or aberrant inflammation can lead to tubal dysfunction.  In 
women, inflammatory insults can be caused by retrograde flow of endometrial fluid 
or exposure to pathogens resulting in oviduct epithelial cell secretion of 
proinflammatory cytokines and chemokines that recruit leukocytes and induce a 
cellular immune response [68].  Although innate and adaptive immune responses 
are critical, persistent or recurrent inflammation can lead to oviduct scarring, 
fibrosis, pelvic inflammatory disease, infertility, and potentially the formation of 
serous ovarian cancer [2, 69].   
Currently, methods to investigate tubal inflammation in women involve in 
vitro cell culture systems or in vivo mouse models; however, obstacles exist with 
these models as repeatability and variability are difficult to overcome.  A common 
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approach to investigating the immune response in the oviduct is through the use of 
chlamydia trachomatis induced inflammation using mice as a model for women.  C. 
trachomatis is the most frequently reported sexually transmitted bacterium in the 
United States [70] and recurrent or untreated infection can lead to tubal factor 
infertility [71].  Overall, the evidence suggests that once C. trachomatis has 
established infection within epithelial cells, the innate immune response allows for 
the production of pro-inflammatory cytokines such as interleukins 1, 6, 8, (Il-1, Il-6, 
Il-8) tumor necrosis factor-α (Tnf-α), and colony stimulating factor 2 (Csf2) [72].  
Regulation by cytokines, chemokines, and other inflammatory mediators is involved 
in the recruitment of immune cells such as natural killer cells and phagocytes [73, 
74].  The T-cell mediated immune response is another critical element and has been 
found to contribute to pathology following infection where Th1 cells limit 
replication of C. trachomatis, but Th2 cells inhibit Th1 responses leading to 
continued production of pro-inflammatory molecules which can lead to fibrosis 
[75].  Although these findings help us understand the inflammatory response by 
oviductal epithelial cells, there are large discrepancies in disease outcomes 
following infection due in part by host genetic factors, pathogenic strain, and 
experimental methods used.    
 Recently, Kowsar et al., 2014, investigated factors involved in the regulation 
of immune function in the bovine oviduct.  In this study an in vitro model of cultured 
bovine oviductal epithelial cells was used to determine the expression and secretion 
of alpha 1-acid glycoprotein (AGP), an acute phase protein regulated by ovarian 
steroids and potentially involved in regulating the inflammatory response in the 
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oviduct.  Interestingly, when bovine oviductal epithelial cells were stimulated with 
AGP and LPS in vitro, a decrease in TNF-α and TLR-2 gene expression was observed 
suggesting a role of AGP in modulating the immune response [76].  Local immune 
responses were further investigated in bovine oviductal epithelial cells in response 
to LPS stimulation and the interaction of ovarian steroids on LPS induced 
inflammatory mediators [77].  The results provided key information on the 
upregulation of pro-inflammatory molecules such as TLR-4, Interleukin 1β, and 
tumor necrosis factor α and provided evidence that ovarian steroids may play a role 
in controlling pro-inflammatory responses after oviductal epithelial cells are 
exposed to pathological agents [77].    
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CHAPTER 3. 
STATEMENT OF THE PROBLEM 
Existing literature recognizes the significance of the oviduct in gamete 
storage, maturation and transport, fertilization and subsequent zygote 
development.  The early reproductive events that occur within the oviduct are 
therefore critical for the successful establishment of pregnancy; however, the 
mechanisms regulating function of this organ are not well understood.   
Of the factors found to be influencing fertility in humans, 37% are reported 
to be due to female factor infertility [78] with the prevalence of oviductal 
dysfunction comparable or greater than endometriosis or ovulatory defects [3].  In 
cattle, up to 43% of reproductive failure can be attributed to loss of the conceptus 
prior to day 16 after ovulation; however, the role of the oviduct in these losses has 
yet to be elucidated [79].   
Using microarray and NanoString based transcriptional profiling, the 
objectives of this dissertation were (1) to delineate steroid-driven mechanisms 
regulating oviductal function as a whole (Chapter 4 and 5), and (2) to specifically 
examine the inflammatory response within this reproductive organ (Chapter 6 and 
Appendix 1).  Delineating the inflammatory response within the oviduct is of 
particular interest as aberrant inflammation is reported as one of the most common 
forms of pelvic inflammatory disease which can lead to fibrosis, tubal infertility 
and/or ectopic pregnancy in women [2].   
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Below is a detailed description of the hypothesis and objectives of each study 
included in this dissertation. 
Chapter 4:  
Title: A transcriptomal analysis of oviductal epithelial cells collected during the 
follicular versus luteal phase in cattle 
Hypothesis: Gene expression profiles of bovine oviductal epithelial cells will differ 
between the follicular phase (estrogenic environment) versus the luteal phase 
(progestogenic environemtn) within the ampulla and isthmus. 
Objectives: Using microarray based transcriptional profiling, identify spatial and 
steroid-dependent changes in mRNA and miRNA expression in epithelial cells 
isolated from the ampulla and isthmus of heifers. 
Chapter 5: 
Title: Regulation of oviductal function through estrogen-receptor alpha (ESR1): a 
transcriptomal analysis using transgenic mice 
Hypothesis: Gene expression profiles of the mouse oviduct will differ between 
ESR1KO and WT littermates after administration of PMSG at 23 days of age. 
Objectives: Using an ESR1 knockout mouse model, perform microarray based 
analysis to identify genes induced by estradiol production and regulated by ESR1. 
Chapter 6: 
Title: Intraperitoneal administration of lipopolysaccharide induces differential 
expression of mRNA encoding inflammatory mediators in the oviducts of mice 
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Hypothesis: Intraperitoneal (IP) administration of E. Coli -derived 
lipopolysaccharide (LPS) induces the expression of inflammatory mRNAs in the 
mouse oviduct.   
Objectives: With LPS as a systemic inflammatory insult, determine expression 
changes of inflammatory mRNAs in the oviducts of mice following IP injection with 
LPS from E. Coli using a targeting Nanostring assay to provide evidence of a reliable 
and repeatable model for the study of oviductal inflammation. 
Appendix 1: 
Title: Differential expression of mRNA encoding cytokines and chemokines in the 
reproductive tract after infection of mice with chlamydia trachomatis 
Hypothesis: mRNA encoding pro-inflammatory cytokines and chemokines will be 
differentially expressed in the female reproductive tract of mice infected with C. 
trachomatis at both 28 and 35 days post-infection compared to controls.   
Objectives: Using target superarray gene expression analysis, determine within the 
reproductive tract the concurrent level of expression of mRNA encoding 
inflammatory mediators during the later phases of infection using a relatively low 
infectious load of C. trachomatis biovar, serovar D, one of the most prevalent 
serovars involved in urogenital infections of humans. 
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CHAPTER 4. 
A TRANSCRIPTOMAL ANALYSIS OF OVIDUCTAL EPITHELIAL CELLS COLLECTED 
DURING THE FOLLICULAR VERSUS LUTEAL PHASE IN CATTLE 
Abstract 
 Reproductive success depends on a functional oviduct for gamete storage, 
maturation, fertilization, and early conceptus development.  The ovarian-derived 
steroids estradiol and progesterone are key regulators of oviductal function.  The 
objective of this study was to investigate luteal and follicular phase-specific 
oviductal epithelial cell function by using microarray-based transcriptional 
profiling, to increase our understanding of mRNA regulating epithelial cell 
processes, and to identify novel genes and biochemical pathways that may be found 
to affect fertility in the future.  Six normally cycling Angus heifers were assigned to 
either luteal phase (LP, high progesterone, n=3) or follicular phase (FP, high 
estradiol, n=3) treatment groups.  Heifers in the LP group were killed between day 
11 and 12 after ovulation.  Heifers in the FP group were treated with 25 mg PGF2α 
(Lutalyse, Pfizer, NY) at 8 pm on day 6 after ovulation and killed 36 h later.  
Transcriptional profiling by microarray analysis was performed using total RNA 
from epithelial cells isolated from sections of the ampulla and isthmus collected 
from LP and FP treatment groups.  Differentially expressed genes were subjected to 
gene ontology classification and bioinformatic pathway analyses.  Statistical one-
way ANOVA using Benjamini-Hochberg multiple testing correction for false 
discovery rate (FDR) and pairwise comparison of epithelial cells in the ampulla of 
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FP versus LP groups revealed 972 and 597 transcripts up- and down-regulated, 
respectively (P < 0.05).  Within epithelial cells of the isthmus in FP versus LP groups, 
946 and 817 transcripts were up- and down-regulated, respectively (P < 0.05).  Up-
regulated genes from both ampulla and isthmus were found to be largely involved in 
cholesterol biosynthesis and cell cycle pathways, while down-regulated genes were 
found in numerous inflammatory response pathways.  Microarray-based 
transcriptional profiling revealed steroid-dependent changes in the expression of 
mRNA and miRNA within the epithelium of the oviducts’ ampulla and isthmus.   
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Introduction  
 
 Reproductive success depends on a functional oviduct for gamete storage 
and maturation, fertilization, and early conceptus development.  Ovarian-derived 
steroids are well known regulators of oviductal function, both estrogen and the 
progesterone receptors are abundant in the bovine oviducts’ mucosal epithelium 
[80-85], yet our understanding of how the steroidal environment affects the ability 
of the oviduct to function remains only partially understood.  Maturation of gametes 
and breeding will occur in an estrogen dominant environment, fertilization and 
early cleavage after the steroidogenic shift and later stages of cleavage and 
formation of the morula occur within an oviduct exposed to increasing 
concentrations of circulating progesterone.  Increasing our understanding of the 
steroidal control of oviductal function is critical to the design and implementation of 
interventions used to manage breeding and the establishment of a pregnancy. 
 Functionally, the oviduct is divided into two distinct segments: the upper 
ampulla situated immediately below the ovarian bursa and infundibulum, and the 
lower isthmus which spans the interval from the ampulla to the uterus.  The 
epithelial mucosa within these two sections consists of ciliated and secretory simple 
columnar epithelial cells [17], the ratio of  which is regulated by steroid hormones 
[86, 87].  Steroidal regulation of processes that facilitate sperm binding [88], sperm 
release [89], capacitation [90] and hyperactivation [91] are all established in the 
literature.  Epithelial cells are also an active site of biosynthesis and secretion.  A 3- 
to 5-fold increase in the rate of oviductal secretions can be expected around the time 
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of estrus [92] and amino acids including glycine, glutamate, aspartate, alanine and 
lysine are all found in higher concentrations in oviductal fluid than in peripheral 
plasma [93].  Overall, steroid-regulated epithelial cell secretions can be considered 
an important mediator of the microenvironment that facilitates gamete and zygote 
health and early development.   
 While major efforts have been directed at investigating the ovary and uterus 
at the transcriptional level [94-96], less extensive investigation has been directed 
towards the oviduct.   Suppressive subtractive hybridization was used in the 
detailed study of Bauersachs et al., 2004 [18], in which changes in gene expression 
within the oviductal epithelium were determined in heifers killed on the morning of 
estrus or 12 days thereafter; our report expanding on their analysis with the use of 
more current transcriptomal profiling technologies and the determination of spatial 
differences between the ampulla and the isthmus.   
The objective of this descriptive study was therefore to determine global 
oviductal epithelial cell gene expression profiles during the follicular and luteal 
phases of the estrous cycle.  Specifically, microarray-based transcriptional profiling 
was used to identify spatial and phase of the cycle-dependent changes in mRNA 
expression in epithelial cells isolated from the ampulla and isthmus, with the overall 
goals of increasing our understanding of epithelial processes and identifying novel 
genes that may be identified as key regulators of fertility in the future.  Our results 
must be interpreted, however, with the knowledge that this analysis does not 
extract potential spatial (isthmus to ampulla and visa versa) signaling mechanisms 
that could affect oviductal epithelial cell gene expression profiles independent to 
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phase of the estrous cycle.  Given the size of the dataset generated by this analysis, 
our approach to this descriptive study is not to provide a detailed discussion of 
genes or processes affected by phase of the estrous cycle, but to summarize the 
results generated, provide our bioinformatic analyses (as Tables and Supplemental 
Tables) and make available our data for further analysis by others.  The microarray 
raw data (*.cel files) collected with the GCOS software, plus the RMA-normalized 
and log2 transformed transcript data (Park Genomics Suite [97]), have been 
deposited into the Gene Expression Omnibus (National Center for Biotechnology 
Information, http://www.ncbi.nlm.nih.gov/geo) as accession number GSE63969. 
 
Methods 
 
Animals and Tissue Collection 
 
 Animal procedures involved in this study were approved by the University of 
Kentucky Animal Care and Use Committee.  Six normally cycling Angus heifers were 
used and at least one spontaneous ovulation was observed in each animal prior to 
being included in the study.  All animals were monitored for behavioral estrus and 
examined a minimum of every other day by trans-rectal ultrasonography 
throughout the study period, as described before [98, 99].  After ovulation was 
confirmed, heifers were assigned to either luteal phase (LP) or follicular phase (FP) 
treatment groups.  Heifers in the LP group (n=3) were killed between day 11 and 12 
after ovulation.  The rationale for collection of LP oviducts on Day 11 or 12 post-
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ovulation was to collect samples under a stable, high progestogenic environment, at 
a time when the oviduct is undergoing progesterone-dependent remodeling and 
repair.  Heifers in the FP group (n=3) were treated with 25 mg PGF2α (Lutalyse, 
Pfizer, New York, NY) at 8 pm on day 6 after ovulation and killed 36 h later.  This is 
an established protocol in which the dominant follicle of the first follicular wave of 
the estrous cycle is induced to differentiate into a preovulatory follicle [98-101].  
The diameter of the preovulatory follicle (FP group) and the corpus luteum (LP 
group) prior to retrieval of the tissues was 14.6 +/- 1.0 mm and 21.5 +/- 0.8 mm, 
respectively.  Stage of the cycle was confirmed by visual appearance of the ovaries 
collected at slaughter. 
 Heifers were killed by stunning with a captive-bolt pistol and exsanguinated 
in the Department of Animal and Food Sciences’ USDA approved Meat Science Lab.  
Immediately after exsanguination, the oviduct ipsilateral to the corpus luteum (LP 
group) or preovulatory follicle (FP group) was dissected free from surrounding 
connective tissue.  Epithelial cells were isolated from small sections of the ampulla 
and isthmus by using a well-established technique for the collection of bovine 
oviductal epithelial cells [32, 102, 103].  Briefly, sections of ampulla and isthmus 
were gently squeezed with fine forceps under a dissecting microscope to separate 
epithelial cells from residual stroma.  Epithelial cells were briefly centrifuged to 
form a pellet and then snap-frozen in liquid N2 for later extraction of RNA.  Small 
sections of the ampulla and isthmus were also fixed for 24 h in Bouin’s fixative 
(Sigma-Aldrich, St. Louis, MO) then processed, sectioned and stained by the 
University of Kentucky Imaging Facility.  Tissues were processed through an 
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ascending series of graded ethyl alcohols, xylene and paraffin then embedded in 
paraffin.  Embedded tissues were sectioned on a microtome at 5 µm, floated on to 
SuperFrost Plus slides then heat-fixed for a minimum of 2 hours at 48OC on a slide 
warmer.  Hematoxylin and Eosin staining was performed using a ThermoShandon 
GLX Slide Stainer with Hematoxylin (EKI hematoxylin solution Gills III) and Eosin Y. 
 
RNA Extraction and Analysis 
 
 Epithelial cells were isolated from the ampulla and isthmus of the oviduct 
ispilateral to the ovary bearing the preovulatory follicle (FP group) or the corpus 
luteum (LP group).  Total RNA was extracted from each sample of epithelial cells 
using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA, USA) and purified with 
RNeasy columns (QIAGEN, Valencia, CA) according to the manufacturer’s 
instructions.  RNA quality was analyzed by determining the RNA integrity number 
(RIN) using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) at the 
University of Kentucky Microarray Core Facility.  RNA integrity numbers were 
greater than 9.2 and 28S/18S rRNA absorbance ratios greater than 1.5 for all 
samples.  RNA concentration was then determined via spectrophotometry using a 
NanoDrop 2000 (Thermo Fischer Scienctific-NanoDrop products, Wilmington, DE, 
USA).  Spectrophotometry results revealed 260/280 absorbance ratios greater than 
1.95 and 260/230 absorbance ratios greater than 1.5 for all samples.   
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Microarray Analysis 
 
 The Bovine gene 1.0 ST array (GeneChip, Affymetrix, Inc., Santa Clara, CA) 
was used.  Microarray analysis was conducted according to the manufacturer’s 
instructions at the University of Kentucky Microarray Core Facility, as described 
before [23, 104].  Briefly, RNA (3 g/sample) was reverse transcribed to cDNA using 
primers containing T7 RNA polymerase, so that the resulting cDNA contained the T7 
sequence.  In-vitro transcription was then used for the preparation and labeling of 
cRNA.  The biotinylated cRNA were further fragmented and used as probes to 
hybridize the GeneChips in the GeneChip Hybridization Oven 640, using 1 chip per 
RNA sample.  The raw expression intensity values generated by microarray 
hybridization were imported into Partek Genomics Suite 6.6 (Partek Inc., St. Louis, 
MO).  Robust Multiarray Analysis algorithm, quantile normalization, and Median 
Polish were applied for GeneChip background correction, log base2 transformation, 
conversion of expression values and probeset summarization [105, 106].  
Transcripts were annotated using NetAffx annotation database for the Bovine gene 
1.0 ST array and last updated in June 2014. 
 After data were processed for background adjustment, normalization and 
log2 transformed, quality of data was assessed using light intensity expression 
values on a per chip and per gene basis.  For statistical analysis, Partek Genomics 
Suite 6.6 (Partek Inc.) was used to complete an F-test on least-square means to 
determine significance of each transcript in each comparison.  Benjamini-Hochberg 
multiple testing correction for false discovery rate (FDR) was applied and 
 
27 
 
significance set to FDR adjusted P-value < 0.05.  A post-hoc pairwise comparison of 
FP compared to LP epithelial cells from the ampulla and isthmus was completed 
using Fisher’s Least Significant Difference (LSD) to determine which means differed 
[107, 108].  Only transcripts with a fold-change value in expression of at least 1.5 
were included in the results.  The raw data (*.cel files), plus the RMA-normalized 
and log2 transformed transcript data (Park Genomics Suite [106], have been 
deposited into the Gene Expression Omnibus (National Center for Biotechnology 
Information [109]) as accession number GSE63969 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63969). 
 
Real-time RT-PCR Analysis 
 
Real-time RT-PCR was performed using RNA samples from each tissue and 
phase of the estrous cycle to determine the expression of mRNA for neurotensin 
(NTS), binder of sperm 3 (BSP3), lactate dehydrogenase A (LDHA), cyclin D2 
(CCND2), early growth response 1 (EGR1) and hydroxysteroid (17 ) dehydrogenase 
7 (HSD17B7) using an Eppendorf Mastercycler ep realplex2 system (Eppendorf, 
Hamburg, Germany) with iQ SYBR Green Supermix (Bio-RAD, Hercules, CA), as 
described before [23].  Additional validation of the Bovine gene 1.0 ST array has 
been reported by our laboratory [110].  The following oligonucleotide primer pairs 
(5´ to 3´) were used:  NTS, F: GTG TGG AAA TGT GAC AGA GCA C and R: GGT AGG 
CTA GAC TTT GCG GT; BSP3, F: ATT CCT GTG GTG TTC CCT CG and R: GCT CAG AGC 
ATC ACC TTT GC; LDHA, F: CCA ACA TGG CAG CCT TTT CC and R: ACC GCT TTC CAC 
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TGT TCC TT; CCND2, F: CCG ACA ACT CCA TCA AGC CT and R: TGA AGT AGT GGC 
GCA CAG AG; EGR1, F: AGA AAG TTT GCC AGG AGC GA and R: GGA GGG ACG GAG 
GAG TAT GT; HSD17B7, F: ACA GCT GAA GGA CTG CTG AC and R: CCA GAC AGT GCT 
TCT GTT CCA; and 18S, F: CGG GGA GGT AGT GAC GAA A and R: CCG CTC CCA AGA 
TCC AAC TA. 
Briefly, cDNA was synthesized using the SuperScript III 1st Strand Synthesis 
System (Invitrogen), with 0.5 µg of RNA used for each reverse transcription 
reaction.  Real-time RT-PCR was performed with a total volume of 25 μL per 
reaction, with each reaction containing 5 μL of cDNA, 1 μL of a 10 μM stock of each 
primer (forward and reverse), 12.5 μL of 2× SYBR Green PCR Master Mix, and 5.5 μL 
of nuclease-free water.  The typical dissociation curves of these cDNA, plus 18S as 
the housekeeping gene was confirmed.  RT-PCR reactions were run in triplicate and 
gene expression was analyzed by the 2ΔΔCT method [111]. 
 
Gene Ontology and Pathway Analysis 
 
Differentially expressed transcripts were interrogated for their gene 
ontology classes using Partek Genomics Suite 6.6 (Partek Inc.).  Partek derives 
biological processes, molecular functions and cellular components from 
geneontology.org and/or the affymetrix database.  GO hierarchies leads to division 
of the gene list into significant classifications using Fischer’s exact test, right-tailed. 
When the observed number of genes in a GO category is greater than expected, the 
GO category is enriched. Pathway analysis was completed by importing 
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differentially expressed transcripts into QIAGEN’S Ingenuity Pathway Analysis (IPA, 
QIAGEN, Redwood City, CA, USA, www.qiagen.com/ingenuity).  Ingenuity Pathway 
Analysis uses data from multiple databases to extrapolate significant pathways and 
Fischer’s exact test was used to determine significant pathways.  Significance was 
set to P-value < 0.05. 
 
Results and Discussion 
 
Real-time RT- PCR Analysis of Selected Transcripts 
 
 The effect of stage of the estrous cycle and tissue on the expression of mRNA 
for NTS, BSP3, LDHA, CCND2, EGR1 and HSD17B7 was performed by real-time RT-
PCR.   A comparison of the results obtained by RT-PCR and microarray analysis is 
described in Table 4.1 as a validation of the microarray platform.  Additional 
validation of this Bovine gene 1.0 ST array by real-time RT-PCR performed within 
our laboratory has been reported [112].  Overall, RT-PCR revealed the same 
directional trends in gene expression as microarray analysis, with the magnitude of 
these changes typically lower after analysis using the microarray platform (ratio 
compression phenomena), as described by others [113].  For example, the 
expression of mRNA for NTS was found to increase by 32.4- and 150-fold within 
epithelial cells of the ampulla, and 21.6- and 88-fold within the epithelial cells of the 
isthmus, in the FP versus the LP groups by microarray analysis and real-time RT-
PCR, respectively.   
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Table 4.1. Comparison of gene expression for selected mRNA by microarray and 
real-time RT-PCR. 
Ampulla Microarray Real-time RT-PCR 
Gene 
Symbol 
FP vs. 
LP Fold-
Change 
FP vs. 
LP P-
value 
FP 
Mean 
SEM LP 
Mean 
SEM FP vs. 
LP Fold-
Change 
FP vs. 
LP P-
value 
NTS 32.44 <0.001 1.05 0.12 0.007 0.001 150 <0.001 
BSP3 -1.09 0.79 ND      
LDHA 2.22 <0.001 1.13 0.2 0.43 0.1 2.63 0.002 
CCND2 1.23 0.35 1.19 0.21 0.91 0.12 1.31 0.27 
EGR1 -9.13 0.005 1.19 0.23 111.9 34.2 -94 <0.001 
HSD17B7 1.03 0.76 1.07 0.21 0.86 0.12 1.24 0.36 
Isthmus Microarray Real-time RT-PCR 
Gene 
Symbol 
FP vs. 
LP Fold-
Change 
FP vs. 
LP P-
value 
FP 
Mean 
SEM LP 
Mean 
SEM FP vs. 
LP Fold-
Change 
FP vs. 
LP P-
value 
NTS 21.57 <0.001 1.51 0.47 0.02 0.008 88 <0.001 
BSP3 -7.58 <0.001 1.91 0.74 30.47 11.39 -16 0.01 
LDHA 2.34 <0.001 1.05 0.12 0.29 0.08 3.64 <0.001 
CCND2 2.36 0.003 1.09 0.18 0.8 0.17 1.38 0.24 
EGR1 -5.35 0.019 1.07 0.13 108.4 35.2 -101 <0.001 
HSD17B7 -1.13 0.27 1.05 0.12 1.76 0.36 -1.67 0.25 
For statistical analysis of the microarray dataset, an F-test on least-square means 
was used to determine significance of each transcript in each comparison. 
Benjamini-Hochberg multiple testing correction for false discovery rate (FDR) was 
applied and significance set to FDR adjusted P-value < 0.05. A post-hoc pairwise 
comparison of FP compared to LP epithelial cells was completed using Fisher’s Least 
Significant Difference (LSD) to determine which means differed.  For the analysis of 
gene expression by real-time RT-PCR, mean level of expression and SEM are 
indicated for FP and LP epithelial cells of the ampulla and isthmus, as well as fold 
change in relative expression (FP vs. LP).  For statistical analysis of relative gene 
expression by real-time RT-PCR, P-values to determine the significance of each 
transcript were determined using the Student’s t-test.  ND: Not detectable by real-
time RT-PCR. 
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Microarray Quality Control and Principal Component Analysis 
 
 Box plots revealed mean intensity values were similar across all chips and 
overlapping histograms indicated the frequency of transcripts at specific intensity 
values for each chip were similar (Supplementary Figure 1 and 2).  Quantification of 
signal intensity to noise revealed that spatial location and phase of the cycle, not 
error, accounted for the variation within the data set (mean F Ratio for attribute = 
30.78, versus mean F value for error = 1.0).  Consistent with this, principal 
component analysis (PCA), which allows for the visualization of patterns through 
the distribution of samples to highlight similarities and differences [106], revealed 
clear differences between LP and FP groups, as well as tissue-specific differences 
within the same phase of the estrous cycle (Figure 4.1).  Total variance was 55.5% is 
the cumulative percent of variance accounted for in our datasets based upon 
eigenvector multivariate analysis.  PC#1 (x-axis, 28%) indicates that the largest 
proportion of variability is due to phase of the estrous cycle.  PC#2 (y-axis, 17.8%) 
indicates variability between the ampulla and isthmus.  PC#3 (z-axis, 9.7%) 
indicates the variability between phase of the estrous cycle and tissues. 
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Figure 4.1.  Principal component analysis of microarray transcriptome results of 
epithelial cells from the ampulla and isthmus taken from heifers killed in the 
follicular phase (FP) and luteal phase (LP) of the estrous cycle.  Red: FP ampulla, 
Blue: FP isthmus, Green: LP ampulla, Purple: LP isthmus. Each Bovine 1.0 ST array 
includes 26,775 probesets.  
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Pairwise Comparisons 
 
It is well known that function of the mammalian oviduct is influenced by 
estradiol and progesterone, with previous studies confirming the presence of mRNA 
and protein for estrogen receptor alpha (ERα) and beta (ERβ) as well as the nuclear 
and membrane progesterone receptors (PR, PGRMC1, PGRMC2) within this organ 
[19, 85].  After chip normalization, a statistical one-way ANOVA and pairwise 
comparison (LSD test) of gene expression in epithelial cells of the ampulla and 
isthmus in the FP and LP groups was performed to generate a list of 2374 
differentially expressed genes (DEGs).  Table 4.2 indicates the number of DEGs in 
each pairwise comparison.  As expected, there were a large number of DEGs 
identified by FP (1563 DEGs) and LP (1758 DEGs) pairwise comparisons.  Among 
these DEGs, 947 DEGs overlapped between contrasts (Figure 4.2).  By pairwise 
comparison, 616 DEGs were exclusive to the ampulla and 811 DEGs were exclusive 
to the isthmus.  
Table 4.2.  Number of differentially expressed genes (DEGs) in epithelial cells of 
the ampulla and isthmus between follicular and luteal phase groups (FDR adjusted 
P < 0.05). 
Parameter DEGs Up-regulated Down-regulated 
FP vs. LP (Ampulla) 1563 968 (62%) 595 (38%) 
FP vs. LP (Isthmus) 1758 943 (54%) 815 (46%) 
Heifers in the follicular phase group (n=3) were treated with 25 mg PGF2  at 8 pm 
on Day 6 of the estrous cycle and killed 36 h later.  Heifers in the luteal phase 
group (n=3) were killed on Day 11 or 12 of the estrous cycle.  For statistical 
analysis, an F-test on least-square means was used to determine significance of 
each transcript in each comparison.  Benjamini-Hochberg multiple testing 
correction for false discovery rate (FDR) was applied and significance set to FDR 
adjusted P-value < 0.05. 
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Figure 4.2.  Venn diagram depicting the number of differentially expressed genes in 
follicular phase versus luteal phase epithelial cells from the ampulla and isthmus 
(FDR adjusted P < 0.05). 
 
DEGs in Epithelial Cells of the Ampulla 
 
The ampulla is situated immediately below the ovarian bursa and 
infundibulum and is the site of fertilization.  Histological evaluations have shown the 
ampulla to have an elaborate, extensively folded epithelial layer adjacent to a thin 
layer of smooth muscle (Figure 4.3A).  Evaluation of the oviducts of cattle [28, 77, 
92] confirm that this is a dynamic tissue with multiple, ongoing biological processes 
that include cell proliferation [17] and tissue remodeling [114].  The most highly up- 
and down-regulated DEGs within epithelial cells of the ampulla in FP versus LP 
groups are provided as Table 4.3.   
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Table 4.3.  Most highly up- and down-regulated DEGs within epithelial cells of the 
ampulla in follicular versus luteal phase groups (FDR adjusted P < 0.05). 
Gene Symbol Gene Description P-value Fold-
Change 
NTS Neurotensin < 0.001 32.44 
PRND prion protein 2 (dublet) < 0.001 18.30 
CDC20B cell division cycle 20 homolog B (S. 
cerevisiae) 
< 0.001 17.49 
bTrappin-5 trappin 5 < 0.001 11.14 
TMEM45A transmembrane protein 45A 0.004 10.69 
CRELD2 cysteine-rich with EGF-like domains 2 < 0.001 9.98 
SLC2A10 solute carrier family 2 (facilitated 
glucose transporter), member 10 
< 0.001 9.54 
SDF2L1 stromal cell-derived factor 2-like 1 < 0.001 9.29 
MIR449C microRNA mir-449c < 0.001 9.20 
KRT23 keratin 23 (histone deacetylase 
inducible) 
0.004 8.40 
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, 
member 11 
< 0.001 6.92 
MANF mesencephalic astrocyte-derived 
neurotrophic factor 
< 0.001 6.90 
MFSD2A major facilitator superfamily domain 
containing 2A 
< 0.001 6.70 
CLPH  calcium-binding protein, spermatid-
specific 1 (CABS1) 
< 0.001 6.61 
PLA2G4D phospholipase A2, group IVD (cytosolic) < 0.001 6.61 
CBLN4 cerebellin 4 precursor < 0.001 6.57 
SERPINE3 serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator inhibitor 
type 1), member 3 
< 0.001 6.54 
RRM2 ribonucleotide reductase M2 < 0.001 6.52 
H4 histone H4 < 0.001 6.30 
INSIG1 insulin induced gene 1 < 0.001 6.21 
Gene Symbol Gene Description P-value Fold-
Change 
EGR1 early growth response 1 0.005 -9.13 
FOS FBJ murine osteosarcoma viral oncogene 
homolog 
0.002 -8.55 
VCAM1 vascular cell adhesion molecule1 < 0.001 -7.11 
GABRP gamma-aminobutyric acid (GABA) A 
receptor, pi 
< 0.001 -6.76 
GPR174 G protein-coupled receptor 174 0.003 -5.15 
ZBTB16 zinc finger and BTB domain containing 
16 
 
0.001 -4.62 
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Table 4.3. (Continued) 
BMP4 bone morphogenetic protein 4 0.001 -4.44 
LOC777601 uncharacterized LOC777601 < 0.001 -4.37 
FIGF c-fos induced growth factor (vascular 
endothelial growth factor D) 
< 0.001 -4.12 
KLRK1 killer cell lectin-like receptor 
subfamily K, member 1 
0.003 -4.09 
PDK4 pyruvate dehydrogenase kinase, 
isozyme 4 
0.001 -3.93 
LOC1002976
76 
C-type lectin domain family 2 member 
G-like 
0.003 -3.78 
LOC1003371
83 
contactin associated protein-like 3-
like 
0.008 -3.71 
LOC768255 GTPase, IMAP family member 4-like 0.001 -3.64 
TRAT1 T cell receptor associated 
transmembrane adaptor 1 
0.007 -3.48 
CAPN6 calpain 6 0.007 -3.48 
CAV1 caveolin 1, caveolae protein, 22kDa 0.005 -3.44 
LOC541007 Similar to protein jade-2(PHD finger 
protein 15) (BT24231-RA) 
< 0.001 -3.34 
CHRDL1 chordin-like 1 0.002 -3.31 
MIR29C microRNA mir-29c 0.001 -3.29 
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Figure 4.3.  Representative images of the ampulla (A,B) of the bovine oviduct.  Scale 
bar:  A= 1000 µM; B= 250 µM.  Images are from one heifer collected during the 
follicular phase of the estrous cycle.  Sections were stained with hematoxylin and 
eosin. 
 
As indicated above, a detailed discussion of the role for individual genes 
identified by this analysis is not our objective, however examples of consistency 
among our profiling results and more targeted analyses performed by others is 
warranted.  Of the up-regulated genes, the expression of mRNA for neurotensin 
(NTS) was found to increase by 32.4-fold within epithelial cells of the ampulla in the 
FP versus the LP groups.  Neurotensin has multiple functions and evidence suggests 
that NTS plays a role in gamete and conceptus transport within the oviduct [115].  
Receptors for NTS are expressed on spermatozoa, and increasing NTS 
administration facilitates sperm protein tyrosine phosphorylation, which is a 
measure of sperm capacitation [44].  Furthermore, the acrosome reaction is 
promoted in capacitated spermatozoa in the presence of increasing concentrations 
of NTS [44], consistent with the increased expression of NTS observed in the 
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follicular phase, herein.  In contrast to this established role of NTS, and consistent 
with our objective to identify novel genes that may be revealed as critical mediators 
of function in the future, the transcription factor early growth response 1 (EGR1) 
was observed to display the highest fold-change (9.1-fold) among down-regulated 
genes within epithelial cells of the ampulla in the FP versus the LP groups.  A 
gonadotropin-dependent induction of EGR1 has been reported prior to ovulation in 
bovine follicles [116], however no reports to date are apparent on the function, or 
importance, of this transcription factor in the epithelium of the oviducts’ ampulla.   
Up- and down-regulated DEGs were analyzed for enriched gene ontology 
classifications.  Gene ontology analysis of up-regulated DEGs within epithelial cells 
of the ampulla in the FP versus the LP groups resulted in 117 significant biological 
processes, 65 significant cellular components, and 46 significant molecular 
functions (P < 0.05).  Cell cycle, cholesterol biosynthetic process, cell division, 
mitosis and protein folding were the top biological processes identified, which is not 
surprising considering the cell proliferation and secretory activity required to 
prepare the ampulla for the arrival of the gametes.  With respect to cholesterol 
biosynthesis, steroid-dependent effects on the oviduct are documented in the 
literature.  Cholesterol will affect the ability of spermatozoa to fertilize an oocyte 
[117], with the process of capacitation well established to require efflux of 
cholesterol from the plasma membrane of spermatozoa (reviewed in [118]).  High 
density lipoproteins are elevated in bovine oviductal fluid during the follicular 
phase of the estrous cycle [119]; however, the synthesis and release of cholesterol 
by oviductal epithelial cells appears to be greater under a progesterone dominant 
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environment.  Esterified-cholesterol containing lipid droplets from oviductal 
epithelial cells were observed in greater numbers when collected from luteal-phase 
cows [120] and the concentration of cholesterol was increased in isthmic but not 
ampullary oviductal fluid collected from the luteal phase versus non-luteal phase 
animals [121].  Further analysis of the biochemical relationship among the DEGs 
expressed within these top cholesterol-associated pathways may increase our 
understanding of the role of cholesterol during the processes of capacitation and 
fertilization, critical events that occur within the oviduct.  Top cellular components 
of up-regulated DEGs within epithelial cells of the ampulla in the FP versus the LP 
groups included endoplasmic reticulum lumen and membrane, cytoplasm, and 
mitochondrion.  Top molecular functions involved protein disulfide isomerase 
activity, FK506 binding, peptidyl-prolyl cis-trans isomerase activity, oxidoreductase 
activity, and dolichyl-diphosphooligosaccharide-protein glycotransferase activity. 
Analysis of down-regulated DEGs within epithelial cells of the ampulla in the 
FP versus the LP revealed 118 significant biological processes, 18 significant cellular 
components, and 49 significant molecular functions (P <0.05).  The top biological 
processes were the innate immune response, response to nicotine, myoblast 
proliferation, negative regulation of MAP kinase activity, and bone morphogenetic 
protein (BMP) signaling pathway.   With respect to immune responses, it can be 
postulated that increases in estradiol during the follicular phase decrease the 
induction of pro-inflammatory factors, with the results of our study consistent with 
an investigation on the effect of ovarian steroids on lipopolysaccharide (LPS)-
induced responses in bovine oviductal epithelial cells in vitro [77].  In their report, 
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estradiol reversed the effect of LPS on pro-inflammatory gene expression and we 
have previously demonstrated ESR1-dependent as well as cyclic changes in the 
expression of the hematopoetic form of prostaglandin D synthase, a putative 
regulator of inflammation, in the mouse oviduct [23].  Given that the oviductal 
epithelium must continually repair itself from any damage caused by exposure to 
gametes, seminal fluids and post-ovulatory follicular debris, steroid-dependent 
changes in inflammatory response mechanisms can be considered physiologically 
important biological processes.  Lastly, top cellular components associated with the 
down-regulated DEGs were plasma membrane, cytoplasm, extracellular region, 
cytosol, and tight junction and top molecular functions were pancreatic 
ribonuclease activity, transmembrane signaling receptor activity, protein-L-
isoaspartate (D-aspartate) O-methyltransferase activity, serine hydrolase activity, 
and phosphatidylinositol-3,4-bisphosphate binding. 
Canonical pathway analysis of DEGs within epithelial cells of the ampulla in 
the FP versus the LP was then determined using QIAGEN’S Ingenuity Pathway 
Analysis (IPA, QIAGEN, Redwood City, www.qiagen.com/ingenuity).  Top pathways 
up-regulated in the follicular phase largely reflected cholesterol biosynthesis 
(Superpathway of Cholesterol Biosynthesis, Cholesterol Biosynthesis I, Cholesterol 
Biosynthesis II (via 24,25-dihydrolanosterol), Cholesterol Biosynthesis III (via 
Desmosterol)), and Oxidative Phosphorylation (P < 0.05, Supplementary Figure 3A), 
which was consistent with the results of the gene ontology analysis discussed above.  
The top pathways for down-regulated genes included Hepatic Fibrosis / Hepatic 
Stellate Cell Activation, Role of Pattern Recognition Receptors in Recognition of 
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Bacteria and Viruses, Colorectal Cancer Metastasis Signaling, Ovarian Cancer 
Signaling, and Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis (P < 0.05, Supplementary Figure 3B).  Again, this canonical pathway 
analysis is consistent with steroid-dependent regulation of inflammation and 
immune responses extracted by the gene ontology analysis.  Worthy to note, given 
the increasing interest in oviductal epithelial cells as progenitors for ovarian cancer 
[122-124], down-regulation of the DEGs in the ovarian cancer signaling canonical 
pathway (MMP7, ARRB1, FZD4, FGF9, SMO, FIGF, CCND1, PDGFC, FZD7, EGFR and 
BCL2) could provide useful clues that can advance that important field of study.  In 
addition, potential effects of the presence of the conceptus to the oviductal 
epithelium should not be overlooked.  We observed down-regulation of 7 DEGs, 
including that of insulin-like growth factor binding protein 3 (IGFBP3) in epithelial 
cells of the ampulla in FP versus LP groups, whose expression in primary bovine 
oviductal epithelial cells in vitro is increased by the addition of a conceptus to their 
culture [125]. 
 
DEGs in Epithelial Cells of the Isthmus 
 
Similar to the ampulla, the mucosa of the isthmus appears well defined in 
histological evaluations (Figure 4.4A and B).  However, in contrast to the ampulla, 
the mucosa of the isthmus is located adjacent to a prominent musculature with this 
smooth musculature playing a key role in the movement of gametes to the site of 
fertilization and passage of the early conceptus to the uterus [126-128].  Several of 
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the DEGs within epithelial cells of the isthmus in the FP versus the LP were similar 
to those identified within the ampulla; however, there were also many DEGs unique 
to this spatial location.  Among the up-regulated DEGs in the epithelium of the 
isthmus (Table 4.4), the increased expression of mRNA encoding phospholipase A2, 
group IVD (cytosolic) (PLA2G4D) and phospholipase A2, group IVF (PLA2G4F) is 
interesting, especially when considering the key role for prostaglandins within the 
oviduct [33, 127, 129] and the noted regulations of prostaglandin synthesis by 
ovarian steroids as reported by us [23] and others [58, 130].  
Figure 4.4.  Representative images of the isthmus (A,B) of the bovine oviduct.  Scale 
bar:  A = 1000 µM; B= 250 µM.  Images are from one heifer collected during the 
follicular phase of the estrous cycle.  Sections were stained with hematoxylin and 
eosin.  
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Table 4.4.  Most highly up- and down-regulated DEGs within epithelial cells of the 
isthmus in follicular phase versus luteal phase groups (FDR adjusted P < 0.05). 
Gene 
Symbol 
Gene Description P-
value 
Fold-
Change 
KRT23 keratin 23 (histone deacetylase inducible) < 0.001 22.57 
NTS Neurotensin < 0.001 21.57 
PRND prion protein 2 (dublet) < 0.001 12.36 
STRA6 stimulated by retinoic acid gene 6 homolog 
(mouse) 
< 0.001 11.22 
TMEM45A transmembrane protein 45A 0.004 10.56 
PKHD1L1 polycystic kidney and hepatic disease 1 
(autosomal recessive)-like 1 
0.004 9.86 
LPL lipoprotein lipase < 0.001 9.40 
SLC7A11 solute carrier family 7 (anionic amino acid 
transporter light chain, xc- system), member 11 
< 0.001 8.92 
CLEC3A C-type lectin domain family 3, member A < 0.001 8.69 
GFAP glial fibrillary acidic protein < 0.001 8.09 
CRELD2 cysteine-rich with EGF-like domains 2 < 0.001 7.69 
CA2 carbonic anhydrase II < 0.001 7.68 
PLA2G4D phospholipase A2, group IVD (cytosolic) < 0.001 7.64 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.001 7.34 
SDF2L1 stromal cell-derived factor 2-like 1 < 0.001 7.31 
PPP2R2C protein phosphatase 2, regulatory subunit B, 
gamma 
0.000 7.30 
P2RX2 purinergic receptor P2X, ligand-gated ion 
channel, 2 
0.002 6.86 
PLA2G4F phospholipase A2, group IVF < 0.001 6.85 
SLC2A10 solute carrier family 2 (facilitated glucose 
transporter), member 10 
< 0.001 6.69 
CDC20B cell division cycle 20 homolog B (S. cerevisiae) 0.001 6.35 
Gene 
Symbol 
Gene Description P-
value 
Fold-
Change 
KLF17 Kruppel-like factor 17  < 0.001 -14.70 
KSR2 kinase suppressor of ras 2 < 0.001 -8.94 
LOC100337
391 
predicted protein-like < 0.001 -7.77 
BSP3 binder of sperm 3 < 0.001 -7.58 
OR9Q2 olfactory receptor, family 9, subfamily Q, member 
2 
0.001 -6.87 
ZBTB16 zinc finger and BTB domain containing 16 < 0.001 -5.91 
EGR1 early growth response 1 0.019 -5.35 
LOC522479 ovalbumin-like  < 0.001 -5.34 
CWH43 cell wall biogenesis 43 C-terminal homolog (S. 
cerevisiae) 
0.001 -5.09 
TFF3 trefoil factor 3 (intestinal) < 0.001 -4.98 
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Table 4.4. (Continued) 
LOC100335
668 
mitochondrial import inner membrane 
translocase subunit Tim9 pseudogene 
0.001 -4.94 
LOC617981 family with sequence similarity 55, member C-
like 
< 0.001 -4.92 
MEGF10 multiple EGF-like-domains 10 < 0.001 -4.81 
LOC100337
183 
contactin associated protein-like 3-like 0.003 -4.75 
AK5 adenylate kinase 5 < 0.001 -4.74 
FOS FBJ murine osteosarcoma viral oncogene 
homolog 
0.012 -4.54 
CA10 carbonic anhydrase X 0.001 -4.40 
NDP Norrie disease (pseudoglioma) < 0.001 -4.34 
SEMA5A sema domain, seven thrombospondin repeats 
(type 1 and type 1-like), transmembrane domain 
(TM) and short cytoplasmic domain, 
(semaphorin) 5A 
< 0.001 -4.26 
CAV1 caveolin 1, caveolae protein, 22kDa 0.003 -4.14 
 
Both PLA2G4D and PLA2G4F belong to the phospholipase A2 (PLA2) family, 
group 4.  The PLA2 family of enzymes catalyzes the hydrolysis of phospholipids to 
liberate free fatty acids, among other molecules.  Of these free fatty acids, 
arachidonic acid released by PLA2 enzymes acts as the precursor for the synthesis 
of prostaglandins [131, 132].  Consistent with our results, in ovariectomized rabbits, 
PLA2 activity in epithelial cells of the ampulla is reported to be increased after 
treatment of rabbits with estradiol [133].  Given that PLA2G4D and PLA2G4F do not 
appear to be described within the oviduct, our results can be considered as new 
information on the local regulation of phospholipases and potentially prostaglandin 
secretion within this organ.  Of the down-regulated DEGs expressed by epithelial 
cells of the isthmus, the expression of binder of sperm 3 (BSP3) is also identified as 
a novel transcript.  BSP3 is reported to be secreted by seminal vesicles and binds to 
sperm [134], and identified within the epithelial cells of the isthmus herein.  Again, 
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the potential to modify the epithelial cell transcriptome by the presence of a 
conceptus must be acknowledged.  We observed down-regulation of 10 DEGs, 
including that of the apoptosis regulator XIAP associated factor-1 (XAF1) in 
epithelial cells of the isthmus in FP versus LP groups, whose expression has been 
reported to be increased by the addition of a conceptus to cultures of primary 
bovine oviductal epithelial cells [125].  
Gene ontology classification of up-regulated DEGs within epithelial cells of 
the isthmus in the FP versus the LP revealed 97 significant biological processes with 
top biological processes being protein folding, cell cycle, cell division, mitosis, and 
electron transport chain (P < 0.05).  Similar to the ampulla, there were 57 significant 
cellular components affected by stage of the cycle within epithelial cells of the 
isthmus, including endoplasmic reticulum lumen and membrane, cytoplasm, and 
mitochondrion and 46 significant molecular functions.  Gene ontology analysis of 
the down-regulated DEGs within epithelial cells of the isthmus revealed 101 
significant biological processes, 26 significant cellular components, and 45 
significant molecular functions (P < 0.05).  Top biological processes were negative 
regulation of fibroblast growth factor receptor signaling pathway, calcium-
independent cell-cell adhesion, inactivation of MAPK activity, brown fat cell 
differentiation, and SMAD protein signal transduction.  Top cellular components 
were similar to those observed within the ampulla and included cytoplasm, plasma 
membrane cytosol, extracellular region, and tight junction. 
Again, QIAGEN’S Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood City, 
www.qiagen.com/ingenuity) was used to identify the canonical pathways affected 
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by stage of the cycle within epithelial cells of the isthmus.  Up-regulated DEGs within 
epithelial cells of the isthmus in FP versus LP were oxidative phosphorylation, 
mitochondrial dysfunction, superpathway of cholesterol biosynthesis, 
superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate), and 
melavonate pathway I (P < 0.05, Supplementary Figure 4A).  Similar to that 
observed in the ampulla, cholesterol biosynthesis stands out as a key pathway with 
gene expression increased under an estrogen dominant environment.  Consistency 
in response was also observed among down-regulated DEGs.  Top pathways for 
down-regulated DEGs included molecular mechanisms of cancer, basal cell 
carcinoma signaling, role of osteoblasts, osteoclasts and chondrocytes in 
rheumatoid arthritis, Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis, and Corticotropin Releasing Hormone Signaling (P < 0.05, 
Supplementary Figure 4B). 
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Conclusions 
 
At the genome level, estrous cycle stage-dependent effects on epithelial cell 
gene expression are not well defined.  The current study therefore investigated 
changes in the expression of mRNA within the epithelium of the ampulla and 
isthmus of the bovine oviduct during the luteal and follicular phases of the estrous 
cycle.  This transcriptomal profiling analysis was performed to increase our 
understanding of gene expression and potentially epithelial cell processes 
important for oviductal function and fertility, and to identify novel mRNA that may 
prove critical for fertility after analysis in the future.  
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CHAPTER 5. 
REGULATION OF OVIDUCTAL FUNCTION THROUGH ESTROGEN-
RECEPTOR ALPHA (ESR1): A TRANSCRIPTOMAL ANALYSIS USING TRANSGENIC 
MICE 
Abstract 
The oviduct provides the microenvironment necessary for gamete storage 
and maturation, fertilization, and early development of the conceptus.  Within the 
oviduct, ESR1 is the predominant estrogen receptor expressed mediating the effects 
of estrogens on a variety of oviductal functions.  Specifically, transcriptional 
regulation whereby hormone bound receptors target the estrogen responsive 
element (ERE) on DNA gene sites to either enhance or repress transcription.  
Considering the early reproductive events that occur in the oviduct during the 
estrogen dominant phase, ESR1 is essential for reproductive success.  The objective 
of this study was to determine ESR1-dependent changes in gene expression in the 
oviducts of mice using the Affymetrix Genechip Mouse Genome 430-2.0 arrays 
(Affymetrix Inc., CA).  Whole oviducts were collected from immature mice with a 
global deletion of ESR1 (ESR1KO) and their wild-type (WT) littermates at 23 days of 
age or 48 hr after treatment of ESR1KO or WT littermates with 5 IU of PMSG.  
Stimulation with PMSG and collection of oviducts 48 hr later is an established 
protocol in which to induce follicular development and production of estradiol.  
Oviducts from 3-4 mice were pooled for each genotype and time point and total RNA 
extracted and purified using TRIzol and RNeasy columns. Three independent 
 
49 
 
replicates were collected for microarray analysis.  Following microarray 
hybridization, the resulting dataset was analyzed using Partek Genomics Suite 6.6 
(Partek Inc., MO).  GC-RMA, quantile normalization, and Median Polish were applied 
for GeneChip background correction, log base2 transformation, conversion of 
expression values and probeset summarization.  Statistical 2-way ANOVA revealed 
2428 genes affected by genotype and treatment (P < 0.01, FDR <0.13) and a 
pairwise comparison of ESR1KO PMSG treatment versus WT PMSG treatment 
identified 496 significantly up-regulated genes and 690 significantly down-
regulated genes with at least a 2 fold difference between groups (P < 0.01).  
Differentially expressed genes from the pairwise comparison were subjected to 
pathway analysis using Fischer’s exact test to determine significant pathways.  Up-
regulated genes were found to be involved in immune response and cell signaling 
pathways, while down-regulated genes were found in pathways related to 
cholesterol biosynthesis and reflected functions such as cellular hypertrophy, lipid 
metabolism, molecular transport, and cellular morphology.  These results indicate 
many biological processes regulated by ESR1 and may reveal the identity of novel 
genes involved in oviduct function for future analysis. 
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Introduction  
 
 Reproductive success depends on a functional oviduct for gamete storage, 
maturation, fertilization, and early-conceptus development.  Ovarian-derived 
estradiol is a known regulator of oviductal function with the transcription factor, 
estrogen receptor-α (ESR1) being the predominant estrogen receptor expressed in 
the oviduct [135, 136].  ESR1 is essential for reproductive function and plays a 
diverse role such as, transcriptional regulation, whereby hormone bound receptors 
target the estrogen responsive element (ERE) on DNA gene sites to either enhance 
or repress transcription [137, 138].  The expression of ESR1 in the oviduct has been 
localized to ciliated and secretory epithelial cells, stromal cells, and muscle cells 
throughout the estrous cycle with cyclic changes in circulating concentrations of 
estradiol regulating ESR1 protein expression [19, 21, 25].  Several studies have 
described the morphological and functional dependence of the oviduct on estrogens 
and ESR1 [21, 83].  For example, long term administration of exogenous estradiol 
leads to cellular hypertrophy and increased protein synthesis in secretory epithelial 
cells from the mouse oviduct in vivo [21].  Furthermore, our lab has previously 
reported a proposed regulator of inflammation within the oviduct, hematopoietic 
form of prostaglandin D synthase (HPGDS), which was found to be dependent upon 
ESR1 expression [23].  However, genome-wide reports on estradiol and ESR1 
regulation of oviductal function remain limited.   
The development of estrogen receptor knockout mouse models has advanced 
our understanding of the physiological role of ESR1 in reproductive tissues.  
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Estrogens are known to stimulate epithelial cell proliferation and differentiation in 
the uterus and ESR1KO mice are infertile due to underdeveloped and hyperplastic 
uteri [139].  ESR1KO females also develop cystic ovaries due to elevated 
concentrations of estradiol leading to aberrant regulation of the hypothalamic-
pituitary axis [139, 140].   
Given that the incidence of tubal dysfunction is comparable to endometriosis 
and impaired ovarian function and as a reason for woman to seek treatment for 
infertility, our objective herein was to identify estradiol and ESR1-dependent 
changes in mRNA expression in the oviduct.  Specifically, microarray-based 
transcriptional profiling was performed using oviducts collected from mice bearing 
a global deletion of ESR1 (ESR1KO) and their control littermates (WT).  Global gene 
expression profiles were also determined in oviducts collected from ESR1KO and 
WT controls after ovarian estradiol production was stimulated by treatment with 
PMSG.  Given the size of the dataset generated by this analysis, our approach is not 
to provide a detailed discussion of genes or processes affected by genotype, but to 
summarize the results and provide our bioinformatics analysis (as Tables and 
Supplementary Tables) and make our data available for further analysis by others.  
In addition, the differentially expressed gene list generated from, PMSG-treated 
ESR1KO versus PMSG-treated WT mice was subjected to gene ontology and 
pathway analysis to increase our understanding of oviductal processes dependent 
on estradiol and ESR1 that may be identified as key regulators of fertility in the 
future.
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 Methods 
 
Animals and Tissue Collection 
 
All animal procedures were approved by the University of Kentucky 
Institutional Care and Use Committee.  Mice with a global deletion of ESR1 
(ESR1KO) on a C57BL/6 background were generated as previously described [23, 
141].  Briefly, two transgenic mouse lines were used, male ESR1flox/flox were bred 
with female Zp3cre to produce a line expressing cre recombinase in the oocyte.  The 
F1 heterozygotes (ESR1flox/+Zp3cre) were bred with ESR1flox/flox resulting in 
ESR1flox/floxZp3cre mice, where females produce oocytes that are ESR1-.  The ESR1- 
oocytes were then fertilized with sperm from ESR1flox/flox males resulting in 
ESR1flox/- progeny.  Inbreeding of two ESR1flox/- mice produces a litter where one 
fourth of progeny are ESR1-/-.  Female littermates that expressed ESR1 served as 
wild-type (WT) controls.  Genomic DNA was extracted from ear punches using the 
Easy DNA kit (Invitrogen, Carlsbad CA) to confirm genotypes, as previously 
described [23, 141].  Whole oviducts were collected for extraction of RNA from 
immature female mice (ESR1KO and WT) killed at 23 days of age, or ESR1KO and 
WT mice treated with 5 IU PMSG at 23 days of age and killed 48 h later.   
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RNA Extraction and Analysis 
 
Oviducts were pooled from 3-4 mice per treatment group and total RNA was 
extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) and purified through 
RNeasy columns (Qiagen, Valencia, CA), as described before [23].  RNA was analyzed 
for quality and quantified by spectrophotometry using an Eppendorf BioPhotometer 
Plus (Eppendorf, Hamburg, Germany) with a mean 260/280 ratio of 1.75±0.10 
among all samples.  Aliquots of the same total RNA were used for both microarray 
and real-time reverse-transcription PCR (real-time RT-PCR).   
 
Microarray Hybridization and Analysis 
 
A total of 12 microarray hybridizations were performed using the Affymetrix 
Genechip Mouse Genome 430-2.0 arrays (GeneChip, Affymetrix, Inc., Santa Clara, 
CA) according to the manufacturer’s instructions at the University of Kentucky 
Microarray Core Facility, as described before [142].  Three replicates using different 
mice were generated for each treatment group.    
 Microarray data were analyzed by importing raw expression intensity values 
(*.cel files) into Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO), where the GC-
Robust Multiarray Analysis algorithm (GC-RMA), quantile normalization, and 
Median Polish was applied for GeneChip background correction, log base 2 
transformation, conversion of expression values and probeset summarization.  
Annotation was performed using NetAffx annotation database (Release 34) on 
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December 3rd, 2014.  Quality of data was assessed using light intensity expression 
values on a per chip and per gene basis and visualized as box plots (Figure 5.1).  
Principal component analysis (PCA) was conducted to determine the quality of the 
microarray hybridization and visualize the general data variation among the chips 
(Figure 5.2), as previously described [106].   
 
Figure 5.1.  Box plot of the log2 expression signal for each sample (microarray chip). 
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Figure 5.2.  Principal component analysis of microarray transcriptome results of 
oviducts collected from ESR1KO and WT littermates with or without PMSG 
treatment.  Red: 0 hr ESR1KO, Blue: 0 hr WT, Green: PMSG-treated ESR1KO, Purple: 
PMSG-treated WT mice. 
 For statistical analysis, to detect differentially expressed genes (DEG’s) and 
the interaction between genotype and PMSG treatment, the normalized and 
background adjusted microarray data were imported into Partek Genomics suite 6.6 
(Partek, Inc.) and a two-way ANOVA performed with factor 1 being genotype and 
factor 2 being PMSG treatment.  Statistical significance of difference for each gene 
was set to P-value <0.01 with Benjamini-Hochberg multiple testing correction for 
false discovery rate (FDR) < 0.13.  Genes considered significant in the overall model 
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(P < 0.01, FDR < 0.13) were then subjected to pairwise comparisons using Fischer’s 
Least Significant Difference (LSD) test to estimate the significance of difference for 
each gene in each comparison.  Genes showing a mean difference in signal intensity 
of at least 2-fold change and a P-value < 0.01 were considered differentially 
expressed.  
All the microarray raw data (13 *.cel files) collected and GCRMA-normalized 
and log2 transformed intensity values will be deposited into the Gene Expression 
Omnibus (National Center for Biotechnology Information, 
http://www.ncbi.nlm.nih.gov/geo). 
 
Gene Ontology Analysis 
 
 The DEG list (1185 DEG’s) from, PMSG-treated ESR1KO versus PMSG-treated 
WT mice was subjected to gene ontology and pathway analysis.  Differentially 
expressed genes were interrogated for their gene ontology (GO) classes using Partek 
Genomics Suite 6.6 (Partek, Inc.).  Partek derives gene ontology classifications from 
geneontology.org and/or the affymetrix database.  GO hierarchies leads to the 
division of the gene list into significant classifications when the observed number of 
differentially expressed genes in a GO category is greater than expected.   Statistical 
analysis for significant classifications was performed using Fischer’s exact test, 
right-tailed.  A P-value < 0.01 is suggestive of an over representation of genes from 
within a particular GO category, indicative of a functional effect. 
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Pathway Analysis 
  
 The list of DEG’s from PMSG-treated ESR1KO versus PMSG-treated WT mice 
was then subjected to Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) which uses multiple databases to extrapolate 
significant pathways based on the number of significant genes within our list and 
known to be involved in a particular pathway.  To determine significant pathways in 
the oviducts of PMSG-treated ESR1KO versus PMSG-treated WT treated mice, a 
Fischer’s exact test was performed with significance set to P-value < 0.05. 
 
Real-time RT-PCR Analysis 
 
Pathway analysis revealed that the most significant pathways were reflective 
of immune responses.  Therefore, to validate the microarray analysis, real-time RT-
PCR for a selection of mRNA known to be involved in immune response pathways 
was performed using an Eppendorf Mastercycler ep realplex2 system (Eppendorf) 
using iQ SYBR Green Supermix (Bio-RAD, Hercules, CA), as described before [23].  
Briefly, cDNA was synthesized using the SuperScript III 1st Strand Synthesis System 
(Invitrogen), with 0.5 µg of RNA used for each reverse transcription reaction.  Real-
time RT-PCR was performed with a total volume of 25 μl per reaction, with each 
reaction containing 5 μL of cDNA, 1 μL of a 10 μM stock of each primer (forward and 
reverse), 12.5 μL of 2× SYBR Green PCR Master Mix, and 5.5 μL of nuclease-free 
water.  Gene expression was analyzed by the 2−ΔΔCT method [111].  The typical 
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dissociation curves of these cDNA, plus Gapdh as the housekeeping gene was 
confirmed. The following oligonucleotide primer pairs were used:  Ccl5: F: CCT CAC 
CAT ATG GCT CGG AC and R: ACG ACT GCA AGA TTG GAG CA; Cyp26a1: F: AGC TCC 
TGA TTG AGC ACT CG and R: GGA GGA TTC AAT CGC AGG GT; Hpgds: F: CAC TAG 
TTT CCT GGC TAG GGT and R: TGT CAC AGC TCC TTT CCT TGT; Il18rap: F: TGC AAT 
GAA GCG GCA TCT GT and R: CCG GTG ATT CTG TTC AGG CT; Lrat: F: GTC GCC CAT 
CTA ATG CCT GA and R: CTG TGG ACT GAT CCG AGA GC; Ptgs2: F: CAT CCC CTT CCT 
GCG AAG TT and R: CAT GGG AGT TGG GCA GTC AT; S100a8: F: CTT TCG TGA CAA 
TGC CGT CTG and R: AGA GGG CAT GGT GAT TTC CT; Upk1a: F: TGA GCA AGA GTG 
TTG TGG CA and R: CAC GAT ATG CCC CAC GTG TA; Gapdh: F: CCC CCA ATG TGT CCG 
TCG TGG and R: TGA GAG CAA TGC CAG CCC CG.  
For statistical analysis of real-time RT-PCR results, datasets were first tested 
for normality and equal variance.  When appropriate, data were transformed before 
statistical analysis.  A one-way ANOVA using SigmaStat 3.5 (Systat Software, Inc., 
Point Richmond, CA, USA) was used to determine differences in levels of mRNA.  
When differences were detected a Fischer’s Least Significant Difference (LSD) test 
was used to determine which genes differed.
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Results 
 
Real-time RT-PCR Analysis of Selected mRNA 
 
The expression of mRNA for Ccl5, Cyp26a1, Hpgds, Il18rap, Lrat, Ptgs2, 
S100a8, and Upk1a in the oviducts of PMSG-treated ESR1KO versus PMSG-treated 
WT mice was determined by real-time RT-PCR.  A comparison of the results 
obtained by real-time RT-PCR and microarray analysis is presented in Table 5.1.  
Overall, real-time RT-PCR revealed the same directional trends in gene expression 
that were observed by microarray analysis. 
Table 5.1. Comparison of gene expression for selected mRNA by 
Microarray and Real-time RT-PCR in oviducts collected from PMSG-
treated ESR1KO versus PMSG-treated WT mice. 
ESR1 KO + PMSG trt vs. WT + PMSG trt  
  Microarray Real-time RT-PCR 
Gene Symbol  Fold-Change 
P- 
value 
Fold-Change 
P-
value 
Ccl5 2 0.166 4.2 < 0.001 
Cyp26a1 -131.1 < 0.001 -27.4 < 0.001 
Hpgds -73.4 < 0.001 -13.4 < 0.001 
Il18rap 1 0.22 6.2 < 0.001 
Lrat -53.5 < 0.001 -21.8 < 0.001 
Ptgs2 (Cox2) 1.57 0.24 2.19 < 0.001 
S100a8  20.7 0.0006 18.02 < 0.001 
Upk1a  -77.1 < 0.001 -38.9 < 0.001 
Fold-Change in gene expression and P-values are indicated after 
analysis by microarray and by independent real-time RT-PCR. 
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Detection of differentially expressed genes by Microarray Analysis 
 
 After chip normalization, a statistical two-way ANOVA and pairwise 
comparison (LSD test) was performed to generate a list of 2428 differentially 
expressed genes (Table 5.2, P < 0.01, FDR < 0.13).  Genotype affected the expression 
of 2215 genes, PMSG affected the expression of 465 genes, and Genotype x PMSG 
affected the expression of 438 genes.  Following removal of unannotated and 
duplicate probesets, DEGs were further subdivided between up- and down-
regulated genes.
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In PMSG-treated ESR1KO versus PMSG-treated WT oviducts, the identity of 
most highly up- and down-regulated genes is provided in Table 5.3 and the total 
differentially regulated genes from this pairwise comparison are provided as 
Supplementary Table 1. 
Table 5.3. Most highly up- and down-regulated genes from PMSG-treated 
ESR1KO versus PMSG-treated WT mouse oviducts. Significance set to P < 
0.01. Cutoff is 2 fold-change in expression. 
Gene Symbol Gene Description 
P-
value 
Fold-
Change 
BC048679 cDNA sequence BC048679 <0.001 222.15 
Apod apolipoprotein D <0.001 98.02 
Cdh16 cadherin 16 <0.001 50.13 
Chodl Chondrolectin <0.001 48.14 
Sult1e1 sulfotransferase family 1E, member 1 <0.001 46.32 
G6pc2 glucose-6-phosphatase, catalytic, 2 <0.001 42.88 
Pla2g10 phospholipase A2, group X <0.001 40.8 
Fgf18 fibroblast growth factor 18 <0.001 38.17 
Avpr1a arginine vasopressin receptor 1A <0.001 35.78 
Aldh1a3 
aldehyde dehydrogenase family 1, 
subfamily A3 
<0.001 34.76 
Lrrtm1 
leucine rich repeat transmembrane 
neuronal 1 
<0.001 29.44 
Serpina1b 
serine (or cysteine) preptidase 
inhibitor, clade A, member 1B 
<0.001 27.57 
Ager 
advanced glycosylation end product-
specific receptor 
<0.001 22.77 
Synpr Synaptoporin <0.001 22.32 
S100a8 
S100 calcium binding protein A8 
(calgranulin A) 
<0.001 20.77 
Adamts16 
a disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 mo 
<0.001 19.82 
Il18r1 interleukin 18 receptor 1 <0.001 19.45 
S100a9 
S100 calcium binding protein A9 
(calgranulin B) 
0.0015 17.86 
Atp6v1b1 
ATPase, H+ transporting, lysosomal V1 
subunit B1 
<0.001 17.8 
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Table 5.3. (Continued) 
Wnt7a 
wingless-related MMTV integration 
site 7A 
<0.001 17.49 
Dcpp3 demilune cell and parotid protein 3 <0.001 -770.92 
2300002M23Rik RIKEN cDNA 2300002M23 gene <0.001 -524.94 
Cyp26a1 
cytochrome P450, family 26, subfamily 
a, polypeptide 1 
<0.001 -131.13 
Tshr thyroid stimulating hormone receptor <0.001 -121.71 
Dcpp1/2/3  
demilune cell and parotid protein 
1/2/3 
<0.001 -106.94 
Syn2 synapsin II <0.001 -91.45 
Slc6a2 
solute carrier family 6 
(neurotransmitter transporter, 
noradrenalin), member 2 
<0.001 -77.2 
Upk1a uroplakin 1A <0.001 -77.14 
Hpgds 
hematopoietic prostaglandin D 
synthase 
<0.001 -73.37 
Klk1b24 kallikrein 1-related peptidase b24 <0.001 -73.19 
Greb1 
gene regulated by estrogen in breast 
cancer protein 
<0.001 -64.6 
Klk1b1 kallikrein 1-related peptidase b1 <0.001 -62.94 
Klk1b21 kallikrein 1-related peptidase b21 <0.001 -53.58 
Lrat 
lecithin-retinol acyltransferase 
(phosphatidylcholine-retinol-O-
acyltransferase) 
<0.001 -53.53 
Gria1 
glutamate receptor, ionotropic, AMPA1 
(alpha 1) 
<0.001 -46.45 
Akr1c14 
aldo-keto reductase family 1, member 
C14 
<0.001 -45.65 
Stat5a 
signal transducer and activator of 
transcription 5A 
<0.001 -44.22 
Col6a4 collagen, type VI, alpha 4 <0.001 -43.1 
Rasd1 RAS, dexamethasone-induced 1 <0.001 -42.74 
Adh7 
alcohol dehydrogenase 7 (class IV), mu 
or sigma polypeptide 
<0.001 -42.46 
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Gene Ontology and Ingenuity Pathway Analysis of DEG’s in the oviducts of PMSG-
treated ESR1KO versus PMSG-treated WT mice 
 
 To determine the molecular functions, cellular components, and biological 
processes of DEG’s expressed in the oviducts of PMSG-treated ESR1KO versus 
PMSG-treated WT mice, Gene Ontology and Ingenuity Pathway Analyses were 
performed with significance set to enrichment P-value < 0.01.  The significantly 
enriched molecular function categories using GO are indicated in Figure 5.3A.  The 
five categories with the highest enrichment score within molecular functions were 
binding, protein binding, receptor binding, catalytic activity, and calcium ion 
binding.  Significantly enriched cellular component categories are indicated in 
Figure 5.3B.  The most highly enriched cellular component categories were 
extracellular region, extracellular region part, extracellular space, extracellular 
matrix, and membrane.  Significantly enriched biological processes are indicated in 
Figure 5.3C, with the most highly enriched categories being single organism process, 
positive regulation of biological process, single organism cellular process, regulation 
of multicellular organismal process, and positive regulation of cellular process. 
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A. 
B. 
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Figure 5.3.  Gene ontology analysis from PMSG-treated ESR1KO versus PMSG-
treated WT mice. Significance of gene enrichment set to P-value < 0.01. 
Canonical pathway analysis of DEG’s from PMSG-treated ESR1KO versus 
PMSG-treated WT mice was performed using QIAGEN’S Ingenuity Pathway Analysis 
(IPA, QIAGEN, Redwood City, www.qiagen.com/ingenuity).  The six most significant 
pathways identified by Ingenuity Pathway Analysis software are provided in Figure 
5.4, all are reflective of ESR1-regulation of the immune response (P<0.05).   
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Discussion and Conclusions  
 
 A normally functioning oviduct is essential for gamete maturation and 
transport, fertilization, and early conceptus development.  Although immune 
responses and inflammation in the oviduct is a required physiological occurrence, 
aberrant inflammation can lead to oviductal disease and/or ectopic pregnancy 
necessitating woman to seek treatment for infertility.  Estradiol is a known 
regulator of oviductal function with estrogen receptor alpha (ESR1) expression 
abundant in the epithelial mucosa; however, estradiol and ESR1-dependent changes 
in mRNA expression in the oviduct have yet to be fully elucidated.  Furthermore, 
increasing our understanding of the role of estradiol and ESR1 in immune responses 
may lead to the development of novel treatment options that specifically target 
inflammatory responses.  The objective of this study was to identify estradiol and 
ESR1 dependent differences in gene expression between whole oviducts collected 
from ESR1 knockout and wild-type littermates at 0 hr as well as 48 hr after 
treatment with PMSG using Affymetrix Mouse 430-2.0 genome arrays.  Overall, 2428 
genes were differentially regulated within our model with significance set to P < 
0.01.  Real-time RT-PCR performed on selected mRNA confirmed expression results 
obtained my microarray.   
For the purposes of this study and of physiological importance we evaluated 
gene expression changes between ESR1KO and WT littermates 48 hr after PMSG 
treatment.  The present study utilized immature mice because abnormal ovarian 
histology is not observed in ESR1KO females until after puberty and the 
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steroidogenic capacity of mature WT mice will clearly have an effect on gene 
expression.  After the 2428 DEGs from our model were identified a pairwise 
comparison of PMSG treated ESR1KO and WT mice was performed and revealed 
1185 differentially regulated genes with at least a 2 fold-change in signal intensity 
and a P-value < 0.01. 
Our objective herein is not to discuss the role of individual genes identified as 
differentially regulated in detail, but rather provide examples of consistency among 
our profiling results with previous targeted analyses performed by others.  Several 
of the top up-regulated DEGs were found to be involved in the inflammatory 
response with specific functions associated with chemotaxis and activation of 
immune cells.  Understanding the molecular mechanisms of the immune response 
within the oviduct is of particular interest as aberrant inflammation is one of the 
major causes of pelvic inflammatory disease in women [143].  For example, S100 
calcium binding protein A8 and A9 (S100A8/9) were found to increase 21-and 18-
fold, respectively in ESR1KO mice when compared to WT after PMSG treatment.  
The S100 calcium binding proteins have been implicated in the regulation of cell 
growth and differentiation, but more interestingly are associated with many chronic 
inflammatory diseases [142].  As reviewed by Passey et al., 1999, S100A8/9 have 
pro- and anti-inflammatory properties depending on cellular expression and 
physiological condition however, the specific role of these proteins is unclear but 
have been suggested to modulate leukocyte trafficking [144, 145].  Also of note is 
the 19-fold increased expression of interleukin 18 receptor 1 (Il18r1) in PMSG-
treated ESR1KO mice.  The Il-18 receptor consists of two subunits with the Il18r1 
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subunit being involved in ligand binding and mRNA levels have been found to 
increase during estrus.  The ligand for Il18r1 is interleukin-18 (IL-18) which acts as 
a pro-inflammatory cytokine involved in stimulating Interferon-γ (Ifn-γ) during 
chronic inflammatory conditions [146].  Studies have reported Il-18 expression in 
the uterus [147] and ovaries [148] of mice and down-regulation by estrogen has 
been noted [147, 149].  Our study did not identify Il-18 as differentially regulated 
however, Otsuki et al., 2007, reported increases in Il18r1 mRNA expression in the 
mouse endometrium after ovariectomy and estradiol-17β reversed this effect [150].  
The findings of the current study support the regulation of Il18r1 by estrogen and 
ESR1 expression in the oviduct.   
Of the 1185 DEGs in PMSG-treated ESR1KO versus PMSG-treated WT mice, 
496 (42%) were down-regulated.  The hematopoietic form of prostaglandin D 
synthase (HPGDS) was recently localized to the oviduct’s epithelium and a 
dependence of HPGDS expression on ESR1is reported [23].  This synthase is 
hypothesized to be a regulator of oviductal inflammation and our current data 
supports this hypothesis as a 73 fold decrease in HPGDS mRNA expression was 
observed in our dataset.  Of interest are the demilune cell and parotid protein 1/2/3 
(Dcpp1/2/3) genes which were found to decrease significantly in our study.    
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Previously, Dcpp expression has been localized to the oviduct epithelium and 
are suggested estrogen responsive genes as expression increasing during estrus and 
is up-regulated in ovariectomized mice treated with estrogen [151].  The specific 
functions of Dcpp in the oviduct are not clear, but Dcpp immunostaining has been 
described in mouse embryos and the presence of embryos is reported to modulate 
Dcpp expression in the mouse oviduct suggesting a role of this gene in 
embryogenesis [151].   
Gene ontology classification of the 1185 DEGs from PMSG-treated ESR1KO 
versus PMSG-treated WT mice revealed an over representation of genes associated 
with binding from within the GO Category “molecular functions” and the 
extracellular region in the GO category “cellular compartment”. Taken together an 
enrichment of gene products associated with binding activities and localized to the 
extracellular region in the PMSG-treated ESR1KO mice may be reflective of gene 
product transport and release into the oviduct lumen.  Futhermore, gene 
enrichment for the GO category “biological process” depicts the response of the 
oviduct to stimuli, such as steroid hormones.   
To further understand the biological roles of ESR1 in the mouse oviduct, the 
1185 DEGs from PMSG-treated ESR1KO versus PMSG-treated WT mice was 
analyzed using Ingenuity Pathway Analysis (IPA®, QIAGEN), which uses multiple 
databases to extrapolate significant canonical pathways based on the number of 
genes expected to be expressed within each pathway.  The top canonical pathway, 
axonal guidance signaling, relates to functions associated with cell morphology, 
cellular assembly and organization, cellular function and maintenance.  Previous 
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studies have reported normal oviduct morphology in immature ESR1KO mice [23], 
however the current results warrant further investigation in to the potential 
morphological differences between ESR1KO and WT mouse oviducts.  Several 
pathways associated with the immune response were significant in our dataset 
including leukocyte extravasation signaling which is the process of leukocyte 
migration from blood to tissue during the inflammatory response.  Adult ESR1KO 
mice are known to display altered hormone profiles including elevated testosterone 
and luteinizing hormone levels which could in itself affect the immune response 
[152].  The current study, however utilized immature mice to reduce these affects 
suggesting ESR1 dependent mechanisms involved in modulating the immune 
response within the oviduct.   
To conclude, these results give us further insights into the genes regulated by 
estrogen and ESR1 expression.  Pathway analysis underline the complex role of 
estrogens in regulating the immune response within the oviduct and potential ESR1 
dependent molecules involved.  
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CHAPTER 6. 
INTRAPERITONEAL ADMINISTRATION OF LIPOPOLYSACCHARIDE INDUCES 
DIFFERENTIAL EXPRESSION OF mRNA ENCODING INFLAMMATORY 
MEDIATORS IN THE OVIDUCTS OF MICE 
Abstract 
Infection with gram-negative bacteria is a major cause of aberrant 
inflammation in the oviduct; consequences can include tubal infertility and/or 
ectopic pregnancy in women.  Understanding inflammatory responses due to 
bacterial infection is necessary for the development of novel treatment options that 
specifically target inflammatory responses. Our objective was to test the hypothesis 
that intraperitoneal (IP) administration of E. Coli -derived lipopolysaccharide (LPS) 
induces the expression of inflammatory mRNAs in the mouse oviduct.  On the day of 
estrus, 6-8 week old CD1 mice (n=4/treatment) were treated IP with 0 (control), 2 
ug (low dose) or 10 ug (high dose) of LPS from E. Coli serotype 055:B5 in 100 ul PBS.  
Mice were killed 24 h later and the oviducts collected for determination of 
inflammatory gene expression by a targeted nanostring approach using the 
nCounter GX Mouse Inflammation Kit (Nanostring Technologies, Seattle, Wa).  Real-
time PCR was used to validate selected mRNAs.  The effect of LPS was evaluated by 
one-way ANOVA and treatment means of differentially expressed mRNA (P<0.05) 
were separated using a post-hoc LSD test.  56/179 targeted genes were affected by 
treatment (P<0.05).  Pairwise comparison revealed 8 mRNA differentially expressed 
in control vs low dose, 50 mRNAs in control vs high dose and 43 mRNAs in low vs 
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high dose (P<0.05).  These results indicate that systemic treatment with LPS induces 
inflammation in the oviducts of mice and provides evidence of a new model to 
investigate the regulation of oviductal inflammation in the future.  
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Introduction 
 
Infection with gram-negative bacteria is a major cause of aberrant 
inflammation in the reproductive tract of animals and humans.  If left untreated the 
bacteria can ascend to and infect the oviduct; consequences can include pelvic 
inflammatory disease (PID), oviduct epithelial cell death, tubal infertility and/or 
ectopic pregnancy [2, 153].   Knowledge of gene expression patterns involved with 
inflammatory response mechanisms in the oviduct is not as extensive compared to 
other regions of the reproductive tract.  Understanding inflammatory responses due 
to bacterial infection is necessary for the development of novel treatment options 
that specifically target inflammatory responses.  
When bacteria are introduced, Toll-like receptors present on immune cells 
recognize and bind LPS, initiating a pro-inflammatory response with the production 
of cytokines and chemokines [154-156].  A systemic and local LPS induced immune 
response has been described previously for in vitro and in vivo models investigating 
implantation, conceptus viability, and pregnancy loss [157-160].  Recently, Brecchia 
et al., 2014, described an in vivo rabbit model of systemic inflammation by intra-
peritoneal administration of LPS and assessed the effects on uterine and oviductal 
function.  The results showed that IP-LPS treatment in female rabbits negatively 
affected reproductive function [161].  
However, few in vivo studies specifically target oviductal inflammatory gene 
expression in response to systemic administration of LPS.   Considering the oviduct 
plays a critical role in gamete transport and maturation, fertilization, and early 
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conceptus development, there is a need for a reliable and repeatable animal model 
that allows for the study of inflammatory mechanisms in the oviduct.  Using LPS as 
an independent inflammatory insult, the objective of this study was to provide 
evidence for a model of systemic inflammation and determine expression changes of 
inflammatory mRNAs in the oviducts of mice following IP injection with 0 (control), 
2 ug (low dose) or 10 ug (high dose) of LPS from E. Coli in 100 ul PBS.   
 
Methods 
 
Animals and Tissue Collection 
 
Animal procedures involved in this study were approved by the University of 
Kentucky Animal Care and Use Committee.  Prior to treatment, normal estrous cycle 
was confirmed in 6-8 week old CD1 mice by analysis of vaginal cytology, as 
described previously [142].  Briefly, vaginal smears were collected daily, at the same 
time each day, using PBS and a bent, blunted borosilicate glass pipette.  Vaginal 
cytology’s were evaluated under a Motic AE21 inverted microscope (Motic 
Instruments, Richmond, British Columbia, Canada) and classified according to well-
established morphological criteria and digital images recorded for later reference 
[162].  On the day of estrus, mice were treated with 0 (control), 2 ug (low dose) or 
10 ug (high dose) of LPS from E. Coli serotype 055:B5 in 100 ul PBS (Sigma-Aldrich, 
Saint Louis MO) via intraperitoneal (IP) injection (n=4/treatment).  Twenty four 
hours later, vaginal smears were collected to determine whether treatment affected 
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estrous cycle progression and mice were killed for collection of oviducts.  Tissues 
for gene expression analysis were snap-frozen for later extraction of RNA.  
 
RNA Extraction and Analysis 
 
 Total RNA was extracted from single oviducts using Trizol reagent  
(Invitrogen Corporation, Carlsbad, CA, USA) and purified with RNeasy columns 
(Qiagen, Valencia, CA, USA) according to manufacturer’s instructions.  RNA quality 
was analyzed by determining the RNA integrity number (RIN) using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA) at the University of Kentucky 
Microarray Core Facility.  RNA integrity numbers were greater than 9.7 and 
28S/18S rRNA absorbance ratios greater than 2.0 for all samples and all samples 
passed the quality control measurements required for this platform. 
 
NanoString nCounter® Gene Expression Profiling 
 
Nanostring analysis was performed using the nCounter® GX Mouse 
Inflammation Kit (Nanostring Technologies, Seattle, Wa) which consists of 179 
inflammation related genes and six internal reference genes.  Analysis was 
performed according to the manufacturer’s instructions at the University of 
Kentucky Microarray Core Facility as described previously [163].  The Digital 
multiplexed NanoString nCounter analysis system uses molecular barcodes to detect 
and count transcripts.  Briefly, 100 ng of total RNA from each sample was hybridized 
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with reporter and capture probes which hybridize directly to target molecules.  
After hybridization sample processing allows for probe/target complexes to be 
immobilized on the nCounter cartridge and unbound probes removed.  After sample 
processing digital data acquisition allows for barcodes on reporter probes to be 
tabulated for each target molecule.  The raw reported code count data generated 
from the nCounter Digital Analyzer was exported to nSolver software (NanoString 
Technologies) for normalization, background assessment, and molecule count 
summarization as previously described [164].  For NanoString nCounter data, 
positive control normalization is used to reduce sources of variation associated with 
hybridization, purification, and binding efficiency.  This is accomplished through 
positive spike-in RNA hybridization controls to estimate the experimental variables 
based on a calculated positive control scaling factor.  Gene normalization was 
performed to correct for differences in sample input between assays by using the 
geometric mean of 3 reference genes (Gapdh, Pgk1, Tubb5), which expression 
values did not differ between treatments.  Negative control probes are also included 
in the assay which is used to assess background counts and decrease false discovery 
rate by determining the presence or absence of target molecules.   
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 Following normalization procedures, background adjustment, and count 
summarization, the resulting data were imported into Partek Genomics Suite 6.6 
(Partek Inc., St. Louis, MO, USA) for statistical analysis.  One-way ANOVA was used to 
determine differences in relative molecule count and significance was set to P-value 
< 0.05.  If differences were detected, treatment means were separated using 
Fischer’s Least Significance difference (LSD) test to determine which means differed 
[107, 108].  An expression difference between treatments of P-value < 0.05 was 
considered statistically significant. 
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Real-time RT-PCR Analysis 
 
Real-time PCR was performed to validate expression of mRNAs for 
Chemokine (C-C motif) ligand 5 (Ccl5), Chemokine (C-X-C motif) ligand 1 (Cxcl1), 
Chemokine (C-X-C motif) ligand 10 (Cxcl10), Chemokine (C-X-C motif) receptor 2 
(Il8rb), Interleukin 18 receptor accessory protein (Il18rap) using an Eppendorf 
Mastercycler ep realplex2 system (Eppendorf, Hamburg, Germany) with iQ SYBR 
Green Supermix (Bio-RAD, Hercules, CA USA), as described before [23].  The 
following oligonucleotide primer pairs were used: Ccl5, F: CCT CAC CAT ATG GCT 
CGG AC and R: ACG ACT GCA AGA TTG GAG CA; Cxcl1, F: ACT CAA GAA TGG TCG CGA 
GG and R: GTG CCA TCA GAG CAG TCT GT; Cxcl10, F: CTA TCC TGC CCA CGT GTT GA 
and R: TCC ACT GGG TAA AGG GGA GT; Il8rb, F: CTT AGC CAA GGA GGG AAG GC and 
R: GGG CTC TGC TAA GAA CGGT GA; Il18rap, F: TGG AAT GAA GCG GCA TCT GT and 
R: CCG GTG ATT CTG TTC AGG CT; Gapdh, F: CCC CCA ATG TGT CCG TCG TGG and R: 
TGA GAG CAA TGC CAG CCC CG. 
Briefly, cDNA was synthesized using the SuperScript III 1st Strand Synthesis 
System (Invitrogen), with 0.5 µg of RNA used for each reverse transcription 
reaction.  Real-time RT-PCR was performed with a total volume of 25 μL per 
reaction, with each reaction containing 5 μL of cDNA, 1 μL of a 10 μM stock of each 
primer (forward and reverse), 12.5 μL of 2× SYBR Green PCR Master Mix, and 5.5 μL 
of nuclease-free water.  The typical dissociation curves of these cDNA, plus Gapdh as 
the housekeeping gene was confirmed and gene expression was analyzed by the 
2ΔΔCT method [111].  For real-time RT-PCR analysis, expression values within a 
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transcript were tested for normality and homogeneity of variance and, when 
appropriate (Il18rap, Il8rb), a natural log transformation was conducted to 
normalize variation before statistical analysis of LPS treatment effects by one-way 
ANOVA using SigmaStat 3.5 (Systat Software, Inc., Point Richmond, CA).  When 
affected (P < 0.05), the treatment means were separated using Fischer’s LSD test.   
 
Results 
 
Real-time RT-PCR Analysis of Selected Transcripts 
 
 To test the hypothesis that IP injected e.coli derived LPS effects inflammatory 
mRNAs in the oviduct, gene expression analysis using the NanoString nCounter GX 
Mouse Inflammation Kit (Nanostring Technologies) was performed.  The expression 
of selected mRNAs as described in the materials and methods were reevaluated by 
independent real-time RT-PCR.  The results obtained by NanoString and real-time 
RT-PCR were consistent (Table 6.1). 
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NanoString nCounter Gene Expression Analysis 
 
 Of the 179 targeted genes within the nCounter GX Mouse Inflammation Kit, 
56 were affected by treatment with LPS (P < 0.05).  As depicted in the venn diagram 
(Figure 6.1), two genes (Il8rb and Ccl8) overlapped between the contrasts.  In 
oviducts collected from mice treated with low dose (2 ug) LPS, the expression of 
mRNA encoding 6 inflammation related genes increased and 2 genes decreased 
compared to mice treated with PBS only (Table 6.2, P < 0.05). 
Figure 6.1.  Venn diagram depicting the number of differentially genes between 
high dose (10 ug LPS), low dose (2 ug LPS) and control oviducts collected from CD1 
mice. 
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In oviduct samples collected after treatment with high dose (10 ug) LPS, the 
expression of mRNA encoding 50 inflammation related genes were differentially 
expressed (P < 0.05) with expression of all mRNA increasing compared to controls 
(Table 6.3).  Mean values of significant mRNA (P<0.05) in oviducts collected from 
high dose (10 ug) LPS versus low dose (2 ug) LPS were separated using Fischer’s 
LSD test and revealed 43 mRNA differentially expressed with only  the expression of 
one mRNA (Pik3c2g) decreasing in the high dose when compared to the low dose 
(Table 6.4).
Table 6.2. Differentially expressed transcripts between low dose (2 ug LPS) and 
control (PBS only) oviducts collected from CD1 mice (P < 0.05). 
Gene 
Symbol 
Gene Description Fold-
change 
P- 
value 
Ccl22 Chemokine (C-C motif) ligand 0.62 0.01 
Shc1 src homology 2 domain-containing transforming 
protein C1 (Shc1), transcript variant 2 
0.90 0.01 
Il8rb chemokine (C-X-C motif) receptor 2 4.95 0.02 
C3ar1 complement component 3a receptor 1 1.86 0.03 
Ccl8 Chemokine (C-C motif) ligand 4.76 0.03 
C1qa complement component 1, q subcomponent, alpha 
polypeptide 
2.21 0.04 
C1qb complement component 1, q subcomponent, beta 
polypeptide 
1.96 0.04 
Ccr7 chemokine (C-C motif) receptor 7  3.51 0.05 
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Table 6.3. Differentially expressed transcripts between high dose (10 ug LPS) and 
control (PBS only) oviducts collected from CD1 mice (P < 0.05). 
Gene 
Symbol 
Gene Description Fold-
change 
P-
value 
Ccl7 Chemokine (C-C motif) ligand 17.69 < 0.001 
C1r complement component 1, r subcomponent A  4.33 < 0.001 
Cxcl10 Chemokine (C-X-C motif) ligand 15.50 < 0.001 
Ccl2 Chemokine (C-C motif) ligand 13.87 < 0.001 
C1s complement component 1, s subcomponent 4.55 < 0.001 
Il8rb chemokine (C-X-C motif) receptor 2 (Cxcr2) 10.81 < 0.001 
Cd40 
tumor necrosis factor receptor superfamily 
member 5 
2.82 < 0.001 
C3 complement component 3 3.91 < 0.001 
Tlr2 toll-like receptor 2  2.87 < 0.001 
Cfb complement factor B 26.94 < 0.001 
Il15 Interleukin 15 1.81 < 0.001 
Ccl8 Chemokine (C-C motif) ligand 9.00 < 0.001 
Csf1 colony stimulating factor 1  1.93 < 0.001 
C4a complement component 4A 3.53 < 0.01 
Cxcl9 Chemokine (C-X-C motif) ligand 45.79 < 0.01 
Tnfsf14 
tumor necrosis factor (ligand) superfamily, 
member 14  
2.43 < 0.01 
Stat1 signal transducer and activator of transcription 1  3.35 < 0.01 
Il18rap interleukin 18 receptor accessory protein 3.05 < 0.01 
Il23r interleukin 23 receptor 2.84 < 0.01 
Ccl4 Chemokine (C-C motif) ligand 4 3.47 < 0.01 
Cxcl1 Chemokine (C-X-C motif) ligand 7.07 < 0.01 
C2 complement component 2  2.33 < 0.01 
C3ar1 complement component 3a receptor 1 2.41 < 0.01 
Ly96 Lymphocyte Antigen 96 1.38 < 0.01 
C1qb 
complement component 1, q subcomponent, beta 
polypeptide 
2.70 < 0.01 
Il1b interleukin 1 beta 2.45 < 0.01 
Tgfb1 transforming growth factor, beta 1  1.44 < 0.01 
Ccl19 Chemokine (C-C motif) ligand 19 2.71 < 0.01 
C1qa 
complement component 1, q subcomponent, alpha 
polypeptide 
2.91 < 0.01 
Ltb lymphotoxin B 2.08 < 0.01 
Tnf tumor necrosis factor  4.14 0.01 
Mapkap
k2 
MAP kinase-activated protein kinase 2 1.20 0.01 
Itgb2 integrin beta 2 2.42 0.01 
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Table 6.3. (Continued) 
Nfkb1 
nuclear factor of kappa light polypeptide gene 
enhancer in B cells 1 
1.25 0.01 
Ccl3 Chemokine (C-C motif) ligand 3.36 0.01 
Mafk 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein K 
1.41 0.01 
Ccr1 chemokine (C-C motif) receptor 1  1.97 0.01 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.32 0.01 
Maff 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein F  
1.67 0.01 
Nos2 nitric oxide synthase 2, inducible  1.94 0.01 
Ccr7 chemokine (C-C motif) receptor 7  4.45 0.01 
Cxcl5 Chemokine (C-X-C motif) ligand 6.56 0.01 
Gusb glucuronidase, beta  1.19 0.01 
Ripk2 
receptor (TNFRSF)-interacting serine-threonine 
kinase 2  
1.50 0.02 
Cxcl2 Chemokine (C-X-C motif) ligand 4.57 0.02 
Il1rn interleukin 1 receptor antagonist 2.29 0.02 
Ccl17 Chemokine (C-C motif) ligand 1.73 0.02 
Ccl5 Chemokine (C-C motif) ligand 27.21 0.02 
Prkcb1 protein kinase C, beta 1  1.30 0.03 
Il7 Interleukin 1.29 0.03 
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Table 6.4. Differentially expressed transcripts between high dose (10 ug LPS) and 
low dose (2 ug LPS) oviducts collected from CD1 mice (P < 0.05). 
Gene 
Symbol 
Gene Description Fold-
Change 
P-
value 
Ccl7 Chemokine (C-C motif) ligand 8.58 < 0.001 
C1r complement component 1, r subcomponent A  2.54 < 0.001 
Ccl2 Chemokine (C-C motif) ligand 5.73 < 0.001 
Cxcl10 Chemokine (C-X-C motif) ligand 4.59 < 0.001 
C1s complement component 1, s subcomponent 2.50 < 0.001 
Cd40 
tumor necrosis factor receptor superfamily member 
5 
2.00 < 0.001 
Csf1 colony stimulating factor 1  1.91 < 0.001 
C3 complement component 3 2.30 < 0.001 
Tlr2 toll-like receptor 2  2.03 < 0.01 
Il23r interleukin 23 receptor 2.39 < 0.01 
Il8rb chemokine (C-X-C motif) receptor 2 2.18 < 0.01 
Cxcl1 Chemokine (C-X-C motif) ligand 4.62 < 0.01 
Cfb complement factor B 3.16 < 0.01 
Il15 Interleukin 1.47 < 0.01 
C4a complement component 4A 2.27 < 0.01 
Stat1 signal transducer and activator of transcription 1  2.42 < 0.01 
Cxcl9 Chemokine (C-X-C motif) ligand 3.97 < 0.01 
Tgfb1 transforming growth factor, beta 1  1.37 0.01 
Ccl4 Chemokine (C-C motif) ligand 1.97 0.01 
C2 complement component 2  1.66 0.01 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.32 0.01 
Daxx Fas death domain-associated protein 1.23 0.01 
Ripk1 
receptor (TNFRSF)-interacting serine-threonine 
kinase 1  
1.23 0.01 
Tnfsf14 
tumor necrosis factor (ligand) superfamily, member 
14 
1.58 0.01 
Pik3c2g 
phosphatidylinositol 3-kinase, C2 domain 
containing, gamma polypeptide 
0.42 0.01 
Il7 Interleukin 1.36 0.01 
Mafk 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein K 
1.35 0.01 
Ccl8 Chemokine (C-C motif) ligand 1.89 0.01 
Il1b interleukin 1 beta 1.75 0.01 
Tnf tumor necrosis factor  2.62 0.02 
Hspb2 heat shock protein 2  1.52 0.02 
Ccl19 Chemokine (C-C motif) ligand 1.87 0.02 
Ccr1 chemokine (C-C motif) receptor 1  1.70 0.02 
 
88 
 
Table 6.4. (Continued) 
Ly96 Lymphocyte Antigen 96 1.22 0.02 
Cxcl5 Chemokine (C-X-C motif) ligand 4.11 0.02 
Il18rap interleukin 18 receptor accessory protein 1.58 0.03 
Il1rn interleukin 1 receptor antagonist 2.06 0.03 
Ccl22 Chemokine (C-C motif) ligand 1.44 0.03 
Prkcb1 protein kinase C, beta 1 (Prkcb1) 1.27 0.03 
Ltb lymphotoxin B 1.51 0.04 
Ccl17 Chemokine (C-C motif) ligand 1.55 0.04 
Nos2 nitric oxide synthase 2, inducible  1.53 0.05 
Maff 
v-maf musculoaponeurotic fibrosarcoma oncogene 
family, protein F  
1.40 0.05 
 
Discussion and Conclusions 
 
 We hypothesized that systemic treatment with LPS would lead to an increase 
in inflammatory mediators in the oviduct.  Similar to studies of the mouse ovary and 
uterus [158, 165], treatment of LPS as an independent inflammatory insult resulted 
in an increase in inflammatory mRNAs in the oviduct.  Using NanoString nCounter 
technology, our results revealed that IP treatment with E.coli derived-LPS induced 
changes in mRNA encoding inflammation related genes in the oviduct of mice.   
 In agreement with a previous in vitro study by Ibrahim et al., 2015, on the 
effects of LPS on bovine oviductal epithelial cells, increases in gene expression for 
Csf1, Il1b, and Tgfb1 were observed in treated animals compared to controls 
suggesting that the use of IP administered LPS could be a useful in vivo model for 
understanding inflammatory mechanisms in the oviduct [166].  Furthermore, mRNA 
encoding Ccl5, Cxcl1, Cxcl10, Il8rb, and Il18rap were found to increase in treated 
animals compared to controls and was confirmed by independent real-time RT-PCR.  
Of note, mRNA encoding Ccl5 has been reported to increase in the oviducts of 
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Chlamydia trachomatis infected woman [167] and mice [73] and is a 
chemoattractant for monocytes and Th1 cells.  Prolonged production of Ccl5 is also 
associated with tubal damage and scarring after repeated exposure to Chlamydia 
trachomatis [167].  Similar to Ccl5, mRNA levels for the C-X-C motif chemokine Cxcl1 
increased significantly in both the high and low dose animals and is associated with 
gram-negative bacterial infections.  Cxcl1 exerts its neutrophil attractant activity 
through the chemokine receptor Il8rb [168]. Interestingly, increases in the 
expression of Il8rb have been suggested to be associated with inflammation induced 
tubal ectopic pregnancies in woman; however, it has not been determined whether 
Il8rb expression plays a role in the development of ectopic pregnancy or is induced 
by ectopic pregnancy [169].   
In conclusion, understanding regulators of inflammation in the oviduct can 
aid in improving the reproductive health of woman.  The results of this study 
provide evidence of a useful model to further investigate inflammation in the 
oviduct. 
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CHAPTER 7. 
CONCLUSIONS AND IMPLICATIONS 
 Genomic based studies are an increasingly important area in discovery based 
research to understand and analyze the function of biological systems.  In this 
dissertation the oviduct is of interest because this complex organ has received less 
attention in terms of whole genome investigation than other areas of the 
reproductive tract such as the uterus and the ovary.   With advances in bovine 
specific microarray technology, transgenic mouse models, and targeted NanoString 
nCounter technology it is possible to investigate the function of the oviduct at the 
transcriptional level to increase our knowledge and generate data which will serve 
as a base for future studies.   
 The objective of this dissertation was to delineate steroid dependent gene 
expression changes in the oviduct using bovine and mouse models and to further 
analyze the inflammatory response of this organ.  In Chapter 4, bovine oviductal 
epithelial cells were isolated from sections of the ampulla and isthmus during the 
follicular or luteal phase of the estrous cycle to gain a better understanding of the in 
vivo conditions of the oviduct.  Investigating gene expression changes during these 
two phases gives us a baseline for understanding mechanisms regulating oviductal 
function.  In addition, through bioinformatic analyses, important pathways related 
to oviduct function were identified.  For example, pathways upregulated in the 
oviduct during the follicular phase were representative of cholesterol biosynthesis 
which is necessary for the oviduct to prepare for gametes.  In addition, the oxidative 
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phosphorylation pathway was among the most highly upregulated pathways during 
the follicular phase which is indicative of the energy requirements needed for 
cellular processes related to epithelial cell secretions.  Previous bovine studies of 
gene expression changes in the bovine oviduct have largely focused on targeted 
evaluations of gene expression.  The results of the current study not only provided 
support to previous targeted studies, but also identified numerous novel genes 
which may be revealed as mediators of oviductal function in the future.  For 
example, further localizing characterizing novel genes like binder of sperm 3 (BSP3) 
in the oviduct, which is previously described to be secreted by seminal vesicles in 
males and thought to be involved in the formation of the sperm reservoir in the 
oviduct.  The approach in this study utilized young, normally cycling females 
therefore, the data generated could be used as a comparison tool for gene 
expression studies of the oviduct from sub-fertile animals or females undergoing 
estrous cycle manipulation to determine candidate genes which could be used as 
biomarkers of fertility.  Overall, this study provides global oviductal epithelial cell 
gene expression profiles in young, normally cycling heifers.  
 It is well known that the function of the oviduct is dependent on the ovarian-
derived steroid hormones progesterone and estradiol.  The study reported in 
Chapter 5 investigated gene expression in the mouse oviduct collected from ESR1 
mutant mice and WT littermates after treatment of PMSG to identify candidate 
genes and biomolecular processes that may be dependent on ESR1 expression.  
Similar to the transcriptomal study conducted with the bovine oviductal epithelial 
cells in Chapter 4, this study aimed to give insight into ESR1 dependent mechanisms 
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through gene profile lists and bioinformatics analyses.  The implications of the data 
generated identify biological processes that are likely regulated by ESR1 such as cell 
proliferation and differentiation and genes associated with the inflammatory 
response.  In summary, the results indicate many genes and processes regulated by 
ESR1 and may be targets for future analysis for the management of fertility and/or 
oviductal disease.  
 The objective of Chapter 6 was to evaluate an in vivo mouse model of 
systemic inflammation by intra-peritoneal administration of LPS to investigate the 
response of the oviduct regarding inflammatory mediators.  The hypothesis stated 
in Chapter 6 was generated after the gene expression evaluation reported in 
Chapter 5 and appendix 1.  Many genes associated with inflammation were 
differentially regulated in the ESR1 transgenic mouse model leading to the necessity 
to continue to evaluate inflammatory mediators in the oviducts in vivo.  
Furthermore, the study reported in Appendix 1 involved the use of a mouse model 
of genital infection by C. trachomatis; however, the variability in results observed in 
Appendix 1 confirms previous reports with regards to the genetic component of 
susceptibility to C. trachomatis infection in mice.  Considering the importance of the 
oviduct in early reproductive events and infection with gram-negative bacteria is a 
major cause of aberrant inflammation in animals and humans it is necessary to 
establish a repeatable and reliable in vivo model.  Using a targeted NanoString 
approach, the results of chapter 6 indicated an increased expression of pro-
inflammatory molecules after treatment with LPS suggesting that the use of IP 
administered LPS could be a useful model for understanding the mechanisms of 
 
93 
 
inflammation in the oviduct.  Moreover, future studies are planned to investigate the 
potential regulatory miRNAs induced by LPS treatment.   
The translational impact of these genomic studies has the potential to 
identify target molecules and processes to improve production animal and human 
fertility.  By understanding how the oviduct responds to steroidogenesis and 
pathogens, strategies and methodologies to improve reproductive efficiency can be 
explored in the future.  Furthermore, this dissertation provides evidence of a model 
for oviductal dysfunction, which could have widespread impacts to the development 
of treatment options that targets pro-inflammatory molecules.    
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APPENDIX 1. 
DIFFERENTIAL EXPRESSION OF MRNA ENCODING CYTOKINES AND 
CHEMOKINES IN THE REPRODUCTIVE TRACT AFTER INFECTION OF MICE 
WITH CHLAMYDIA TRACHOMATIS. 
Abstract 
Infection with Chlamydia trachomatis targets epithelial cells within the 
genital tract which respond by secreting chemokines and cytokines.  Persistent 
inflammation can lead to fibrosis, tubal infertility and/or ectopic pregnancy; many 
infections are asymptomatic.  Most studies have investigated the inflammatory 
response in the initial stages of infection, less is known about the later stages of 
infection, especially with a low, potentially asymptomatic, bacterial load.  Our 
objective was to determine the inflammatory mediators involved in clearance of 
low-grade infection and the potential involvement in chronic inflammation.  Six to 
eight week old C3H/HeJ mice were pretreated with 2.5 mg medroxyprogesterone 
acetate on day -10 and -3 before infection.  Mice (n=3 for 28 d, n=3 for 35 d) were 
infected with 5 x 102 inclusion-forming units of C. trachomatis, serovar D; vaginal 
cultures were obtained weekly to monitor infection.  Control mice (n=3 for 28 d, n=3 
for 35 d) were sham infected.  Mice were killed on day 28 (experiment 1) and day 35 
(experiment 2) post-infection and vaginal tissue, uterine horns and oviducts 
collected for analysis of mRNAs encoding inflammatory cytokines and chemokines.  
Total RNA was isolated and a superarray analysis performed using mouse Cytokines 
and Chemokines PCR arrays (Qiagen, Valencia, CA).  Statistical differences in gene 
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expression were determined using a paired Students t-test.  At 28 days after 
infection, the expression of mRNA encoding 6, 35 and 3 inflammatory genes differed 
from controls in vaginal, uterine and oviductal tissues, respectively (P < 0.05).  At 35 
days after infection, the expression of mRNA encoding 16, 38 and 14 inflammatory 
genes differed from controls in vaginal, uterine and oviductal tissues, respectively (P 
< 0.05).  Understanding the mechanisms involved in the inflammatory response at 
later stages of infection should aid in the development of treatment options that 
minimize the development of asymptomatic, chronic inflammation-induced 
infertility.  
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Introduction 
 
Chlamydia trachomatis is an obligate intracellular pathogen and the most 
frequently reported sexually transmitted bacteria in the United States [170].  C. 
trachomatis targets epithelial cells within the genital tract initiating an immune 
response.  Infectious load is correlated to clinical pathogenesis [171, 172]; infection 
with C. trachomatis is often asymptomatic.  If left untreated the bacteria can ascend 
to and infect the oviducts [73, 173].  Untreated C. trachomatis infection can lead to 
persistent or recurrent inflammation, fibrosis, scarring, pelvic inflammatory disease 
(PID), tubal infertility, and/or an increased susceptibility to ectopic pregnancy [174, 
175].   
Upon infection, C. trachomatis elementary bodies (EBs) invade host epithelial 
cells in the genital tract.  Within the host cells, EBs differentiate into reticulate 
bodies (RBs) which actively replicate within the host cell cytoplasm and then 
reorganize back into infectious EBs.  This biphasic life cycle as well as adaptation to 
evade the immune response allows C. trachomatis to persist for extended periods 
within host epithelial cells, inducing a chronic inflammatory response [72, 74, 176-
178]. 
Previous studies have investigated the inflammatory response of C. 
trachomatis in the initial stages of infection, including regulation by cytokines, 
chemokines and inflammatory mediators involved in the recruitment of immune 
cells [72-74, 179, 180].  For example, Rasmussen et. al, [72] demonstrated that once 
C. trachomatis has established infection within epithelial cells, the innate immune 
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response allows for the production of pro-inflammatory cytokines such as 
interleukins 1, 6, 8 (Il-1, Il-6, Il-8), tumor necrosis factor-alpha (Tnf-α), and colony 
stimulating factor 2 (Csf2).  Secretion of these cytokines and chemokines recruit 
immune cells such as natural killer (NK) cells and phagocytes.  Following an 
established intracellular infection, the T-cell mediated immune response then 
becomes the critical element required for clearance [181].  However, evidence 
suggests that this T-cell response also contributes to the pathology following 
infection.  Th1 cells limit replication of C. trachomatis, but Th2 cells inhibit Th1 
responses leading to continued production of pro-inflammatory cytokines which 
can lead to fibrosis [75].  C. trachomatis also induces production of Tnf-α, which 
promotes apoptosis of infected and bystander cells [182].  Overall, understanding 
cytokine and chemokine regulation during both acute and chronic phases of 
infection may contribute to the development of treatment options that will 
minimize the long-term inflammatory consequences attributed to this disease.   
Limited investigation of the later stages of infection has been performed, 
especially after infection with a low bacterial load.  Maxion and Kelly [73] reported 
that cytokine and chemokine expression differs in anatomically distinct regions of 
the genital tract; these authors investigated the expression of chemokines 
associated with Th1 and Th2 responses in the oviducts and cervical-vaginal regions 
of the reproductive tract during the induction phase (0-14 days) and resolution 
phase (14-35 days) of infection.  Spatially distinct regulation was noted; however, 
the authors focused their experiments on the evaluation of chemokine expression 
related to Th1 and Th2 responses using the mouse pneumonitis biovar of C. 
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trachomatis.  Our objective was to determine within the reproductive tract the 
concurrent level of expression of mRNA encoding inflammatory mediators during 
the later phases of infection using a relatively low infectious load of C. trachomatis 
biovar, serovar D, one of the most prevalent serovars involved in urogenital 
infections of humans [183].  Two separate experiments were performed, with 
tissues collected at 4 and 5 weeks after infection (experiment 1 and 2, respectively).  
Our hypothesis was that mRNA encoding pro-inflammatory cytokines and 
chemokines will be differentially expressed in the female reproductive tract of mice 
infected with C. trachomatis at both 28 and 35 days post-infection compared to 
controls.   
 
Methods 
 
Animals and Tissue Collection 
 
All animal experiments were performed according to the guidelines and 
protocol approved by the University of California Irvine Institutional Animal Care 
and Use Committee (protocol # 2009-2868).  Using a previously described model of 
confirmed genital infection by C. trachomatis, serovar D, female C3H/HeJ mice, 6 -to 
8 -week old, (Jackson Laboratories, Sacramento, CA) were pretreated with 2.5 mg 
medroxyprogesterone acetate (SICOR Pharmaceuticals) on Days -10 and -3 before 
infection [184, 185].  In both experiments mice were infected via vaginal challenge 
with 5 x 102 inclusion-forming units (IFUs) of C. trachomatis, serovar D in 0.01 mL of 
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Eagle Minimal essential media (MEM, Gibco) on Day 0, as previously described [184, 
185].  Control mice were also pretreated with medroxyprogesterone acetate, but 
were sham infected with Eagle Minimal essential media (MEM, Gibco) alone.  
Vaginal swabs were obtained twice weekly after infection and cell cultures were 
performed to monitor infection as previously described [184-186].  Mice were killed 
on day 28 (n = 3 for control and infected) in experiment 1 and day 35 (n = 3 for 
control and infected) in experiment 2.  Immediately before being sacrificed vaginal 
cultures were obtained and all mice inoculated vaginally with C. trachomatis 
remained culture positive but at a significantly lower level than that obtained 
throughout the first two weeks of infection.  Results of vaginal cultures following 
infection with this strain/dose of C. trachomatis, serovar D have been reported, 
including number of IFUs recovered [185].  Vaginal tissue, uterine horns and the 
oviducts were collected and snap-frozen for later extraction of RNA.   
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RNA Extraction and Analysis 
 
Total RNA was extracted from each tissue sample using TRIzol reagent 
(Invitrogen, Carlsbad, CA) and purified through RNeasy columns (Qiagen, Valencia, 
CA).  To determine the effect of treatment on the expression of genes involved in the 
inflammatory response, a targeted real-time PCR SuperArray analysis was 
performed using RT2 Profiler PCR arrays for mouse Cytokines and Chemokines 
(Qiagen), as previously described [23].  Real-time PCR were performed on an 
Eppendorf Mastercycler ep realplex2 system (Eppendorf, Hamburg, Germany).  Gene 
expression was standardized against GAPDH as a housekeeping gene and analyzed 
by the 2−ΔΔCT method [111].  Statistical differences in the expression of mRNA were 
determined using a paired Students t-test.  
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Results 
 
Experiment 1: Expression of mRNA encoding inflammatory genes in vaginal, uterine 
and oviduct tissues at 28 days post-infection 
 
Gene expression analysis was used to determine the effect of infection on the 
expression of inflammatory mRNAs at 28 days post-infection.  In vaginal tissue 
collected at 28 days after infection, the expression of mRNA encoding 6 
inflammatory genes increased and no genes decreased when compared to controls 
(Table A1.1).    
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Table A1.1. Effect of treatment on the expression of 
mRNAs in the vagina at 28 and 35 days post-infection. 
28 day infected vs control 
Gene 
Symbol 
Control Avg. 
Δ Ct ± SEM 
Infected Avg.  
Δ Ct ± SEM 
Fold 
change 
p-
value 
Ccl24 12.79 ± 0.76 10.62 ± 0.53 4.5 0.007 
Ccl3 10.18 ± 0.54 7.81 ± 1.00 5.5 0.025 
Ccl4* 9.03 ± 0.59 6.28 ± 0.44 6.7 0.036 
Cd40lg 14.01 ± 0.30 11.05 ± 0.36 7.8 0.011 
Cxcl1 9.00 ± 0.25 6.18 ± 0.24 7.1 0.028 
Il22 15.96 ± 0.37 15.03 ± 0.39 1.9 0.024 
35 day infected vs control 
Gene 
Symbol 
Control Avg.  
Δ Ct ± SEM 
Infected Avg.  
Δ Ct ± SEM 
Fold 
change 
p-
value 
Bmp7 6.43 ± 0.17 6.51 ± 0.25 0.5 0.032 
Csf3 4.88 ± 0.05 5.47 ± 0.06 0.5 <0.001 
Ccl4* 9.03 ± 0.58 6.28 ± 0.23 4.2 0.019 
Ctf1 6.67 ± 0.15 7.19 ± 0.12 0.6 0.023 
Hprt 1.65 ± 0.14 1.81 ± 0.04 0.6 0.022 
Ifna2 11.3 ± 0.19 11.41 ± 0.24 0.4 0.014 
Ifng 13.04 ± 0.54 9.68 ± 0.43 8.5 0.035 
Il10 9.94 ± 0.38 8.35 ± 0.32 2.8 0.048 
Il11 11.76 ± 0.07 10.52 ± 0.23 2.3 0.03 
Il18 5.86 ± 0.22 6.54 ± 0.06 0.4 0.014 
Il1a 7.13 ± 0.09 5.97 ± 0.04 1.4 0.007 
Il1rn 6.36 ± 0.37 5.95 ± 0.13 1.9 0.042 
Mif 0.43 ± 0.12 0.76 ± 0.08 0.7 0.045 
Pf4 5.15 ± 0.19 5.26 ± 0.06 0.6 0.031 
Thpo 12.95 ± 0.6 13.76 ± 0.16 3.7 0.019 
Tnf 8.4 ± 0.19 6.86 ± 0.09 2.4 0.002 
The normalized average Δ Ct value was calculated using 
GAPDH as the house-keeping gene.  Fold change values 
(infected over control) in gene expression are presented 
as average fold change (2-(average ΔΔCt)) for differentially 
expressed mRNAs (P < 0.05). 
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 In uterine samples collected at 28 days after infection, the expression of 
mRNA encoding 32 inflammatory genes increased and 3 genes decreased when 
compared to controls (Table A1.2). Of the 6 inflammatory mRNAs that increased 
within vaginal tissue after infection, 4 were also differentially affected by treatment 
in uterine samples.  
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In oviducts collected at 28 days post-infection, the expression of mRNA 
encoding 2 inflammatory genes increased and 1 gene decreased (Table A1.3).  Of the 
3 inflammatory genes affected by treatment within the oviduct, mRNA encoding 1 
gene, chemokine (c-c motif) ligand 12 (Ccl12), was also increased in uterine 
samples.   
 
 
 
 
 
 
 
 
 
 
 
Table A1.3. Effect of treatment on the expression of 
mRNAs in the oviduct at 28 and 35 days post-infection. 
28 day infected vs control 
Gene 
Symbol 
Control Avg. 
Δ Ct ± SEM 
Infected Avg. 
Δ Ct ± SEM 
Fold 
change 
p-value 
Ccl12 6.81 ± 0.37 4.39 ± 0.51 5.3 0.045 
Il13 10.45 ± 0.21 11.69 ± 0.28 0.4 0.029 
Il23a 11.43 ± 0.10 10.96  ± 0.08 1.4 0.021 
35 day infected vs control 
Gene 
Symbol 
Control Avg. 
Δ Ct ± SEM 
Infected Avg. 
Δ Ct ± SEM 
Fold 
change 
p-value 
Bmp7 7.97 ± 0.21 6.99 ± 0.12 2 0.011 
Ccl17 7.11 ± 0.52 6.19 ± 0.32 6.1 0.021 
Cd40lg 13.02 ± 0.30 10.40 ± 0.36 6.2 0.03 
Cx3cl1 5.16 ± 0.21 4.16 ± 0.18 2 0.025 
Cxcl1 12.57 ± 0.25 9.99 ± 0.24 6 0.007 
Fasl 12.75 ± 0.66 8.79 ± 0.34 15.6 0.019 
Gpi1 2.71 ± 0.04 1.56 ± 0.26 2.2 0.039 
Hsp90a
b1 
0.53 ± 0.18 1.98 ± 0.26 2.7 0.027 
Il12b 13.10 ± 0.24 10.47 ± 0.17 6.2 0.003 
Il1a 11.42 ± 0.22 9.65 ± 0.23 3.4 0.011 
Il9 7.16 ± 0.21 8.21 ± 0.26 0.5 0.044 
Lif 10.03 ± 0.38 8.77 ± 0.08 2.4 0.016 
Mif 1.55 ± 0.09 0.17 ± 0.29 2.6 0.044 
Osm 11.50 ± 0.44 9.93 ± 0.33 3 0.047 
The normalized average Δ Ct value was calculated using 
GAPDH as the house-keeping gene.  Fold change values 
(infected over control) in gene expression are presented 
as average fold change (2-(average ΔΔCt)) for differentially 
expressed mRNAs (P < 0.05). 
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Experiment 2: Expression of mRNA encoding inflammatory genes in vaginal, uterine 
and oviduct tissues at 35 days post-infection 
 
In vaginal tissue collected 35 days after infection, the expression of mRNA 
encoding 8 inflammatory genes was increased and 8 decreased when compared to 
controls (Table A1.1).  In uterine samples collected at 35 days after infection, the 
expression of mRNA encoding 32 inflammatory genes increased and 6 genes 
decreased compared to controls (Table A1.4).  Of the 16 inflammatory mRNAs 
affected by treatment in vaginal tissue, 7 were also differentially expressed in 
uterine samples and 3 in oviduct samples.  In oviducts collected at 35 days post-
infection, the expression of mRNA encoding 13 inflammatory genes was increased 
and 1 gene decreased (Table A1.3).  Of the 14 inflammatory mRNAs affected by 
treatment within the oviduct, 5 were also differentially expressed in uterine 
samples and 3 in vaginal tissue.
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Discussion and Conclusions 
 
 The host response to infection with C. trachomatis includes the induction of 
pro-inflammatory cytokines and chemokines which leads to innate and adaptive 
immune cell recruitment and activation [187].  Although the immune response is 
critical to the clearance of infection, the cellular immune response in particular can 
cause tissue damage that promotes fibrosis and can lead to infertility [75].  
Considering that infection with C. trachomatis is often asymptomatic, the objective 
of these two experiments was to identify inflammatory mediators induced during 
the later phases of low-dose C. trachomatis genital infection in order to advance our 
understanding of disease progression and the immune response involved in 
potentially asymptomatic chronic inflammation.  
 It is well known that susceptibility to C. trachomatis infection is genetically 
controlled in mice.  Both Tuffrey et al., [188-190] and Peterson et al., [184-186] have 
shown that human serovars of C. trachomatis can infect the genital tract of mice, 
specifically C3H/HeJ mice.  Progesterone pretreatment is necessary, but this strain 
of mice remains culture positive for more than 4 weeks following infection [185].  In 
the current study, infected mice continued to have positive vaginal C. trachomatis 
cultures for the duration of the experiments with IFUs lower when the mice were 
killed compared to the first two weeks of infection.   
In experiment 1, mice were killed 28 days post-infection.  In vaginal tissue, 
mRNA encoding several cytokines and chemokines was affected by infection with C. 
trachomatis.  Among differentially-regulated genes in vaginal samples, the 
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expression of mRNA encoding chemokine (c-c motif) ligand 4 (Ccl4), also known as 
macrophage inflammatory protein-1β (MIP-1 ), a potent lymphocyte 
chemoattractant, was induced at 28 days of infection, with greater than a 6-fold 
increase compared to controls.  C-C motif chemokines are a subgroup of chemokines 
with two adjacent cysteine residues near the amino terminus [191].  Yilma et al., 
2013, reported an increase in Ccl4 production in mouse macrophages during the 
early response to C. trachomatis infection; therefore, our results suggest that this 
cytokine is actively involved in both the early response and late phases of infection.  
[192].  Interestingly, Ccl4 is highly related to macrophage inflammatory protein-1α 
(Ccl3) and it is thought that these C-C motif chemokines are co-secreted to recruit 
specific T cell subsets during the immune response [193, 194].  In our study, 
expression of mRNA encoding Ccl3 in the vagina was also increased at 28 days post-
infection.  Of all the differentially affected mRNAs in vaginal tissue, the largest fold-
change in 28 day infected samples was seen in the induction of mRNA encoding 
CD40 ligand (Cd40lg).  Cd40lg is mostly found on the surface of CD4+ T cells and its 
interaction with Cd40 is required in the activation of humoral and cellular immune 
responses [195]. 
Within the uterus, treatment affected the expression of mRNA for five C-X-C 
motif chemokines.  C-X-C motif chemokines are a subgroup of chemokines that have 
amino terminus cysteine residues separated by one amino acid [191].  Most notable 
is the induction of mRNA encoding chemokine (c-x-c motif) ligand 9 (Cxcl9).  
Previous studies have reported that Cxcl9 peaks during the early phases of infection 
in the upper genital tract and may be involved in Th1 responses [73], our results 
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suggest that within the uterus, Cxcl9-mediated inflammation remains ongoing even 
after the initial phase of infection.  The expression of mRNA encoding several 
interleukins was also induced in the infected mouse uterus at 28 days post-
infection, including Il1b, Il12a, Il12b, Il16, Il18, and Il27.  Notably, Il12 is also 
reported to be involved in Th1 responses [196].  In our results, mRNA for Il12 
subunit alpha (Il12a) and subunit beta (Il12b) was induced at 28 days after 
infection.  Several tumor necrosis factor family members and interferons were also 
induced, supporting the hypothesis that inflammation remains active and ongoing 
within the uterus during the late, resolution phase of infection.   
When compared to the response observed in vaginal and uterine tissues at 
28 days, the oviduct had fewer mRNA differentially expressed after infection of mice 
with C. trachomatis.  The expression of mRNA encoding two genes was increased 
and one gene decreased.  C. trachomatis- induced cell death within the oviduct is of 
concern due to long term sequelae, especially when considering that upon initial 
intracellular invasion of epithelial cells, C. trachomatis has the ability to prevent 
apoptosis of infected cells, therefore promoting infection [74, 179, 180].  
Interestingly, the expression of mRNA encoding fas ligand (TNF superfamily, 
member 6; Fasl), a key mediator of apoptosis, was not affected by treatment at 28 
days post infection within the oviduct.  
In experiment 2, mice were killed 35 days post-infection.  The level of mRNA 
encoding 4 interleukins (Il10, Il11, Il1rn, Il1a) was increased and 1 interleukin (Il18) 
decreased in vaginal tissue collected at 35 days post-infection.  Of these, Il18 is 
reported to interact with Il12 to stimulate interferon gamma (Ifn-γ) production 
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from NK cells during the early host response to infection [197].  Although studies 
have reported that Ifn-γ is crucial for immune cell responses to C. trachomatis [197-
199], the expression of mRNA for Il12 did not differ at 35 days after infection and 
there was a decrease in levels of mRNA for Il18.  Furthermore, Ifn-γ had the greatest 
fold change of all differentially induced mRNA in the infected vaginal tissues, 
suggesting that Ifn-γ production is being stimulated by other immunoregulatory 
factors at this later stage of infection.  The increase in expression of mRNA encoding 
Il10 within vaginal samples collected at 35 days after infection was not expected.  
Interleukin-10 is considered an anti-inflammatory cytokine and a recent study using 
C. trachomatis infected HeLa cells demonstrated that exogenous Il10 treatment 
decreased several inflammatory cytokines including Tnf [200, 201].  
Similar to vaginal tissues, uterine samples collected 35 days post-infection 
with C. trachomatis had increased expression of Il10 and Tnf.   Furthermore, an 
increase in adiponectin (Adipoq) was observed.  Similar to Il10, Adipoq has anti-
inflammatory properties including regulating cell defense and survival during stress 
conditions [202, 203].  In addition, a dramatic increase in the expression of mRNA 
for Cxcl11 (102-fold change) was observed.   Cxcl11 shares features with Cxcl9 and 
Cxcl10, including induction by interferons and expression on activated Th1 cells 
[204, 205].  It is reported that the Th1 response is crucial for controlling C. 
trachomatis infection, our results that mRNA for these transcripts were induced 
within the infected uterus is therefore consistent with other studies.   
Within the oviduct mRNA encoding 13 genes was increased and one gene 
decreased at 35 days after infection.  The expression of mRNA encoding fasl 
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increased at 35 days after infection with a 15-fold-change.  In addition, changes in 
mRNA for other inflammatory mediators involved in tissue damage were detected, 
including Il1-a, which is released from lysed cells and acts by stimulating further 
cytokine release from neighboring cells [72].   Interestingly, levels of mRNA for 
Leukemia inhibitory factor (Lif) were increased in 35 day infected oviducts.  Guney 
et al., 2008, demonstrated that LIF expression is increased in the oviducts of woman 
with ectopic pregnancies compared to non-pregnant woman [206].  Furthermore, Ji 
et al., 2009, proposed that LIF facilitates implantation of the conceptus in the 
oviduct when the stromal surface is exposed due to epithelial cell shedding caused 
by chronic inflammation [207].  The results shown here warrant further 
investigation especially since C. trachomatis has the ability to not only disrupt 
infected epithelial cells, but also non-infected cells in proximity to the infection [74]. 
In oviductal epithelia, these changes in gene expression and disruption of cellular 
processes can increase the risk of chronic inflammation-induced pelvic 
inflammatory disease and infertility.   
Overall, this study examined the coordinated and concurrent expression of 
mRNA encoding multiple cytokines in spatially distinct sections of the reproductive 
tract.  We investigated the later stages of infection using a relatively low infectious 
dose in order to obtain a better understanding of the genetic mechanisms involved 
in chronic inflammation and cellular damage.  Differences in the magnitude of 
response to infection in differing regions of the reproductive tract were expected, as 
were differences in the level of expression of specific mRNAs within a tissue over 
time [73], illustrating well the dynamic nature of the inflammatory response to 
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infection and the need for inclusive analyses of inflammatory mediators.  
Understanding the mechanisms involved in the inflammatory response at late stages 
of infection should aid in the development of treatment options that minimize 
chronic inflammation-induced pelvic inflammatory disease and infertility.  
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APPENDIX 2. 
SUPPLEMENTARY TABLES AND FIGURES 
Supplementary Figure 1. Box plot of the log2 expression signal for each sample  
(microarray chip).  
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Supplementary Figure 2. Overlapping sample signal intensity histogram  
indicating the frequency of transcripts at specific signal intensity values. 
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Supplementary Figure 3.  Top 6 Canonical pathways from up- and down-regulated 
differentially expressed genes within epithelial cells of the ampulla in the follicular 
versus luteal phase.  Ingenuity Pathway Analysis software was used to determine 
significant pathways based on the number of significant genes expressed within the 
pathway using Fischer’s Exact test (P < 0.05). 
A) Ampulla: Up-regulated pathways in the follicular versus luteal phases 
 
 
 
 
 
 
 
 
B) Ampulla: Down-regulated pathways in the follicular versus luteal phases 
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Supplementary Figure 4.  Top 6 Canonical pathways from up- and down-regulated 
differentially expressed genes within epithelial cells of the isthmus in the follicular 
versus luteal phase.  Ingenuity Pathway Analysis software was used to determine 
significant pathways based on the number of significant genes expressed within the 
pathway using Fischer’s Exact test (P < 0.05). 
A) Isthmus: Up-regulated pathways in the follicular versus luteal phases 
 
 
 
 
 
 
 
B) Isthmus: Down-regulated pathways in the follicular versus luteal phases 
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Supplementary Table 1. Differentially expressed genes from PMSG-treated 
ESR1KO versus PMSG-treated mouse oviducts. Significance set to P < 0.01, fold-
change > 2. 
Gene Symbol Gene Description p-value Fold-
Change 
1-Mar membrane-associated ring finger (C3HC4) 1 0.001 6.96 
0610007L01Rik RIKEN cDNA 0610007L01 gene < 0.001 -2.71 
0610010O12Rik RIKEN cDNA 0610010O12 gene < 0.001 -3.08 
1110003E01Rik RIKEN cDNA 1110003E01 gene < 0.001 -2.21 
1110017F19Rik RIKEN cDNA 1110017F19 gene 0.003 3.26 
1110018J18Rik RIKEN cDNA 1110018J18 gene 0.001 2.03 
1200015M12Rik/
A130040M12Rik 
RIKEN cDNA 1200015M12 gene/RIKEN 
cDNA A130040M12 gene 
< 0.001 2.66 
1300002E11Rik RIKEN cDNA 1300002E11 gene 0.001 2.32 
1300010F03Rik RIKEN cDNA 1300010F03 gene < 0.001 -2.22 
1700012D14Rik RIKEN cDNA 1700012D14 gene < 0.001 2.00 
1700023E05Rik RIKEN cDNA 1700023E05 gene 0.002 -2.02 
2010109K11Rik RIKEN cDNA 2010109K11 gene < 0.001 2.22 
2010305A19Rik RIKEN cDNA 2010305A19 gene 0.002 -2.06 
2200002K05Rik RIKEN cDNA 2200002K05 gene 0.003 5.75 
2210403K04Rik RIKEN cDNA 2210403K04 gene < 0.001 -2.75 
2300002M23Rik RIKEN cDNA 2300002M23 gene < 0.001 -
524.94 
2310014F06Rik RIKEN cDNA 2310014F06 gene < 0.001 5.57 
2310015A10Rik RIKEN cDNA 2310015A10 gene 0.001 2.29 
2310043J07Rik RIKEN cDNA 2310043J07 gene < 0.001 17.00 
2310046A06Rik RIKEN cDNA 2310046A06 gene 0.001 -9.22 
2610018G03Rik RIKEN cDNA 2610018G03 gene < 0.001 6.14 
2610027K06Rik RIKEN cDNA 2610027K06 gene 0.001 -5.40 
2810030E01Rik RIKEN cDNA 2810030E01 gene 0.001 2.83 
2900010M23Rik RIKEN cDNA 2900010M23 gene 0.001 -2.12 
2900056M20Rik RIKEN cDNA 2900056M20 gene < 0.001 2.05 
3010001F23Rik RIKEN cDNA 3010001F23 gene 0.001 2.36 
LOC100862497 predicted gene 2411/predicted gene 6604 < 0.001 2.08 
3110035E14Rik RIKEN cDNA 3110035E14 gene < 0.001 -6.77 
3632451O06Rik RIKEN cDNA 3632451O06 gene < 0.001 3.77 
4833423F13Rik RIKEN cDNA 4833423F13 gene 0.003 4.52 
4930538K18Rik 
/AU022252 
RIKEN cDNA 4930538K18 gene/expressed 
sequence AU022252 
< 0.001 -22.68 
4930579D07Rik RIKEN cDNA 4930579D07 gene < 0.001 -6.26 
4930579G24Rik RIKEN cDNA 4930579G24 gene < 0.001 -2.14 
5031426D15Rik RIKEN cDNA 5031426D15 gene 0.001 3.71 
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Supplementary Table 1. (Continued) 
5031439G07Rik RIKEN cDNA 5031439G07 gene < 0.001 -10.19 
5430407P10Rik RIKEN cDNA 5430407P10 gene 0.005 2.37 
5730409E04Rik RIKEN cDNA 5730409E04Rik gene < 0.001 2.68 
5730469M10Rik RIKEN cDNA 5730469M10 gene < 0.001 -3.18 
5930412G12Rik RIKEN cDNA 5930412G12 gene 0.001 6.35 
6330403A02Rik RIKEN cDNA 6330403A02 gene 0.003 4.14 
6330403K07Rik RIKEN cDNA 6330403K07 gene < 0.001 13.27 
6330416G13Rik RIKEN cDNA 6330416G13 gene < 0.001 -8.77 
6430548M08Rik RIKEN cDNA 6430548M08 gene 0.001 -8.66 
6720401G13Rik RIKEN cDNA 6720401G13 gene 0.007 2.03 
9030224M15Rik RIKEN cDNA 9030224M15 gene 0.001 -2.97 
9130017K11Rik RIKEN cDNA 9130017K11 gene 0.004 3.06 
9230108I15Rik RIKEN cDNA 9230108I15 gene < 0.001 2.12 
9330159F19Rik RIKEN cDNA 9330159F19 gene < 0.001 8.63 
9430020K01Rik RIKEN cDNA 9430020K01 gene 0.002 2.03 
9430021M05Rik RIKEN cDNA 9430021M05 gene 0.005 3.00 
9530008L14Rik RIKEN cDNA 9530008L14 gene 0.001 -3.24 
9630033F20Rik RIKEN cDNA 9630033F20 gene < 0.001 -2.24 
9930013L23Rik RIKEN cDNA 9930013L23 gene < 0.001 8.06 
9930023K05Rik RIKEN cDNA 9930023K05 gene 0.001 4.31 
A130040M12Rik RIKEN cDNA A130040M12 gene < 0.001 2.04 
A330049M08Rik RIKEN cDNA A330049M08 gene 0.002 -4.35 
A330068G13Rik RIKEN cDNA A330068G13 gene 0.002 2.95 
A630001G21Rik RIKEN cDNA A630001G21 gene 0.009 2.75 
A830039N20Rik RIKEN cDNA A830039N20 gene < 0.001 -3.41 
AA986860 expressed sequence AA986860 < 0.001 12.49 
Aass aminoadipate-semialdehyde synthase < 0.001 -2.15 
AB099516/Higd1
c/Mettl7a1/Mettl
7a2/Mettl7a3 
cDNA sequence AB099516/ HIG1 domain 
family, member 1C/methyltransferase like 
7A1 
< 0.001 -4.95 
Abca5 ATP-binding cassette, sub-family A (ABC1), 
member 5 
0.001 3.37 
Abca8a ATP-binding cassette, sub-family A (ABC1), 
member 8a 
< 0.001 2.48 
Abcb11 ATP-binding cassette, sub-family B 
(MDR/TAP), member 11 
0.003 -5.96 
Abcc4 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
< 0.001 3.41 
Abhd12 abhydrolase domain containing 12 0.002 -4.59 
Abhd14b abhydrolase domain containing 14b 0.002 2.30 
Abhd5 abhydrolase domain containing 5 0.004 -2.01 
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Supplementary Table 1. (Continued) 
Abhd6 abhydrolase domain containing 6 < 0.001 -2.79 
Ablim3 actin binding LIM protein family, member 3 < 0.001 -8.38 
Abp1 amiloride binding protein 1 (amine oxidase, 
copper-containing) 
< 0.001 -3.46 
Acpp acid phosphatase, prostate 0.001 6.38 
Acsf2 acyl-CoA synthetase family member 2 < 0.001 -2.24 
Actn3 actinin alpha 3 < 0.001 9.36 
Acy1 aminoacylase 1 0.001 -2.26 
Ada adenosine deaminase < 0.001 -11.46 
Adamts15 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 mo 
< 0.001 6.24 
Adamts16 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 mo 
< 0.001 19.82 
Adamts3 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 mo 
< 0.001 3.40 
Adamts4 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 mo 
0.001 -4.50 
Adamts8 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 mo 
< 0.001 3.93 
Adcy8 adenylate cyclase 8 0.006 3.75 
Adh7 alcohol dehydrogenase 7 (class IV), mu or 
sigma polypeptide 
< 0.001 -42.46 
Adhfe1 alcohol dehydrogenase, iron containing, 1 0.001 -2.01 
Adig adipogenin < 0.001 -20.62 
Adm adrenomedullin 0.001 -3.55 
Adora1 adenosine A1 receptor < 0.001 3.86 
Adssl1 adenylosuccinate synthetase like 1 0.001 4.14 
Aen apoptosis enhancing nuclease 0.003 -2.09 
Ager advanced glycosylation end product-specific 
receptor 
< 0.001 22.77 
Agr2 anterior gradient 2 (Xenopus laevis) 0.004 -3.42 
Agrn agrin 0.001 2.65 
Ahsp alpha hemoglobin stabilizing protein < 0.001 -17.11 
AI256396 EST AI256396 < 0.001 2.88 
AI314831 expressed sequence AI314831 0.009 2.19 
AI428936 expressed sequence AI428936 < 0.001 3.87 
AI504432 expressed sequence AI504432 < 0.001 2.18 
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Supplementary Table 1. (Continued) 
AI839979 expressed sequence AI839979 0.001 3.65 
Aifm2 apoptosis-inducing factor, mitochondrion-
associated 2 
< 0.001 2.25 
Aipl1 aryl hydrocarbon receptor-interacting 
protein-like 1 
0.002 -7.98 
Akap12 A kinase (PRKA) anchor protein (gravin) 12 < 0.001 2.16 
Akr1c14 aldo-keto reductase family 1, member C14 < 0.001 -45.65 
Akr1c19 aldo-keto reductase family 1, member C19 < 0.001 13.46 
Alas2 aminolevulinic acid synthase 2, erythroid < 0.001 -5.39 
Aldh1a3 aldehyde dehydrogenase family 1, subfamily 
A3 
< 0.001 34.76 
Aldh1a7 aldehyde dehydrogenase family 1, subfamily 
A7 
0.003 2.32 
Aldh1l1 aldehyde dehydrogenase 1 family, member 
L1 
0.009 -2.91 
Aldh3b1 aldehyde dehydrogenase 3 family, member 
B1 
< 0.001 -2.05 
Alg3 asparagine-linked glycosylation 3 (alpha-
1,3-mannosyltransferase) 
0.002 -2.68 
Alpl alkaline phosphatase, liver/bone/kidney < 0.001 -16.48 
Als2cl ALS2 C-terminal like 0.005 2.08 
Alx3 aristaless-like homeobox 3 < 0.001 -2.02 
Amot angiomotin < 0.001 3.39 
Ampd3 adenosine monophosphate deaminase 3 0.001 -4.04 
Angpt4 angiopoietin 4 0.003 4.32 
Angptl1 angiopoietin-like 1 < 0.001 3.93 
Ankrd33b ankyrin repeat domain 33B < 0.001 2.30 
Ankrd46 ankyrin repeat domain 46 < 0.001 -3.03 
Ano4 anoctamin 4 0.003 -12.39 
Ano9 anoctamin 9 0.006 3.70 
Anxa9 annexin A9 < 0.001 14.87 
Aox1 aldehyde oxidase 1 < 0.001 2.61 
Ap1s2 adaptor-related protein complex 1, sigma 2 
subunit 
< 0.001 3.84 
Ap1s3 adaptor-related protein complex AP-1, 
sigma 3 
0.003 2.97 
Ap3b2 adaptor-related protein complex 3, beta 2 
subunit 
< 0.001 6.38 
Aplnr apelin receptor 0.009 -2.64 
Apoc1 apolipoprotein C-I 0.001 7.52 
Apod apolipoprotein D < 0.001 98.02 
Apoe apolipoprotein E < 0.001 2.98 
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Supplementary Table 1. (Continued) 
Apol7a apolipoprotein L 7a 0.001 -8.07 
Apol9a/Apol9b apolipoprotein L 9a/apolipoprotein L 9b 0.004 -4.51 
Aqp5 aquaporin 5 < 0.001 -22.71 
Aqp8 aquaporin 8 < 0.001 -32.48 
Arg1 arginase, liver < 0.001 -6.38 
Arg2 arginase type II 0.002 -2.47 
Arhgap15 Rho GTPase activating protein 15 0.002 2.49 
Arhgap20 Rho GTPase activating protein 20 < 0.001 3.31 
Arhgap4 Rho GTPase activating protein 4 < 0.001 3.25 
Arhgap9 Rho GTPase activating protein 9 < 0.001 4.35 
Arhgef16 Rho guanine nucleotide exchange factor 
(GEF) 16 
0.006 2.02 
Arhgef17 Rho guanine nucleotide exchange factor 
(GEF) 17 
0.001 2.06 
Arl6ip5 ADP-ribosylation factor-like 6 interacting 
protein 5 
< 0.001 -2.60 
Arnt2 aryl hydrocarbon receptor nuclear 
translocator 2 
< 0.001 4.26 
Arsi arylsulfatase i < 0.001 -4.20 
Arsj arylsulfatase J 0.001 -7.15 
Arsk arylsulfatase K 0.001 2.25 
Artn artemin 0.001 8.50 
Asb4 ankyrin repeat and SOCS box-containing 4 < 0.001 -16.71 
Aspa aspartoacylase < 0.001 5.92 
Aspn asporin < 0.001 -7.72 
Asrgl1 asparaginase like 1 < 0.001 -2.31 
Atp10b ATPase, class V, type 10B 0.001 4.55 
Atp1a2 ATPase, Na+/K+ transporting, alpha 2 
polypeptide 
< 0.001 3.70 
Atp6v1b1 ATPase, H+ transporting, lysosomal V1 
subunit B1 
< 0.001 17.80 
Atp6v1c2 ATPase, H+ transporting, lysosomal V1 
subunit C2 
0.002 -15.54 
Atp8a1 ATPase, aminophospholipid transporter 
(APLT), class I, type 8A, member 1 
0.001 2.15 
AU021092 expressed sequence AU021092 < 0.001 3.43 
AU022252 expressed sequence AU022252 < 0.001 -2.43 
AU040972 expressed sequence AU040972 0.003 -2.35 
Auts2 autism susceptibility candidate 2 0.001 3.07 
Avpr1a arginine vasopressin receptor 1A < 0.001 35.78 
AW551984 expressed sequence AW551984 0.001 -8.31 
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Supplementary Table 1. (Continued) 
Axin2 axin2 < 0.001 2.85 
B230216N24Rik RIKEN cDNA B230216N24 gene 0.004 2.71 
B3galt5 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 5 
0.001 -8.42 
B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
< 0.001 2.42 
B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 7 
< 0.001 -4.58 
B3gnt8 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 
< 0.001 -16.37 
B4galnt2 beta-1,4-N-acetyl-galactosaminyl 
transferase 2 
< 0.001 10.08 
B4galt5 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 5 
< 0.001 -2.56 
B4galt6 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6 
0.001 2.63 
Bace2 beta-site APP-cleaving enzyme 2 0.001 -10.49 
Bach2 BTB and CNC homology 2 0.001 3.75 
Bank1 B cell scaffold protein with ankyrin repeats 
1 
0.004 2.12 
BC021891 cDNA sequence BC021891 0.005 2.18 
BC048546 cDNA sequence BC048546 < 0.001 -4.75 
BC048679 cDNA sequence BC048679 < 0.001 222.15 
Bcas3 breast carcinoma amplified sequence 3 < 0.001 -2.56 
Bcat1 branched chain aminotransferase 1, 
cytosolic 
< 0.001 -33.37 
Bche butyrylcholinesterase 0.002 2.47 
Bcl11b B cell leukemia/lymphoma 11B < 0.001 6.18 
Bcl2a1a/Bcl2a1b
/Bcl2a1d 
B cell leukemia/lymphoma 2 related protein 
A1a /// B cell leukemia/lymphoma 2 
related p 
< 0.001 2.56 
Bcl2l15 BCLl2-like 15 < 0.001 -5.77 
Bcl3 B cell leukemia/lymphoma 3 0.002 2.39 
Bdh1 3-hydroxybutyrate dehydrogenase, type 1 0.001 -5.53 
Beta-s/Hbb-
b1/Hbb-b2 
hemoglobin subunit beta-1-like /// 
hemoglobin, beta adult major chain /// 
hemoglobin, b 
< 0.001 -3.72 
Bmf BCL2 modifying factor 0.001 2.28 
Bmp5 bone morphogenetic protein 5 < 0.001 2.16 
Bmper BMP-binding endothelial regulator 
 
0.001 2.91 
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Boc biregional cell adhesion molecule-
related/down-regulated by oncogenes 
(Cdon) binding pr 
< 0.001 2.74 
Bpifc BPI fold containing family C < 0.001 -8.61 
Bst2 bone marrow stromal cell antigen 2 < 0.001 -19.98 
Btbd3 BTB (POZ) domain containing 3 0.006 -3.52 
Btc betacellulin, epidermal growth factor family 
member 
0.006 3.25 
Bysl bystin-like 0.003 -2.63 
C1ra complement component 1, r subcomponent 
A 
< 0.001 3.60 
C1s complement component 1, s subcomponent < 0.001 2.92 
C2 complement component 2 (within H-2S) < 0.001 2.67 
C2/Cfb complement component 2 (within H-2S) / 
complement factor B 
0.004 2.84 
C2cd4b C2 calcium-dependent domain containing 
4B 
0.002 3.13 
C3/LOC10004875
9 
complement component 3/complement C3-
like 
< 0.001 2.17 
C4b/LOC675521 complement component 4B (Chido blood 
group)/complement C4-B-like 
< 0.001 5.36 
Cacna1g calcium channel, voltage-dependent, T type, 
alpha 1G subunit 
< 0.001 9.75 
Cacna2d3 calcium channel, voltage-dependent, 
alpha2/delta subunit 3 
0.001 -4.27 
Cacnb4 calcium channel, voltage-dependent, beta 4 
subunit 
< 0.001 3.66 
Cadm4 cell adhesion molecule 4 0.004 2.27 
Calca calcitonin/calcitonin-related polypeptide, 
alpha 
< 0.001 8.28 
Calcb calcitonin-related polypeptide, beta 0.002 2.96 
Calml3 calmodulin-like 3 0.001 -8.73 
Camk2n2 calcium/calmodulin-dependent protein 
kinase II inhibitor 2 
< 0.001 -2.27 
Camta1 calmodulin binding transcription activator 1 0.001 -7.40 
Capn6 calpain 6 < 0.001 5.87 
Car11 carbonic anhydrase 11 < 0.001 2.89 
Car12 carbonic anyhydrase 12 < 0.001 -9.43 
Car13 carbonic anhydrase 13 < 0.001 -5.04 
Car9 carbonic anhydrase 9 < 0.001 -7.42 
Casp12 caspase 12 < 0.001 2.34 
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Casp4 caspase 4, apoptosis-related cysteine 
peptidase 
0.001 4.09 
Cav1 caveolin 1, caveolae protein < 0.001 -2.05 
Cbs cystathionine beta-synthase < 0.001 -13.39 
Ccdc109b coiled-coil domain containing 109B 0.001 3.69 
Ccdc141 coiled-coil domain containing 141 0.008 -2.39 
Ccdc3 coiled-coil domain containing 3 < 0.001 -15.24 
Ccdc67 coiled-coil domain containing 67 0.002 2.39 
Ccna1 cyclin A1 0.003 2.51 
Ccnd3 cyclin D3 0.005 2.08 
Cd163 CD163 antigen < 0.001 4.54 
Cd163l1 CD163 molecule-like 1 0.001 10.07 
Cd1d1 CD1d1 antigen 0.001 2.36 
Cd44 CD44 antigen < 0.001 2.21 
Cd74 CD74 antigen (invariant polypeptide of 
major histocompatibility complex, class II 
antig 
0.001 5.17 
Cd79b CD79B antigen 0.002 3.41 
Cd84 CD84 antigen 0.001 2.06 
Cda cytidine deaminase 0.004 -4.35 
Cdc42ep3 CDC42 effector protein (Rho GTPase 
binding) 3 
< 0.001 2.68 
Cdc42se2/LOC10
0045021 
CDC42 small effector 2/CDC42 small 
effector protein 2-like 
< 0.001 -3.13 
Cdh11 cadherin 11 < 0.001 2.79 
Cdh16 cadherin 16 < 0.001 50.13 
Cdk5r1 cyclin-dependent kinase 5, regulatory 
subunit 1 (p35) 
0.001 -3.18 
Cdk6 cyclin-dependent kinase 6 0.007 2.01 
Cdkn3 cyclin-dependent kinase inhibitor 3 0.003 -2.02 
Cdo1 cysteine dioxygenase 1, cytosolic 0.006 7.22 
Cdon cell adhesion molecule-related/down-
regulated by oncogenes 
< 0.001 2.68 
Cdv3 carnitine deficiency-associated gene 
expressed in ventricle 3 
0.006 -2.02 
Cebpd CCAAT/enhancer binding protein (C/EBP), 
delta 
< 0.001 3.84 
Celf2 CUGBP, Elav-like family member 2 < 0.001 3.94 
Ces2c/Ces2d-ps carboxylesterase 2C/carboxylesterase 2D, 
pseudogene 
0.007 2.88 
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Cflar CASP8 and FADD-like apoptosis regulator < 0.001 -2.35 
Chac1 ChaC, cation transport regulator 1 0.002 -3.74 
Chchd7 Coiled-coil-helix-coiled-coil-helix domain 
containing 7 
0.003 2.01 
Chdh choline dehydrogenase 0.004 2.14 
Chid1 chitinase domain containing 1 0.003 -2.04 
Chl1 cell adhesion molecule with homology to 
L1CAM 
< 0.001 6.73 
Chn1 chimerin (chimaerin) 1 < 0.001 -2.76 
Chodl chondrolectin < 0.001 48.14 
Chrdl1 chordin-like 1 < 0.001 2.26 
Chrnb1 cholinergic receptor, nicotinic, beta 
polypeptide 1 (muscle) 
< 0.001 3.77 
Chst11 carbohydrate sulfotransferase 11 < 0.001 -2.11 
Chst15 carbohydrate (N-acetylgalactosamine 4-
sulfate 6-O) sulfotransferase 15 
< 0.001 5.43 
Cidea cell death-inducing DNA fragmentation 
factor, alpha subunit-like effector A 
< 0.001 -8.41 
Cish cytokine inducible SH2-containing protein 0.006 2.94 
Clcf1 cardiotrophin-like cytokine factor 1 0.001 3.12 
Clcn5 chloride channel 5 0.002 2.72 
Cldn11 claudin 11 < 0.001 9.17 
Cldn22 claudin 22 < 0.001 -4.69 
Cldn23 claudin 23 < 0.001 -8.06 
Cldn3 claudin 3 0.002 2.64 
Cldn4 claudin 4 0.001 14.66 
Cldn9 claudin 9 < 0.001 10.69 
Clec7a C-type lectin domain family 7, member a 0.001 6.54 
Cnksr3 Cnksr family member 3 < 0.001 2.67 
Cnp 2',3'-cyclic nucleotide 3' phosphodiesterase 0.001 2.15 
Cnr1 cannabinoid receptor 1 (brain) 0.004 4.97 
Cntf/U05342/Zfp
91 
ciliary neurotrophic factor/sequence 
U05342/zinc finger protein 91 
< 0.001 4.98 
Cntnap2 contactin associated protein-like 2 0.002 -10.42 
Coch coagulation factor C homolog (Limulus 
polyphemus) 
< 0.001 5.78 
Col12a1 collagen, type XII, alpha 1 0.001 3.66 
Col13a1 collagen, type XIII, alpha 1 < 0.001 9.69 
Col14a1 collagen, type XIV, alpha 1 < 0.001 5.55 
Col18a1 collagen, type XVIII, alpha 1 0.001 3.28 
Col23a1 collagen, type XXIII, alpha 1 0.001 2.78 
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Col25a1 collagen, type XXV, alpha 1 < 0.001 -9.70 
Col4a5 collagen, type IV, alpha 5 < 0.001 2.25 
Col4a6 collagen, type IV, alpha 6 < 0.001 3.43 
Col6a4 collagen, type VI, alpha 4 < 0.001 -43.10 
Col9a2 collagen, type IX, alpha 2 0.007 4.55 
Copg2as2 coatomer protein complex, subunit gamma 
2, antisense 2 
0.001 4.33 
Coq3 coenzyme Q3 homolog, methyltransferase 
(yeast) 
< 0.001 -2.07 
Cox7a1 cytochrome c oxidase, subunit VIIa 1 < 0.001 -3.11 
Cp ceruloplasmin < 0.001 6.19 
Cpm carboxypeptidase M < 0.001 10.72 
Cpne8 copine VIII 0.001 -3.67 
Cpxm2 carboxypeptidase X 2 (M14 family) < 0.001 4.63 
Crabp2 cellular retinoic acid binding protein II < 0.001 -22.09 
Cradd CASP2 and RIPK1 domain containing 
adaptor with death domain 
0.001 -2.24 
Creb3l4 cAMP responsive element binding protein 
3-like 4 
0.001 -4.08 
Crlf1 cytokine receptor-like factor 1 < 0.001 -39.94 
Csf1r colony stimulating factor 1 receptor 0.001 2.54 
Csf3 colony stimulating factor 3 (granulocyte) < 0.001 -24.43 
Csrnp3 cysteine-serine-rich nuclear protein 3 < 0.001 -9.66 
Ctf1 cardiotrophin 1 < 0.001 2.86 
Ctnnd2 catenin (cadherin associated protein), delta 
2 
< 0.001 4.93 
Ctr9 Ctr9, Paf1/RNA polymerase II complex 
component, homolog (S. cerevisiae) 
< 0.001 -2.07 
Ctsb cathepsin B 0.002 -3.14 
Ctsd cathepsin D < 0.001 4.04 
Ctso cathepsin O < 0.001 2.69 
Cx3cl1 chemokine (C-X3-C motif) ligand 1 0.004 2.25 
Cxcl12 chemokine (C-X-C motif) ligand 12 < 0.001 4.21 
Cxcl14 chemokine (C-X-C motif) ligand 14 0.001 -3.31 
Cxcl17 chemokine (C-X-C motif) ligand 17 0.003 3.68 
Cxcr7 chemokine (C-X-C motif) receptor 7 < 0.001 -3.32 
Cyba cytochrome b-245, alpha polypeptide 0.001 2.20 
Cycs cytochrome c, somatic < 0.001 -3.57 
Cyp26a1 cytochrome P450, family 26, subfamily a, 
polypeptide 1 
< 0.001 -
131.13 
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Cyp27a1 cytochrome P450, family 27, subfamily a, 
polypeptide 1 
< 0.001 3.16 
Cyp2a4/Cyp2a5 cytochrome P450, family 2, subfamily a, 
polypeptide 4/cytochrome P450, family 2, 
subfamily a, polypeptide 5 
0.003 9.40 
Cyp2d22 cytochrome P450, family 2, subfamily d, 
polypeptide 22 
< 0.001 2.04 
Cyp2f2 cytochrome P450, family 2, subfamily f, 
polypeptide 2 
0.002 4.36 
Cyp2j11 cytochrome P450, family 2, subfamily j, 
polypeptide 11 
0.002 5.15 
Cyp2j9 cytochrome P450, family 2, subfamily j, 
polypeptide 9 
0.004 2.83 
Cyp4b1 cytochrome P450, family 4, subfamily b, 
polypeptide 1 
< 0.001 4.90 
Cyp4v3 cytochrome P450, family 4, subfamily v, 
polypeptide 3 
< 0.001 2.27 
Cyth4 cytohesin 4 0.002 -3.19 
D130062J21Rik RIKEN cDNA D130062J21 gene < 0.001 7.59 
D230004N17Rik RIKEN cDNA D230004N17 gene 0.001 5.02 
D3Bwg0562e DNA segment, Chr 3, Brigham & Women's 
Genetics 0562 expressed 
< 0.001 2.22 
D430041D05Rik RIKEN cDNA D430041D05 gene < 0.001 5.36 
D630045J12Rik RIKEN cDNA D630045J12 gene < 0.001 2.18 
Daam1 dishevelled associated activator of 
morphogenesis 1 
0.003 -4.81 
Dapk2 death-associated protein kinase 2 0.003 3.96 
Dapk3 death-associated protein kinase 3 0.001 -2.13 
Dbc1 deleted in bladder cancer 1 (human) 0.001 2.47 
Dcc deleted in colorectal carcinoma < 0.001 -6.57 
Dclk3 doublecortin-like kinase 3 < 0.001 9.33 
Dcpp1/Dcpp2/ 
Dcpp3 
demilune cell and parotid protein 
1/2/3demilun 
< 0.001 -
106.94 
Dcpp3 demilune cell and parotid protein 3 < 0.001 -
770.92 
Dgka diacylglycerol kinase, alpha 0.008 2.06 
Dgkh diacylglycerol kinase, eta 0.001 -4.54 
Dhcr24 24-dehydrocholesterol reductase < 0.001 -12.60 
Dhrs3 dehydrogenase/reductase (SDR family) 
member 3 
< 0.001 2.43 
Dhx58 DEXH (Asp-Glu-X-His) box polypeptide 58 0.003 -4.08 
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Diap3 diaphanous homolog 3 (Drosophila) 0.004 -2.43 
Dio2 deiodinase, iodothyronine, type II 0.001 -8.32 
Dio3os deiodinase, iodothyronine type III, opposite 
strand 
0.001 5.52 
Dkk3 dickkopf homolog 3 (Xenopus laevis) 0.003 -2.88 
Dleu7 deleted in lymphocytic leukemia, 7 < 0.001 -9.50 
Dlk1 delta-like 1 homolog (Drosophila) 0.001 4.52 
Dmrta1 doublesex and mab-3 related transcription 
factor like family A1 
< 0.001 -14.21 
Dnajc19/Gm1511
8 
DnaJ (Hsp40) homolog, subfamily C, 
member 19/predicted gene 15118 
< 0.001 2.14 
Dnase1l2 deoxyribonuclease 1-like 2 0.004 2.55 
Dner delta/notch-like EGF-related receptor 0.003 6.56 
Dock8 dedicator of cytokinesis 8 0.006 -2.54 
Dpp4 dipeptidylpeptidase 4 0.001 3.66 
Dpt dermatopontin < 0.001 3.09 
Dpyd dihydropyrimidine dehydrogenase 0.001 3.37 
Dram1 DNA-damage regulated autophagy 
modulator 1 
0.002 2.30 
Dst dystonin 0.002 -2.66 
Dtd1 D-tyrosyl-tRNA deacylase 1 homolog (S. 
cerevisiae) 
< 0.001 2.00 
Dtna dystrobrevin alpha < 0.001 2.42 
E230013L22Rik RIKEN cDNA E230013L22 gene 0.001 -4.43 
E330020D12Rik Riken cDNA E330020D12 gene 0.001 2.19 
E430024I08Rik RIKEN cDNA E430024I08 gene 0.001 2.05 
Ear1/Ear12/Ear2
/Ear3 
eosinophil-associated, ribonuclease A 
family, member 1/eosinophil-associated, 
ribon 
0.007 3.92 
Ear12/Ear2/Ear3 eosinophil-associated, ribonuclease A 
family, member 12/eosinophil-associated, 
ribo 
< 0.001 5.96 
Echdc2 enoyl Coenzyme A hydratase domain 
containing 2 
0.003 2.25 
Eda2r ectodysplasin A2 receptor < 0.001 2.68 
Edem1 ER degradation enhancer, mannosidase 
alpha-like 1 
< 0.001 -2.49 
Edil3 EGF-like repeats and discoidin I-like 
domains 3 
< 0.001 4.27 
Ednrb endothelin receptor type B 0.002 -2.30 
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Efemp1 epidermal growth factor-containing fibulin-
like extracellular matrix protein 1 
0.002 4.11 
Efnb1 ephrin B1 0.001 2.18 
Efnb2 ephrin B2 0.002 2.35 
Egfl6 EGF-like-domain, multiple 6 0.001 8.00 
Egflam EGF-like, fibronectin type III and laminin G 
domains 
< 0.001 2.31 
Ehd3 EH-domain containing 3 0.005 -2.95 
Elk3 ELK3, member of ETS oncogene family 0.001 -2.06 
Emb embigin < 0.001 -9.71 
Emilin2 elastin microfibril interfacer 2 < 0.001 -11.84 
Enah enabled homolog (Drosophila) < 0.001 -3.90 
Enc1 ectodermal-neural cortex 1 < 0.001 -2.74 
Enpp2 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
< 0.001 3.17 
Enpp3 ectonucleotide 
pyrophosphatase/phosphodiesterase 3 
0.001 3.69 
Entpd5 ectonucleoside triphosphate 
diphosphohydrolase 5 
< 0.001 2.51 
Epas1 endothelial PAS domain protein 1 0.005 -3.48 
Epb4.1l3 erythrocyte protein band 4.1-like 3 < 0.001 2.61 
Epha1 Eph receptor A1 0.001 2.78 
Epha4 Eph receptor A4 < 0.001 3.23 
Ephb2 Eph receptor B2 < 0.001 3.94 
Ephb6 Eph receptor B6 0.004 4.07 
Eppk1 epiplakin 1 < 0.001 -3.60 
Ermp1 endoplasmic reticulum metallopeptidase 1 0.001 2.12 
Ern1 endoplasmic reticulum (ER) to nucleus 
signalling 1 
< 0.001 -2.83 
Esr1 estrogen receptor 1 (alpha) 0.006 -7.50 
Esyt3 extended synaptotagmin-like protein 3 0.004 3.82 
Etfb electron transferring flavoprotein, beta 
polypeptide 
< 0.001 -2.09 
Etl4 enhancer trap locus 4 < 0.001 2.39 
Ets2 E26 avian leukemia oncogene 2, 3' domain < 0.001 -4.50 
Etv1 ets variant gene 1 0.002 2.94 
Exph5 exophilin 5 0.002 3.60 
Expi extracellular proteinase inhibitor < 0.001 -6.76 
F13a1 coagulation factor XIII, A1 subunit < 0.001 3.01 
F2r coagulation factor II (thrombin) receptor < 0.001 2.47 
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Fabp5 fatty acid binding protein 5, epidermal < 0.001 -6.58 
Fabp5/Gm3601 fatty acid binding protein 5, 
epidermal/predicted gene 3601 
< 0.001 -4.47 
Fam105a family with sequence similarity 105, 
member A 
0.003 2.10 
Fam110c family with sequence similarity 110, 
member C 
0.001 -3.82 
Fam176a family with sequence similarity 176, 
member A 
0.009 -2.28 
Fam181b family with sequence similarity 181, 
member B 
0.001 3.46 
Fam184b family with sequence similarity 184, 
member B 
0.001 2.19 
Fam189a1 family with sequence similarity 189, 
member A1 
0.002 -5.13 
Fam194a family with sequence similarity 194, 
member A 
0.001 -3.99 
Fam198b family with sequence similarity 198, 
member B 
0.001 2.73 
Fam47e family with sequence similarity 47, member 
E 
0.003 -2.35 
Fam54b family with sequence similarity 54, member 
B 
< 0.001 -2.21 
Fam57a family with sequence similarity 57, member 
A 
< 0.001 -7.28 
Fam65b family with sequence similarity 65, member 
B 
< 0.001 -13.56 
Fasn fatty acid synthase < 0.001 -2.27 
Fbln1 fibulin 1 < 0.001 5.22 
Fbln2 fibulin 2 < 0.001 -5.96 
Fbxo7 F-box protein 7 < 0.001 -2.27 
Fbxw17 F-box and WD-40 domain protein 17 < 0.001 -2.56 
Fcgbp Fc fragment of IgG binding protein 0.002 2.30 
Fcna ficolin A 0.001 3.14 
Fdft1 farnesyl diphosphate farnesyl transferase 1 < 0.001 -2.08 
Fdps farnesyl diphosphate synthetase < 0.001 -4.01 
Fez1 fasciculation and elongation protein zeta 1 
(zygin I) 
< 0.001 2.76 
Fgf1 fibroblast growth factor 1 0.003 2.92 
Fgf11 fibroblast growth factor 11 < 0.001 4.04 
Fgf18 fibroblast growth factor 18 < 0.001 38.17 
Fgfbp1 fibroblast growth factor binding protein 1 0.002 4.07 
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Fgfrl1 fibroblast growth factor receptor-like 1 0.001 -2.17 
Figf c-fos induced growth factor < 0.001 -3.21 
Fkbp11 FK506 binding protein 11 < 0.001 -6.24 
Flnb filamin, beta < 0.001 -2.55 
Flrt3 fibronectin leucine rich transmembrane 
protein 3 
< 0.001 2.80 
Fmo1 flavin containing monooxygenase 1 < 0.001 10.51 
Fmo2 flavin containing monooxygenase 2 0.003 6.57 
Fmod fibromodulin < 0.001 3.59 
Fn1 fibronectin 1 0.002 -9.25 
Fndc1 fibronectin type III domain containing 1 0.005 2.84 
Fosl2 fos-like antigen 2 < 0.001 -2.31 
Foxq1 forkhead box Q1 0.003 5.61 
Foxred2 FAD-dependent oxidoreductase domain 
containing 2 
0.003 2.53 
Frem1 Fras1 related extracellular matrix protein 1 0.003 3.22 
Frzb frizzled-related protein 0.006 -2.01 
Fxc1 fractured callus expressed transcript 1 < 0.001 -2.17 
Fyn Fyn proto-oncogene < 0.001 -2.65 
Fzd1 frizzled homolog 1 (Drosophila) < 0.001 2.56 
Fzd10 frizzled homolog 10 (Drosophila) 0.001 3.91 
Fzd3 frizzled homolog 3 (Drosophila) < 0.001 3.27 
Fzd5 frizzled homolog 5 (Drosophila) < 0.001 -3.20 
Fzd7 frizzled homolog 7 (Drosophila) < 0.001 2.66 
G0s2 G0/G1 switch gene 2 0.002 3.29 
G6pc2 glucose-6-phosphatase, catalytic, 2 < 0.001 42.88 
G6pc3 glucose 6 phosphatase, catalytic, 3 0.002 -3.02 
G6pd2/G6pdx glucose-6-phosphate dehydrogenase 
2/glucose-6-phosphate dehydrogenase X-
linked 
< 0.001 -7.36 
G6pdx glucose-6-phosphate dehydrogenase X-
linked 
< 0.001 -4.98 
Gabra1 gamma-aminobutyric acid (GABA) A 
receptor, subunit alpha 1 
0.007 2.38 
Gabra3 gamma-aminobutyric acid (GABA) A 
receptor, subunit alpha 3 
< 0.001 3.39 
Gabrp gamma-aminobutyric acid (GABA) A 
receptor, pi 
< 0.001 6.37 
Gadd45a growth arrest and DNA-damage-inducible 
45 alpha 
< 0.001 -9.44 
Gale galactose-4-epimerase, UDP < 0.001 -4.90 
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Ganc glucosidase, alpha; neutral C < 0.001 6.80 
Garnl3 GTPase activating RANGAP domain-like 3 < 0.001 2.01 
Gas2l3 growth arrest-specific 2 like 3 < 0.001 4.87 
Gas6 growth arrest specific 6 0.003 -2.04 
Gatsl2 GATS protein-like 2 < 0.001 -2.15 
Gbp8 guanylate-binding protein 8 < 0.001 -14.28 
Gclc glutamate-cysteine ligase, catalytic subunit < 0.001 -3.53 
Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme 
0.003 2.55 
Gda guanine deaminase < 0.001 -2.61 
Gdap10 ganglioside-induced differentiation-
associated-protein 10 
0.003 2.93 
Gdf10 growth differentiation factor 10 0.001 3.72 
Gfra2 glial cell line derived neurotrophic factor 
family receptor alpha 2 
0.001 3.43 
Ghrh growth hormone releasing hormone < 0.001 -20.55 
Gja1 gap junction protein, alpha 1 0.002 -32.21 
Gja4 gap junction protein, alpha 4 0.002 -3.21 
Gjb2 gap junction protein, beta 2 0.004 4.12 
Gla galactosidase, alpha < 0.001 -2.21 
Glb1l2 galactosidase, beta 1-like 2 0.001 2.67 
Glb1l3 galactosidase, beta 1 like 3 < 0.001 11.48 
Glce glucuronyl C5-epimerase < 0.001 2.35 
Gldc glycine decarboxylase < 0.001 17.16 
Glis2 GLIS family zinc finger 2 0.002 2.65 
Glt25d2 glycosyltransferase 25 domain containing 2 0.003 -8.55 
Gm11545 predicted gene 11545 < 0.001 2.61 
Gm11787/Lyn predicted gene 11787/Yamaguchi sarcoma 
viral (v-yes-1) oncogene homolog 
0.006 -2.11 
Gm13502/Idi1 predicted gene 13502/isopentenyl-
diphosphate delta isomerase 
0.002 -2.14 
Gm14005 predicted gene 14005 < 0.001 -3.27 
Gm17249 predicted gene, 17249 0.001 2.22 
Gm19439 predicted gene, 19439 < 0.001 -5.61 
Gm20033 predicted gene, 20033 < 0.001 2.89 
Gm20245 predicted gene, 20245 0.001 2.09 
Gm266 predicted gene 266 0.003 3.05 
Gm3776/Gsta1/G
sta2 
predicted gene 3776/glutathione S-
transferase, alpha 1 (Ya)/glutathione S-
trans 
< 0.001 3.66 
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Gm8615/Gnpda1 glucosamine-6-phosphate deaminase 1 
pseudogene/glucosamine-6-phosphate 
deaminase 1 
< 0.001 -2.27 
Gmds GDP-mannose 4, 6-dehydratase 0.001 -3.32 
Gmppb GDP-mannose pyrophosphorylase B < 0.001 -2.87 
Gna14 guanine nucleotide binding protein, alpha 
14 
0.004 -2.13 
Gnai1 guanine nucleotide binding protein (G 
protein), alpha inhibiting 1 
< 0.001 2.34 
Gng12 guanine nucleotide binding protein (G 
protein), gamma 12 
< 0.001 -3.73 
Gng2 guanine nucleotide binding protein (G 
protein), gamma 2 
< 0.001 -9.95 
Gng4 guanine nucleotide binding protein (G 
protein), gamma 4 
< 0.001 4.91 
Gnpda1 glucosamine-6-phosphate deaminase 1 < 0.001 -2.40 
Got2 glutamate oxaloacetate transaminase 2, 
mitochondrial 
< 0.001 -3.00 
Gp1bb glycoprotein Ib, beta polypeptide < 0.001 -20.90 
Gp1bb/ Sept5 glycoprotein Ib, beta polypeptide/septin 5 0.004 -2.40 
Gpam glycerol-3-phosphate acyltransferase, 
mitochondrial 
< 0.001 -2.29 
Gpc1 glypican 1 < 0.001 4.53 
Gpc6 glypican 6 < 0.001 2.38 
Gpr160 G protein-coupled receptor 160 < 0.001 3.92 
Gpr182 G protein-coupled receptor 182 < 0.001 3.56 
Gpr30 G protein-coupled receptor 30 0.007 2.98 
Gpr88 G-protein coupled receptor 88 0.002 3.42 
Gprasp2  G protein-coupled receptor associated 
sorting protein 2  
0.001 2.80 
Gpt glutamic pyruvic transaminase, soluble < 0.001 2.46 
Gpx1 glutathione peroxidase 1 0.001 -2.11 
Gramd3 GRAM domain containing 3 < 0.001 3.57 
Gramd4 GRAM domain containing 4 < 0.001 2.27 
Greb1 gene regulated by estrogen in breast cancer 
protein 
< 0.001 -64.60 
Grhpr glyoxylate reductase/hydroxypyruvate 
reductase 
< 0.001 -3.05 
Gria1 glutamate receptor, ionotropic, AMPA1 
(alpha 1) 
< 0.001 -46.45 
Grip1 glutamate receptor interacting protein 1 < 0.001 4.22 
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Grm4 glutamate receptor, metabotropic 4 < 0.001 2.60 
Grm7 glutamate receptor, metabotropic 7 0.003 2.68 
Gsta2 glutathione S-transferase, alpha 2 (Yc2) 0.002 3.01 
Gsta3 glutathione S-transferase, alpha 3 < 0.001 6.74 
Gstm6 glutathione S-transferase, mu 6 0.002 -4.04 
Gstm7 glutathione S-transferase, mu 7 < 0.001 5.36 
Gstt1 glutathione S-transferase, theta 1 < 0.001 2.31 
Gtf2f2 general transcription factor IIF, polypeptide 
2 
0.004 -2.22 
Gucy1a2 guanylate cyclase 1, soluble, alpha 2 0.001 2.79 
Gulo gulonolactone (L-) oxidase < 0.001 -12.69 
Gyk glycerol kinase 0.001 2.07 
H19 H19 fetal liver mRNA < 0.001 10.78 
H2-DMb1/DMb2 histocompatibility 2, class II, locus Mb1/ 
locus Mb2 
0.001 3.10 
Hba-a1/-a2 hemoglobin alpha, adult chain 1/adult chain 
2 
0.001 -4.75 
Hephl1 hephaestin-like 1 < 0.001 -8.97 
Hey1 hairy/enhancer-of-split related with YRPW 
motif 1 
0.001 -3.75 
Hfe hemochromatosis 0.001 2.41 
Higd1a HIG1 domain family, member 1A < 0.001 -2.02 
Hilpda hypoxia inducible lipid droplet associated 0.004 2.18 
Hip1r huntingtin interacting protein 1 related 0.001 -3.75 
Hist1h3b/1h3c/1
h3d/1h3e/1h3f2/
h3b/2h3c1/2h3c
2 
histone cluster 1/2 0.008 -2.41 
Hivep3 human immunodeficiency virus type I 
enhancer binding protein 3 
< 0.001 3.99 
Hlf hepatic leukemia factor 0.001 3.57 
Hmga2 high mobility group AT-hook 2 < 0.001 3.04 
Homer2 homer homolog 2 (Drosophila) < 0.001 3.36 
Hook1 hook homolog 1 (Drosophila) < 0.001 2.74 
Hopx HOP homeobox 0.003 -2.64 
Hoxc5 homeobox C5 0.001 2.04 
Hp haptoglobin < 0.001 -14.47 
Hpca hippocalcin 0.002 6.36 
Hpgds hematopoietic prostaglandin D synthase < 0.001 -73.37 
Hpse heparanase 0.005 2.29 
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Hs3st3a1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 3A1 
0.009 3.46 
Hs6st1 heparan sulfate 6-O-sulfotransferase 1 0.008 2.20 
Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 < 0.001 -9.28 
Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 0.008 -2.02 
Hspb2 heat shock protein 2 < 0.001 -3.70 
Hspb7 heat shock protein family, member 7 
(cardiovascular) 
< 0.001 -9.39 
Hyal1/Nat6 hyaluronoglucosaminidase 1/N-
acetyltransferase 6 
0.003 -2.75 
Icam1 intercellular adhesion molecule 1 < 0.001 3.74 
Id2 inhibitor of DNA binding 2 0.004 2.01 
Idua Iduronidase, alpha-L- < 0.001 -3.04 
Ier3 immediate early response 3 < 0.001 -2.85 
Ifi27l1 interferon, alpha-inducible protein 27 like 1 0.006 -2.49 
Ifi27l2a interferon, alpha-inducible protein 27 like 
2A 
< 0.001 -3.98 
Igf2 insulin-like growth factor 2 < 0.001 6.31 
Igfbp3 insulin-like growth factor binding protein 3 0.001 2.72 
Ikzf1 IKAROS family zinc finger 1 0.001 3.03 
Ikzf4 IKAROS family zinc finger 4 0.001 2.60 
Il13ra2 interleukin 13 receptor, alpha 2 0.003 4.48 
Il15 interleukin 15 < 0.001 2.70 
Il15ra interleukin 15 receptor, alpha chain < 0.001 4.59 
Il17ra interleukin 17 receptor A 0.005 -3.56 
Il17rb interleukin 17 receptor B < 0.001 14.38 
Il17re interleukin 17 receptor E 0.002 3.00 
Il18bp interleukin 18 binding protein < 0.001 -20.01 
Il18r1 interleukin 18 receptor 1 < 0.001 19.45 
Il1r1 interleukin 1 receptor, type I 0.001 2.14 
Il33 interleukin 33 < 0.001 11.69 
Il7 interleukin 7 0.001 3.94 
Irs1 insulin receptor substrate 1 < 0.001 -2.49 
Irs4 insulin receptor substrate 4 < 0.001 11.64 
Islr immunoglobulin superfamily containing 
leucine-rich repeat 
< 0.001 3.85 
Ism1 isthmin 1 homolog (zebrafish) 0.001 2.80 
Itga8 integrin alpha 8 0.001 -2.82 
Itgae integrin alpha E, epithelial-associated 0.001 2.33 
Itgb3 integrin beta 3 0.001 -5.64 
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Itgbl1 integrin, beta-like 1 < 0.001 3.61 
Jakmip1 janus kinase and microtubule interacting 
protein 1 
0.003 2.86 
Jam2 junction adhesion molecule 2 < 0.001 2.81 
Jph4 junctophilin 4 0.001 -6.63 
Jub ajuba 0.002 -2.45 
Kank4 KN motif and ankyrin repeat domains 4 0.002 4.92 
Kcna1 potassium voltage-gated channel, shaker-
related subfamily, member 1 
0.001 5.76 
Kcna5 potassium voltage-gated channel, shaker-
related subfamily, member 5 
< 0.001 6.29 
Kcnc2 potassium voltage gated channel, Shaw-
related subfamily, member 2 
0.002 5.00 
Kcnd2 potassium voltage-gated channel, Shal-
related family, member 2 
< 0.001 3.73 
Kcnf1 potassium voltage-gated channel, subfamily 
F, member 1 
< 0.001 -14.19 
Kcng4 potassium voltage-gated channel, subfamily 
G, member 4 
0.001 6.39 
Kcnip1 Kv channel-interacting protein 1 < 0.001 9.85 
Kcnj8 potassium inwardly-rectifying channel, 
subfamily J, member 8 
0.001 -3.34 
Kcnk13 potassium channel, subfamily K, member 13 < 0.001 -4.63 
Kcnk2 potassium channel, subfamily K, member 2 < 0.001 -6.50 
Kcnk5 potassium channel, subfamily K, member 5 0.006 -2.71 
Kcnma1 potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
0.002 -3.53 
Kcnmb1 potassium large conductance calcium-
activated channel, subfamily M, beta 
member 1 
0.009 -2.73 
Kcnmb4 potassium large conductance calcium-
activated channel, subfamily M, beta 
member 4 
< 0.001 -3.18 
Kctd5 potassium channel tetramerisation domain 
containing 5 
0.005 -2.21 
Kif5c kinesin family member 5C < 0.001 -4.08 
Kirrel kin of IRRE like (Drosophila) < 0.001 2.43 
Kit kit oncogene 0.001 -4.78 
Klf12 Kruppel-like factor 12 0.001 2.75 
Klhdc10 kelch domain containing 10 0.004 -2.51 
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Klhl14 kelch-like 14 (Drosophila) 0.002 2.01 
Klhl29 kelch-like 29 (Drosophila) 0.005 -3.09 
Klk1 kallikrein 1 < 0.001 -9.56 
Klk1b1 kallikrein 1-related peptidase b1 < 0.001 -62.94 
Klk1b21 kallikrein 1-related peptidase b21 < 0.001 -53.58 
Klk1b22/Klk1b9 kallikrein 1-related peptidase b22/ b9 < 0.001 -20.97 
Klk1b24 kallikrein 1-related peptidase b24 < 0.001 -73.19 
Klk8 kallikrein related-peptidase 8 < 0.001 16.42 
Krt13 keratin 13 0.001 10.11 
Krt15 keratin 15 0.002 5.23 
Krt36 keratin 36 0.008 2.28 
Krt85 keratin 85 < 0.001 -5.61 
Ky kyphoscoliosis peptidase 0.001 2.10 
L1cam L1 cell adhesion molecule < 0.001 6.72 
Lamb2 laminin, beta 2 0.001 2.15 
Larp1b La ribonucleoprotein domain family, 
member 1B 
< 0.001 -2.08 
Lass3 LAG1 homolog, ceramide synthase 3 < 0.001 5.46 
Lass4 LAG1 homolog, ceramide synthase 4 < 0.001 2.36 
Lcn2 lipocalin 2 0.001 2.59 
Ldb3 LIM domain binding 3 0.003 -2.38 
Ldha lactate dehydrogenase A < 0.001 -2.10 
Lemd1 LEM domain containing 1 < 0.001 12.18 
Lgals3 lectin, galactose binding, soluble 3 0.006 2.13 
Lgals3bp lectin, galactoside-binding, soluble, 3 
binding protein 
0.002 -2.45 
Lgi1 leucine-rich repeat LGI family, member 1 < 0.001 14.42 
Lgi2 leucine-rich repeat LGI family, member 2 < 0.001 2.93 
Lgi3 leucine-rich repeat LGI family, member 3 0.001 6.93 
Lgr5 leucine rich repeat containing G protein 
coupled receptor 5 
< 0.001 11.36 
Lgr6 leucine-rich repeat-containing G protein-
coupled receptor 6 
0.001 -2.72 
Lhx1 LIM homeobox protein 1 < 0.001 3.97 
Lima1 LIM domain and actin binding 1 < 0.001 2.00 
Ren1/Ren2 renin-1-like/renin 1 structural/renin 2 
tandem duplication of Ren1 
< 0.001 -13.71 
Loxl2 lysyl oxidase homolog 2-like/lysyl oxidase-
like 2 
0.001 -4.56 
LOC621549 uncharacterized LOC621549 < 0.001 3.86 
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Tcrb-J/Trbv1 T-cell receptor beta-2 chain C region-like/T 
cell receptor beta, joining region 
0.001 2.75 
Loxl1 lysyl oxidase-like 1 0.001 2.20 
Lpar3 lysophosphatidic acid receptor 3 0.002 -2.40 
Lpcat2 lysophosphatidylcholine acyltransferase 2 0.008 2.10 
Lrat lecithin-retinol acyltransferase 
(phosphatidylcholine-retinol-O-
acyltransferase) 
< 0.001 -53.53 
Lrig1 leucine-rich repeats and immunoglobulin-
like domains 1 
< 0.001 2.77 
Lrp4 low density lipoprotein receptor-related 
protein 4 
< 0.001 4.81 
Lrpap1 low density lipoprotein receptor-related 
protein associated protein 1 
0.001 2.09 
Lrrc17 leucine rich repeat containing 17 0.001 2.42 
Lrrc31 leucine rich repeat containing 31 0.003 4.04 
Lrrc41 leucine rich repeat containing 41 < 0.001 -2.41 
Lrrc4c leucine rich repeat containing 4C 0.001 2.25 
Lrrc59 leucine rich repeat containing 59 0.001 -2.90 
Lrrc8a/Phyhd1 leucine rich repeat containing 
8A/phytanoyl-CoA dioxygenase domain 
containing 1 
< 0.001 2.59 
Lrrcc1 leucine rich repeat and coiled-coil domain 
containing 1 
< 0.001 3.28 
Lrrn1 leucine rich repeat protein 1, neuronal 0.001 2.63 
Lrrn4 leucine rich repeat neuronal 4 0.001 2.63 
Lrrtm1 leucine rich repeat transmembrane 
neuronal 1 
< 0.001 29.44 
Lsamp limbic system-associated membrane protein 0.009 2.15 
Lsp1 lymphocyte specific 1 0.001 2.41 
Ltbp2 latent transforming growth factor beta 
binding protein 2 
< 0.001 3.85 
Ltbp3 latent transforming growth factor beta 
binding protein 3 
< 0.001 2.31 
Ltf lactotransferrin < 0.001 3.15 
Lum lumican 0.002 -4.30 
Ly6e lymphocyte antigen 6 complex, locus E 0.001 2.17 
Ly6f lymphocyte antigen 6 complex, locus F 0.001 -6.51 
Ly6h lymphocyte antigen 6 complex, locus H 0.001 3.09 
Lynx1 Ly6/neurotoxin 1 0.002 2.74 
Lypd6 LY6/PLAUR domain containing 6 0.010 2.70 
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Lyz1 lysozyme 1 0.001 2.52 
Lyz2 lysozyme 2 0.001 2.84 
Mab21l3 mab-21-like 3 (C. elegans) 0.001 13.96 
Mad2l2 MAD2 mitotic arrest deficient-like 2 < 0.001 -2.13 
Maf avian musculoaponeurotic fibrosarcoma (v-
maf) AS42 oncogene homolog 
< 0.001 3.00 
Mal myelin and lymphocyte protein, T cell 
differentiation protein 
0.003 2.52 
Man2a1 mannosidase 2, alpha 1 < 0.001 2.60 
Maob monoamine oxidase B 0.001 3.32 
Map2k1 mitogen-activated protein kinase kinase 1 0.001 -2.10 
Map2k4 mitogen-activated protein kinase kinase 4 < 0.001 -3.25 
Mapk10 mitogen-activated protein kinase 10 < 0.001 -4.08 
Mapk8ip1 mitogen-activated protein kinase 8 
interacting protein 1 
< 0.001 2.34 
Mapt microtubule-associated protein tau 0.008 2.77 
Matn2 matrilin 2 < 0.001 4.82 
Mboat2 membrane bound O-acyltransferase domain 
containing 2 
< 0.001 -3.32 
Mbp myelin basic protein 0.002 5.82 
Mcoln2 mucolipin 2 0.003 -3.69 
Med12l mediator of RNA polymerase II 
transcription, subunit 12 homolog (yeast)-
like 
< 0.001 2.50 
Meg3 maternally expressed 3 0.005 2.50 
Megf10 multiple EGF-like-domains 10 0.001 -4.19 
Megf6 multiple EGF-like-domains 6 < 0.001 2.08 
Met met proto-oncogene 0.001 2.74 
Mettl7a1 methyltransferase like 7A1 < 0.001 -3.11 
Mfsd2a major facilitator superfamily domain 
containing 2A 
< 0.001 -5.78 
Mfsd4 major facilitator superfamily domain 
containing 4 
< 0.001 -3.59 
Mgat3 mannoside acetylglucosaminyltransferase 3 < 0.001 2.71 
Mgat4a mannoside acetylglucosaminyltransferase 4, 
isoenzyme A 
0.001 2.43 
Mgl2 macrophage galactose N-acetyl-
galactosamine specific lectin 2 
0.001 3.86 
Mgst3 microsomal glutathione S-transferase 3 0.001 -3.26 
Mia1 melanoma inhibitory activity 1 0.001 7.48 
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Mlc1 megalencephalic leukoencephalopathy with 
subcortical cysts 1 homolog (human) 
0.001 -21.79 
Mmd monocyte to macrophage differentiation-
associated 
0.001 -2.13 
Mmd2 monocyte to macrophage differentiation-
associated 2 
0.001 -21.55 
Mmp10 matrix metallopeptidase 10 0.001 7.28 
Mmp16 matrix metallopeptidase 16 < 0.001 2.22 
Mmp23 matrix metallopeptidase 23 < 0.001 2.69 
Mmp9 matrix metallopeptidase 9 < 0.001 2.81 
Mogat2 monoacylglycerol O-acyltransferase 2 0.001 -6.05 
Moxd1 monooxygenase, DBH-like 1 < 0.001 4.24 
Mpp6 membrane protein, palmitoylated 6 
(MAGUK p55 subfamily member 6) 
0.008 2.82 
Mpped2 metallophosphoesterase domain containing 
2 
0.003 -4.04 
Mpzl2 myelin protein zero-like 2 0.001 3.58 
Mrc1 mannose receptor, C type 1 0.001 2.00 
Msrb2 methionine sulfoxide reductase B2 0.001 -2.91 
Mt3 metallothionein 3 < 0.001 -5.88 
Mtap6 microtubule-associated protein 6 < 0.001 -3.47 
Muc1 mucin 1, transmembrane < 0.001 5.44 
Muc4 mucin 4 0.001 8.01 
Mustn1 musculoskeletal, embryonic nuclear protein 
1 
0.002 -3.79 
Mvd mevalonate (diphospho) decarboxylase 0.001 -2.36 
Mybpc2 myosin binding protein C, fast-type < 0.001 5.99 
Myd88 myeloid differentiation primary response 
gene 88 
0.002 2.07 
Myh14 myosin, heavy polypeptide 14 < 0.001 -2.57 
Myh7 myosin, heavy polypeptide 7, cardiac 
muscle, beta 
0.001 -6.27 
Myl4 myosin, light polypeptide 4 0.004 -2.46 
Mylip myosin regulatory light chain interacting 
protein 
< 0.001 2.54 
Myo10 myosin X < 0.001 -3.10 
Myo1f myosin IF 0.001 2.19 
Myo3b myosin IIIB 0.007 4.15 
Naaa N-acylethanolamine acid amidase < 0.001 -2.21 
Nab1 Ngfi-A binding protein 1 0.001 2.99 
Nalcn sodium leak channel, non-selective < 0.001 4.46 
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Nampt nicotinamide phosphoribosyltransferase 0.001 2.40 
Napepld N-acyl phosphatidylethanolamine 
phospholipase D 
0.003 2.19 
Nars2 asparaginyl-tRNA synthetase 2 
(mitochondrial)(putative) 
< 0.001 -2.26 
Nav1 neuron navigator 1 0.001 2.37 
Ncald neurocalcin delta 0.002 -2.70 
Ncbp1 nuclear cap binding protein subunit 1 < 0.001 -2.72 
Ndrg1 N-myc downstream regulated gene 1 0.001 5.53 
Nefl neurofilament, light polypeptide 0.004 4.53 
Nell1 NEL-like 1 (chicken) 0.002 3.24 
Net1 neuroepithelial cell transforming gene 1 < 0.001 -2.65 
Neu2 neuraminidase 2 0.002 2.92 
Nfat5 nuclear factor of activated T cells 5 < 0.001 2.01 
Nfatc2ip nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 2 
interacting p 
0.002 -2.38 
Nfatc4 nuclear factor of activated T cells, 
cytoplasmic, calcineurin dependent 4 
0.001 2.00 
Nfe2l3 nuclear factor, erythroid derived 2, like 3 0.001 7.40 
Nfkbia nuclear factor of kappa light polypeptide 
gene enhancer in B cells inhibitor, alpha 
< 0.001 -2.40 
Nfkbie nuclear factor of kappa light polypeptide 
gene enhancer in B cells inhibitor, epsilon 
0.001 3.00 
Ng23 Ng23 protein < 0.001 2.58 
Nhlrc1 NHL repeat containing 1 0.006 -2.55 
Nid1 nidogen 1 < 0.001 2.07 
Nid2 nidogen 2 < 0.001 3.30 
Nipsnap1 4-nitrophenylphosphatase domain and non-
neuronal SNAP25-like protein homolog 1  
< 0.001 2.96 
Nkd1 naked cuticle 1 homolog (Drosophila) 0.002 2.21 
Nkd2 naked cuticle 2 homolog (Drosophila) < 0.001 3.44 
Nlrp6 NLR family, pyrin domain containing 6 < 0.001 -3.40 
Nmnat2 nicotinamide nucleotide 
adenylyltransferase 2 
0.004 -4.52 
Nostrin nitric oxide synthase trafficker < 0.001 -4.08 
Notum notum pectinacetylesterase homolog 
(Drosophila) 
< 0.001 8.56 
Nov nephroblastoma overexpressed gene 0.001 4.61 
Npas3 neuronal PAS domain protein 3 0.001 2.95 
Npl N-acetylneuraminate pyruvate lyase 0.001 5.70 
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Npnt nephronectin 0.003 2.40 
Npr2 natriuretic peptide receptor 2 < 0.001 -3.36 
Nptx1 neuronal pentraxin 1 < 0.001 -9.91 
Npy2r neuropeptide Y receptor Y2 < 0.001 3.35 
Nr2f2 nuclear receptor subfamily 2, group F, 
member 2 
< 0.001 2.22 
Nrg4 neuregulin 4 0.005 -3.02 
Nrip1 nuclear receptor interacting protein 1 < 0.001 -3.81 
Nrp2 neuropilin 2 0.001 -2.67 
Nsg2 neuron specific gene family member 2 < 0.001 9.18 
Nt5c 5',3'-nucleotidase, cytosolic < 0.001 -2.20 
Nt5e 5' nucleotidase, ecto < 0.001 8.94 
Ntn1 netrin 1 0.001 2.72 
Ntrk2 neurotrophic tyrosine kinase, receptor, type 
2 
< 0.001 2.77 
Ntrk3 neurotrophic tyrosine kinase, receptor, type 
3 
< 0.001 3.63 
Nup50 nucleoporin 50 < 0.001 -2.22 
Nupr1 nuclear protein 1 < 0.001 4.05 
Nus1 nuclear undecaprenyl pyrophosphate 
synthase 1 homolog (S. cerevisiae) 
0.004 -2.85 
Oas1a 2'-5' oligoadenylate synthetase 1A 0.003 -2.87 
Obscn obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
< 0.001 5.78 
Ocln occludin 0.002 2.46 
Ogfrl1 opioid growth factor receptor-like 1 < 0.001 2.57 
Ogn osteoglycin < 0.001 -3.12 
Olfm2 olfactomedin 2 0.001 -10.65 
Olfm4 olfactomedin 4 < 0.001 13.69 
Olfml1 olfactomedin-like 1 < 0.001 3.99 
Olfml3 olfactomedin-like 3 0.001 2.15 
Olig3 oligodendrocyte transcription factor 3 0.003 -3.57 
Omd osteomodulin < 0.001 -7.63 
Osbpl1a oxysterol binding protein-like 1A < 0.001 -7.50 
Osmr oncostatin M receptor < 0.001 4.34 
Osr1 odd-skipped related 1 (Drosophila) 0.002 3.81 
Otub2 OTU domain, ubiquitin aldehyde binding 2 0.002 -3.19 
Oxtr oxytocin receptor < 0.001 -35.01 
P2ry12 purinergic receptor P2Y, G-protein coupled 
12 
< 0.001 2.37 
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Pacsin1 protein kinase C and casein kinase substrate 
in neurons 1 
< 0.001 -15.22 
Pacsin3 protein kinase C and casein kinase substrate 
in neurons 3 
0.004 2.09 
Padi1 peptidyl arginine deiminase, type I < 0.001 -11.65 
Padi2 peptidyl arginine deiminase, type II < 0.001 -24.17 
Pak3 p21 protein (Cdc42/Rac)-activated kinase 3 < 0.001 -16.89 
Palld palladin, cytoskeletal associated protein < 0.001 9.80 
Panx1 pannexin 1 0.002 -2.82 
Pappa2 pappalysin 2 < 0.001 7.12 
Paqr5 progestin and adipoQ receptor family 
member V 
0.003 3.08 
Paqr8 progestin and adipoQ receptor family 
member VIII 
0.002 -2.92 
Pcdh17 protocadherin 17 < 0.001 -25.08 
Pcdh19 protocadherin 19 < 0.001 2.50 
Pcdh8 protocadherin 8 0.002 9.87 
Pcdh9 protocadherin 9 0.001 2.73 
Pcdha1/10/11/1
2/2/3/4/5/6/7/
8/9/Pcdhac1/2 
protocadherin alpha 
1//10/11/12/2/3/4/5/6/7/8/9/ 
0.002 -2.39 
Pcsk5 proprotein convertase subtilisin/kexin type 
5 
0.002 2.33 
Pde4d phosphodiesterase 4D, cAMP specific < 0.001 3.26 
Pde7a phosphodiesterase 7A 0.001 2.00 
Pde8b phosphodiesterase 8B 0.001 -2.25 
Pde9a phosphodiesterase 9A < 0.001 -4.81 
Pdgfc platelet-derived growth factor, C 
polypeptide 
< 0.001 2.44 
Pdgfd platelet-derived growth factor, D 
polypeptide 
< 0.001 2.12 
Pdgfra platelet derived growth factor receptor, 
alpha polypeptide 
< 0.001 2.81 
Pdgfrl platelet-derived growth factor receptor-like < 0.001 3.42 
Pdia5 protein disulfide isomerase associated 5 < 0.001 -2.03 
Pdlim4 PDZ and LIM domain 4 < 0.001 3.24 
Pdzrn4 PDZ domain containing RING finger 4 0.002 -4.84 
Peg3 paternally expressed 3 0.008 2.06 
Pemt phosphatidylethanolamine N-
methyltransferase 
< 0.001 -3.32 
Pet112l PET112-like (yeast) 0.001 -2.28 
Pfkp phosphofructokinase, platelet < 0.001 -2.63 
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Pgk1 phosphoglycerate kinase 1 < 0.001 -2.12 
Pgm2l1 phosphoglucomutase 2-like 1 0.004 -4.08 
Pgp phosphoglycolate phosphatase < 0.001 -2.67 
Pgr progesterone receptor 0.001 -6.76 
Phtf2 putative homeodomain transcription factor 
2 
0.004 -4.05 
Pik3ap1 phosphoinositide-3-kinase adaptor protein 
1 
0.003 2.62 
Pik3r1 phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 
< 0.001 2.38 
Pik3r3 phosphatidylinositol 3 kinase, regulatory 
subunit, polypeptide 3 (p55) 
< 0.001 -2.78 
Pion pigeon homolog (Drosophila) 0.006 2.18 
Pip5k1b phosphatidylinositol-4-phosphate 5-kinase, 
type 1 beta 
< 0.001 -34.98 
Pitpnm3 PITPNM family member 3 < 0.001 -10.74 
Pla2g10 phospholipase A2, group X < 0.001 40.80 
Pla2g15 phospholipase A2, group XV < 0.001 2.16 
Pla2g5 phospholipase A2, group V < 0.001 14.32 
Plat plasminogen activator, tissue < 0.001 3.27 
Plcd3 phospholipase C, delta 3 0.001 2.78 
Plcl2 phospholipase C-like 2 < 0.001 -2.67 
Plcxd3 phosphatidylinositol-specific phospholipase 
C, X domain containing 3 
< 0.001 4.70 
Plekhh1 pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 1 
0.003 -2.14 
Pln phospholamban 0.002 -5.38 
Plod2 procollagen lysine, 2-oxoglutarate 5-
dioxygenase 2 
0.001 -5.50 
Pls1 plastin 1 (I-isoform) < 0.001 -4.26 
Pmm2 phosphomannomutase 2 < 0.001 -2.29 
Pnck pregnancy upregulated non-ubiquitously 
expressed CaM kinase 
0.002 2.59 
Podn podocan 0.001 9.28 
Podxl podocalyxin-like < 0.001 3.75 
Polg2 polymerase (DNA directed), gamma 2, 
accessory subunit 
0.004 2.02 
Poln DNA polymerase N 0.006 4.73 
Ppap2b phosphatidic acid phosphatase type 2B < 0.001 2.09 
Pparg peroxisome proliferator activated receptor 
gamma 
0.002 -12.69 
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Ppargc1a peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha 
0.002 3.37 
Ppargc1b peroxisome proliferative activated receptor, 
gamma, coactivator 1 beta 
0.001 -2.49 
Ppl periplakin < 0.001 5.62 
Ppm1e protein phosphatase 1E (PP2C domain 
containing) 
0.001 -2.29 
Ppp2r2c protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), gamma 
isoform 
< 0.001 -8.28 
Prdm1 PR domain containing 1, with ZNF domain < 0.001 4.10 
Prelid2 PRELI domain containing 2 0.001 2.36 
Prelp proline arginine-rich end leucine-rich 
repeat 
< 0.001 3.19 
Prkcb protein kinase C, beta 0.001 2.89 
Prkce protein kinase C, epsilon < 0.001 -2.96 
Prkd1 protein kinase D1 0.005 3.00 
Prkg2 protein kinase, cGMP-dependent, type II 0.004 3.73 
Prlr prolactin receptor 0.001 -3.32 
Prodh proline dehydrogenase 0.001 2.70 
Prosapip1 ProSAPiP1 protein < 0.001 4.00 
Prr18 proline rich region 18 0.001 -2.26 
Prrg3 proline rich Gla (G-carboxyglutamic acid) 3 
(transmembrane) 
< 0.001 2.99 
Prtg protogenin homolog (Gallus gallus) < 0.001 2.80 
Psmd3 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 3 
0.001 -2.47 
Ptgds prostaglandin D2 synthase (brain) 0.001 3.05 
Ptger4 prostaglandin E receptor 4 (subtype EP4) < 0.001 -2.36 
Ptgs1 prostaglandin-endoperoxide synthase 1 0.002 2.58 
Pthlh parathyroid hormone-like peptide < 0.001 4.58 
Ptn pleiotrophin 0.002 3.94 
Ptpdc1 protein tyrosine phosphatase domain 
containing 1 
< 0.001 2.72 
Ptprr protein tyrosine phosphatase, receptor type, 
R 
0.005 3.13 
Ptpru protein tyrosine phosphatase, receptor type, 
U 
0.004 2.50 
Pycr2 pyrroline-5-carboxylate reductase family, 
member 2 
< 0.001 -2.93 
Qsox1 quiescin Q6 sulfhydryl oxidase 1 0.004 -2.40 
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Rab15 RAB15, member RAS oncogene family 0.001 3.12 
Rab17 RAB17, member RAS oncogene family 0.001 7.62 
Rab20 RAB20, member RAS oncogene family 0.006 -2.42 
Rab37 RAB37, member of RAS oncogene family < 0.001 -30.23 
Rad18 RAD18 homolog (S. cerevisiae) < 0.001 -3.66 
Raly hnRNP-associated with lethal yellow < 0.001 -2.94 
Ramp3 receptor (calcitonin) activity modifying 
protein 3 
< 0.001 -41.52 
Rap1gap2 RAP1 GTPase activating protein 2 0.001 -4.17 
Rapgef3 Rap guanine nucleotide exchange factor 
(GEF) 3 
< 0.001 3.21 
Rapgef4 Rap guanine nucleotide exchange factor 
(GEF) 4 
< 0.001 -4.21 
Rarb retinoic acid receptor, beta < 0.001 9.69 
Rarres2 retinoic acid receptor responder 
(tazarotene induced) 2 
< 0.001 2.04 
Rasd1 RAS, dexamethasone-induced 1 < 0.001 -42.74 
Rasgrf1 RAS protein-specific guanine nucleotide-
releasing factor 1 
0.003 4.64 
Rasl11a RAS-like, family 11, member A < 0.001 2.25 
Rassf2 Ras association (RalGDS/AF-6) domain 
family member 2 
0.002 2.37 
Rassf4 Ras association (RalGDS/AF-6) domain 
family member 4 
< 0.001 3.60 
Rassf5 Ras association (RalGDS/AF-6) domain 
family member 5 
< 0.001 -14.02 
Rbbp9 retinoblastoma binding protein 9 0.003 2.96 
Rbfox3 RNA binding protein, fox-1 homolog (C. 
elegans) 3 
0.004 5.71 
Rbm20 RNA binding motif protein 20 < 0.001 -7.29 
Rbp1 retinol binding protein 1, cellular < 0.001 3.16 
Rbp4 retinol binding protein 4, plasma < 0.001 -2.01 
Rbpms RNA binding protein gene with multiple 
splicing 
0.003 -2.18 
Reck reversion-inducing-cysteine-rich protein 
with kazal motifs 
0.001 3.01 
Reep1 receptor accessory protein 1 < 0.001 2.46 
Reep2 receptor accessory protein 2 < 0.001 -2.32 
Reps2 RALBP1 associated Eps domain containing 
protein 2 
< 0.001 2.16 
Rerg RAS-like, estrogen-regulated, growth-
inhibitor 
0.001 -7.37 
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Retnla resistin like alpha < 0.001 12.77 
Rftn1 raftlin lipid raft linker 1 < 0.001 -2.75 
Rgs13 regulator of G-protein signaling 13 0.007 -7.21 
Rgs18 regulator of G-protein signaling 18 0.002 2.13 
Rhbdl2 rhomboid, veinlet-like 2 (Drosophila) 0.001 2.81 
Rhbdl3 rhomboid, veinlet-like 3 (Drosophila) < 0.001 5.72 
Rhoj ras homolog gene family, member J < 0.001 2.29 
Rhou ras homolog gene family, member U 0.002 2.13 
Rims1 regulating synaptic membrane exocytosis 1 0.001 -3.56 
Rims2 regulating synaptic membrane exocytosis 2 0.009 2.60 
Rmnd5b required for meiotic nuclear division 5 
homolog B (S. cerevisiae) 
0.001 -2.01 
Rnf125 ring finger protein 125 < 0.001 4.09 
Rnf157 ring finger protein 157 0.004 2.99 
Rnf43 ring finger protein 43 0.001 2.97 
Ror1 receptor tyrosine kinase-like orphan 
receptor 1 
< 0.001 2.89 
Rora RAR-related orphan receptor alpha 0.001 2.23 
Rprm reprimo, TP53 dependent G2 arrest 
mediator candidate 
< 0.001 -3.20 
Rrbp1 ribosome binding protein 1 0.004 -2.46 
Rsad1 radical S-adenosyl methionine domain 
containing 1 
< 0.001 -5.91 
Rspo1 R-spondin homolog (Xenopus laevis) < 0.001 4.54 
Rtn1 reticulon 1 < 0.001 -28.78 
Rtn4 reticulon 4 0.002 -2.45 
Rtp4 receptor transporter protein 4 0.005 -2.09 
Runx2 runt related transcription factor 2 0.001 2.41 
S100a8 S100 calcium binding protein A8 
(calgranulin A) 
0.001 20.77 
S100a9 S100 calcium binding protein A9 
(calgranulin B) 
0.001 17.86 
Sacs sacsin 0.007 -2.38 
Samsn1 SAM domain, SH3 domain and nuclear 
localization signals, 1 
< 0.001 2.09 
Sc4mol sterol-C4-methyl oxidase-like < 0.001 -2.32 
Scara3 scavenger receptor class A, member 3 < 0.001 4.61 
Scara5 scavenger receptor class A, member 5 
(putative) 
< 0.001 12.09 
Scarb2 scavenger receptor class B, member 2 < 0.001 -2.85 
Schip1 Schwannomin interacting protein 1 < 0.001 2.95 
Scube2 signal peptide, CUB domain, EGF-like 2 0.004 3.37 
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Scx scleraxis 0.009 2.11 
Sectm1a secreted and transmembrane 1A 0.001 -4.94 
Sema4d sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmi 
0.004 2.23 
Sema5b sema domain, seven thrombospondin 
repeats (type 1 and type 1-like), 
transmembrane domai 
< 0.001 2.18 
Sema6d sema domain, transmembrane domain 
(TM), and cytoplasmic domain, 
(semaphorin) 6D 
0.005 -2.16 
Serpina1b serine (or cysteine) preptidase inhibitor, 
clade A, member 1B 
< 0.001 27.57 
Serpina9 serine (or cysteine) peptidase inhibitor, 
clade A (alpha-1 antiproteinase, antitrypsin) 
< 0.001 -9.58 
Serpinb11 serine (or cysteine) peptidase inhibitor, 
clade B (ovalbumin), member 11 
< 0.001 -34.12 
Serpinf1 serine (or cysteine) peptidase inhibitor, 
clade F, member 1 
0.001 2.20 
Serping1 serine (or cysteine) peptidase inhibitor, 
clade G, member 1 
< 0.001 2.73 
Setd4 SET domain containing 4 < 0.001 -4.28 
Sfmbt2 Scm-like with four mbt domains 2 < 0.001 2.50 
Sfrp1 secreted frizzled-related protein 1 0.002 3.66 
Sfrp2 secreted frizzled-related protein 2 0.001 2.90 
Sftpd surfactant associated protein D < 0.001 -8.90 
Sgk1 serum/glucocorticoid regulated kinase 1 0.002 -2.87 
Sgsm1 small G protein signaling modulator 1 0.005 -6.52 
Sh2d4a SH2 domain containing 4A 0.006 2.42 
Sh3bgr SH3-binding domain glutamic acid-rich 
protein 
< 0.001 2.91 
Sh3gl2 SH3-domain GRB2-like 2 < 0.001 2.60 
Shisa2 shisa homolog 2 (Xenopus laevis) < 0.001 -2.81 
Shisa3 shisa homolog 3 (Xenopus laevis) 0.002 5.84 
Shisa9 shisa homolog 9 (Xenopus laevis) < 0.001 2.01 
Skap1 src family associated phosphoprotein 1 < 0.001 3.49 
Slc10a3 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 3 
0.001 -2.01 
Slc12a2 solute carrier family 12, member 2 0.002 -4.05 
Slc15a2 solute carrier family 15 (H+/peptide 
transporter), member 2 
< 0.001 2.68 
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Slc16a4 Solute carrier family 16 (monocarboxylic 
acid transporters), member 4 
< 0.001 2.15 
Slc1a1 solute carrier family 1 (neuronal/epithelial 
high affinity glutamate transporter, syste 
0.008 2.44 
Slc1a4 solute carrier family 1 (glutamate/neutral 
amino acid transporter), member 4 
0.009 -3.87 
Slc22a21 solute carrier family 22 (organic cation 
transporter), member 21 
< 0.001 2.58 
Slc22a23 solute carrier family 22, member 23 0.002 2.36 
Slc24a3 solute carrier family 24 
(sodium/potassium/calcium exchanger), 
member 3 
< 0.001 3.38 
Slc25a18 solute carrier family 25 (mitochondrial 
carrier), member 18 
0.004 -3.75 
Slc25a35 solute carrier family 25, member 35 0.002 -3.87 
Slc25a5 solute carrier family 25 (mitochondrial 
carrier, adenine nucleotide translocator) 
< 0.001 -2.63 
Slc27a2 solute carrier family 27 (fatty acid 
transporter), member 2 
0.001 4.16 
Slc28a3 solute carrier family 28 (sodium-coupled 
nucleoside transporter), member 3 
< 0.001 -5.08 
Slc30a2 solute carrier family 30 (zinc transporter), 
member 2 
0.003 6.45 
Slc35b1 solute carrier family 35, member B1 < 0.001 -2.48 
Slc38a1 solute carrier family 38, member 1 < 0.001 -4.37 
Slc39a4 solute carrier family 39 (zinc transporter), 
member 4 
0.003 2.73 
Slc43a1 solute carrier family 43, member 1 0.001 4.94 
Slc47a1 solute carrier family 47, member 1 < 0.001 10.81 
Slc52a3 solute carrier protein family 52, member 3 < 0.001 4.39 
Slc6a14 solute carrier family 6 (neurotransmitter 
transporter), member 14 
< 0.001 5.76 
Slc6a2 solute carrier family 6 (neurotransmitter 
transporter, noradrenalin), member 2 
< 0.001 -77.20 
Slc6a4 solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
< 0.001 -16.45 
Slc7a11 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 11 
< 0.001 -4.05 
Slc7a2 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2 
< 0.001 2.42 
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Slco2a1 solute carrier organic anion transporter 
family, member 2a1 
0.002 -3.68 
Slco2b1 solute carrier organic anion transporter 
family, member 2b1 
0.002 2.01 
Slco3a1 solute carrier organic anion transporter 
family, member 3a1 
< 0.001 -7.21 
Slco4c1 solute carrier organic anion transporter 
family, member 4C1 
0.001 4.09 
Slit2 slit homolog 2 (Drosophila) < 0.001 3.31 
Slit3 slit homolog 3 (Drosophila) < 0.001 2.55 
Slpi secretory leukocyte peptidase inhibitor < 0.001 4.64 
Smagp small cell adhesion glycoprotein 0.001 2.35 
Smarcd3 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily d 
0.006 2.68 
Smoc1 SPARC related modular calcium binding 1 0.005 3.87 
Snai2 snail homolog 2 (Drosophila) 0.003 -2.63 
Snca synuclein, alpha < 0.001 -6.03 
Sncaip synuclein, alpha interacting protein 
(synphilin) 
0.005 -2.52 
Snhg11 small nucleolar RNA host gene 11 < 0.001 6.12 
Snhg4 small nucleolar RNA host gene 4 (non-
protein coding) 
0.001 -2.09 
Sntg2 syntrophin, gamma 2 < 0.001 -6.77 
Snx29 sorting nexin 29 0.003 2.25 
Snx30 sorting nexin family member 30 0.001 2.00 
Socs2 suppressor of cytokine signaling 2 0.001 -6.06 
Sorbs1 sorbin and SH3 domain containing 1 < 0.001 2.11 
Sorl1 sortilin-related receptor, LDLR class A 
repeats-containing 
0.001 2.31 
Sowahb sosondowah ankyrin repeat domain family 
member B 
0.004 3.19 
Sox18 SRY-box containing gene 18 < 0.001 -12.80 
Sox2ot SOX2 overlapping transcript (non-protein 
coding) 
0.003 -5.59 
Sox3 SRY-box containing gene 3 < 0.001 -3.92 
Sox9 SRY-box containing gene 9 0.001 -3.39 
Spdef SAM pointed domain containing ets 
transcription factor 
< 0.001 -39.53 
Spdya speedy homolog A (Xenopus laevis) 0.002 3.19 
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Speer4a spermatogenesis associated glutamate (E)-
rich protein 4a 
< 0.001 -4.27 
Speer4b spermatogenesis associated glutamate (E)-
rich protein 4b 
0.001 -4.65 
Sphk1 sphingosine kinase 1 0.002 3.10 
Spink4 serine peptidase inhibitor, Kazal type 4 0.002 -2.80 
Spink8 serine peptidase inhibitor, Kazal type 8 0.001 5.39 
Spnb3 spectrin beta 3 0.008 2.22 
Spon1 spondin 1, (f-spondin) extracellular matrix 
protein 
0.001 -3.68 
Sprr2f small proline-rich protein 2F 0.001 -16.47 
Spsb4 splA/ryanodine receptor domain and SOCS 
box containing 4 
< 0.001 -4.37 
Srprb /// Trf signal recognition particle receptor, B 
subunit /// transferrin 
< 0.001 5.30 
Srpx sushi-repeat-containing protein < 0.001 5.34 
Srr serine racemase 0.001 2.49 
Ssbp2 single-stranded DNA binding protein 2 < 0.001 2.15 
St6gal1 beta galactoside alpha 2,6 sialyltransferase 
1 
< 0.001 4.22 
St6gal2 beta galactoside alpha 2,6 sialyltransferase 
2 
0.001 3.54 
St8sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 2 
0.001 3.26 
St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6 
0.002 2.33 
Stat5a signal transducer and activator of 
transcription 5A 
< 0.001 -44.22 
Stbd1 starch binding domain 1 0.001 -2.18 
Stc2 stanniocalcin 2 < 0.001 -6.51 
Steap2 six transmembrane epithelial antigen of 
prostate 2 
0.001 2.02 
Stk39 serine/threonine kinase 39 0.001 -4.00 
Stoml3 stomatin (Epb7.2)-like 3 < 0.001 -4.41 
Stx1b syntaxin 1B 0.001 6.26 
Stxbp6 syntaxin binding protein 6 (amisyn) 0.001 2.23 
Sulf1 sulfatase 1 < 0.001 3.26 
Sult1d1 sulfotransferase family 1D, member 1 0.003 4.62 
Sult1e1 sulfotransferase family 1E, member 1 < 0.001 46.32 
Sv2b synaptic vesicle glycoprotein 2 b 0.005 -5.12 
Sval2 seminal vesicle antigen-like 2 0.001 -12.93 
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Svep1 sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1 
< 0.001 5.99 
Syn2 synapsin II < 0.001 -91.45 
Synpr synaptoporin < 0.001 22.32 
Syt9 synaptotagmin IX < 0.001 4.27 
Tac1 tachykinin 1 0.008 -2.07 
Tacc1 transforming, acidic coiled-coil containing 
protein 1 
0.010 -3.61 
Tbc1d16 TBC1 domain family, member 16 0.001 2.18 
Tbc1d4 TBC1 domain family, member 4 < 0.001 -3.26 
Tbx2 T-box 2 < 0.001 -3.31 
Tenc1 tensin like C1 domain-containing 
phosphatase 
0.001 3.01 
Tes testis derived transcript 0.004 -2.28 
Tex2 testis expressed gene 2 < 0.001 -6.44 
Tgfb2 transforming growth factor, beta 2 0.001 2.46 
Tgfb3 transforming growth factor, beta 3 < 0.001 2.36 
Tgfbi transforming growth factor, beta induced < 0.001 4.05 
Thbs1 thrombospondin 1 0.006 -5.14 
Thbs1/X99384 thrombospondin 1/cDNA sequence X99384 0.004 -2.69 
Thbs2 thrombospondin 2 0.001 2.25 
Thsd7a thrombospondin, type I, domain containing 
7A 
0.003 3.35 
Tiam2 T cell lymphoma invasion and metastasis 2 0.005 -6.37 
Timp2 tissue inhibitor of metalloproteinase 2 < 0.001 2.20 
Tln2 talin 2 0.007 2.32 
Tlr2 toll-like receptor 2 0.001 2.22 
Tm7sf2 transmembrane 7 superfamily member 2 < 0.001 -3.72 
Tmc7 transmembrane channel-like gene family 7 < 0.001 -8.53 
Tmeff2 transmembrane protein with EGF-like and 
two follistatin-like domains 2 
0.001 -5.45 
Tmem100 transmembrane protein 100 < 0.001 -3.65 
Tmem132c transmembrane protein 132C < 0.001 8.57 
Tmem132e transmembrane protein 132E 0.001 -13.35 
Tmem140 transmembrane protein 140 < 0.001 3.70 
Tmem159 transmembrane protein 159 0.003 2.13 
Tmem191c transmembrane protein 191C 0.002 2.52 
Tmem194b transmembrane protein 194B 0.001 2.72 
Tmem229b transmembrane protein 229B 0.001 -3.30 
Tmem26 transmembrane protein 26 0.001 3.11 
Tmem30b transmembrane protein 30B 0.006 2.39 
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Tmem50b transmembrane protein 50B 0.001 -2.17 
Tmem86a transmembrane protein 86A < 0.001 -7.40 
Tmem90b transmembrane protein 90B 0.001 10.03 
Tmie transmembrane inner ear < 0.001 3.13 
Tmod1 tropomodulin 1 < 0.001 -4.09 
Tmod2 tropomodulin 2 0.001 3.93 
Tmprss13 transmembrane protease, serine 13 < 0.001 12.07 
Tnfrsf1b tumor necrosis factor receptor superfamily, 
member 1b 
< 0.001 2.48 
Tnfrsf21 tumor necrosis factor receptor superfamily, 
member 21 
< 0.001 6.14 
Tnik TRAF2 and NCK interacting kinase 0.002 2.40 
Tnnc1 troponin C, cardiac/slow skeletal 0.001 -6.24 
Tnnt1 troponin T1, skeletal, slow < 0.001 8.93 
Tns4 tensin 4 0.001 -2.10 
Tnxb tenascin XB 0.002 4.43 
Tom1l2 target of myb1-like 2 (chicken) 0.001 -2.08 
Trank1 tetratricopeptide repeat and ankyrin repeat 
containing 1 
< 0.001 7.07 
Trdn triadin < 0.001 -18.32 
Trim62 tripartite motif-containing 62 0.002 -2.47 
Trp53inp2 transformation related protein 53 inducible 
nuclear protein 2 
< 0.001 -3.64 
Trpc4 transient receptor potential cation channel, 
subfamily C, member 4 
< 0.001 -8.59 
Trpc6 transient receptor potential cation channel, 
subfamily C, member 6 
0.006 -2.68 
Trpm3 transient receptor potential cation channel, 
subfamily M, member 3 
0.001 3.95 
Trpm6 transient receptor potential cation channel, 
subfamily M, member 6 
0.001 4.54 
Tshr thyroid stimulating hormone receptor < 0.001 -
121.71 
Tshz2 teashirt zinc finger family member 2 < 0.001 2.34 
Tslp thymic stromal lymphopoietin < 0.001 7.33 
Tspan11 tetraspanin 11 0.001 2.39 
Tspan33 tetraspanin 33 0.001 2.52 
Tspyl3 TSPY-like 3 < 0.001 2.09 
Tstd2 thiosulfate sulfurtransferase (rhodanese)-
like domain containing 2 
0.001 -2.23 
Ttc14 tetratricopeptide repeat domain 14 < 0.001 2.08 
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Ttc3 tetratricopeptide repeat domain 3 < 0.001 2.17 
Ttc39b tetratricopeptide repeat domain 39B 0.003 -2.44 
Ttc39c tetratricopeptide repeat domain 39C < 0.001 -5.48 
Txndc16 thioredoxin domain containing 16 0.001 2.05 
Txndc17 thioredoxin domain containing 17 < 0.001 -2.13 
Tyw1 tRNA-yW synthesizing protein 1 homolog 
(S. cerevisiae) 
0.006 -2.20 
Ube2g2 ubiquitin-conjugating enzyme E2G 2 0.001 -2.12 
Ube2u ubiquitin-conjugating enzyme E2U 
(putative) 
0.002 -2.63 
Umod uromodulin 0.001 2.46 
Unc5cl unc-5 homolog C (C. elegans)-like < 0.001 -16.94 
Upb1 ureidopropionase, beta 0.001 3.20 
Upk1a uroplakin 1A < 0.001 -77.14 
Upk3b uroplakin 3B < 0.001 2.81 
Uqcrq ubiquinol-cytochrome c reductase, complex 
III subunit VII 
0.001 -2.31 
Uroc1 urocanase domain containing 1 0.001 -4.88 
Vldlr very low density lipoprotein receptor 0.001 -3.55 
Vpreb3 pre-B lymphocyte gene 3 0.001 -3.37 
Vps37d vacuolar protein sorting 37D (yeast) 0.001 3.53 
Vstm2a V-set and transmembrane domain 
containing 2A 
< 0.001 8.91 
Vwa1 von Willebrand factor A domain containing 
1 
< 0.001 2.83 
Vwa2 von Willebrand factor A domain containing 
2 
0.001 5.02 
Vwa3b von Willebrand factor A domain containing 
3B 
0.002 -5.39 
Wasf1 WAS protein family, member 1 < 0.001 -3.40 
Wdr91 WD repeat domain 91 0.001 2.29 
Wfdc12 WAP four-disulfide core domain 12 < 0.001 -16.20 
Wfdc2 WAP four-disulfide core domain 2 < 0.001 7.33 
Wfikkn2 WAP, follistatin/kazal, immunoglobulin, 
kunitz and netrin domain containing 2 
< 0.001 13.88 
Wfs1 Wolfram syndrome 1 homolog (human) < 0.001 -3.99 
Wipf3 WAS/WASL interacting protein family, 
member 3 
< 0.001 10.65 
Wisp1 WNT1 inducible signaling pathway protein 
1 
< 0.001 2.99 
Wnk4 WNK lysine deficient protein kinase 4 0.001 2.86 
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Wnt11 wingless-related MMTV integration site 11 < 0.001 4.06 
Wnt5b wingless-related MMTV integration site 5B < 0.001 3.45 
Wnt7a wingless-related MMTV integration site 7A < 0.001 17.49 
Wnt9a wingless-type MMTV integration site 9A 0.001 2.97 
Zc3hc1 zinc finger, C3HC type 1 < 0.001 -2.46 
Zcchc24 zinc finger, CCHC domain containing 24 0.002 2.08 
Zfhx4 zinc finger homeodomain 4 0.003 2.00 
Zfp185 zinc finger protein 185 < 0.001 2.37 
Zfp239 zinc finger protein 239 < 0.001 -2.25 
Zfp354b zinc finger protein 354B < 0.001 2.30 
Zfp52 zinc finger protein 52 0.001 -3.02 
Zfp612 zinc finger protein 612 < 0.001 2.30 
Zfp784 zinc finger protein 784 0.002 2.23 
Zfp882 zinc finger protein 882 0.001 3.31 
Zg16 zymogen granule protein 16 0.001 -9.50 
Zkscan4 zinc finger with KRAB and SCAN domains 4 0.002 2.32 
Zmat1 zinc finger, matrin type 1 0.002 2.10 
Zmpste24 zinc metallopeptidase, STE24 homolog (S. 
cerevisiae) 
< 0.001 2.44 
Zxdc ZXD family zinc finger C < 0.001 -2.28 
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stallions and its relation to the fertility of mares. 
B.S. Animal Science, California Polytechnic State University, San Luis Obispo 
2000-2005 
Summary of Ph.D. Projects 
 Steroidal regulation of oviductal function in cattle and mice 
 Use global expression profiling to determine differences in steroidal 
regulation in the oviducts of heifers. 
 Objectives: Using microarray based transcriptional profiling; identify 
spatial and steroid-dependent changes in mRNA and miRNA expression 
in epithelial cells isolated from the ampulla and isthmus of heifers. 
 
 Determine estrogen receptor alpha (ESR1) dependent changes in gene 
expression in the oviducts using an ESR1 knockout mouse model. 
 Objectives: Using an ESR1 knockout mouse model, microarray based 
analysis performed in order to identify genes induced by estradiol 
production and regulated by ESR1. 
 Regulation of inflammation in the oviducts 
 Determine the effect of lipopolysaccharide (LPS) on inflammation in the 
oviducts of mice. 
 Objectives: With LPS as a systemic inflammatory insult, determine 
expression changes of inflammatory mRNAs in the oviducts of mice 
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following IP injection with LPS from E. Coli using a targeting Nanostring 
assay. 
 
 Effects of trace mineral supplementation on gonadal function in cattle 
 Describe the neonatal testis transcriptome profiles among calves born to 
cows supplemented with different forms of dietary selenium throughout 
gestation. 
 Objectives: A deficiency of selenium reduces fertility in bulls and form 
of selenium supplemented to cows is known to affect tissue-specific gene 
expression; therefore, we hypothesized that the form of selenium 
supplemented to cows during gestation affects the transcriptome of the 
neonatal bull calf testis, specifically, fertility-associated mRNAs.  With 
selenium supplied as either inorganic, organic, or a 50/50 mix for 4 
months prior to breeding and throughout gestation, determine the gene 
expression profiles of the neonatal calf testis.  
 
 Determine ovarian dynamics in grazing cows fed differing forms of 
selenium (Se) in free-choice mineral mixes. 
 Objectives: With selenium supplied as either inorganic, organic, or a 
50/50 mix, investigate preovulatory follicular dynamics and whole 
blood selenium concentrations in grazing cows.  
 
Applicable Skills 
Animal Handling: Experience handling and caring for multiple species including, 
cattle, horses, and mice. 
Molecular Biology: RNA extraction, purification, and quality control; reverse 
transcription; qPCR; nanostring, microarray. 
Bioinformatics and Statistical Evaluation: Transcriptional profiling using Partek 
Genomics Suite, Ingenuity Pathway Analysis (IPA), DAVID bioinformatics resources, 
Kyoto Encyclopedia of Genes and Genomes (KEGG), Statistical Analysis Software 
(SAS), and Excel.  
 
Undergraduate Research Training: Trained 5 undergraduate students in 
molecular techniques (RNA extraction, reverse transcription, real-time RT-PCR) 
needed for targeted gene expression analysis and directed large scale real-time RT-
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PCR experiment, requiring collation of multiple datasets produced from these 
undergraduates using their learned techniques. 
Teaching Opportunities: Guest lectures for the Spring 2015 semester in the 
Department of Animal and Food Sciences (University of Kentucky) instructing ASC 
364: Reproductive Physiology of Farm Animals. 
Professional Memberships 
American Society of Animal Science (2013-present) 
Society for the Study of Reproduction (2013-present) 
American Embryo Transfer Association (2013-present) 
Animal and Food Sciences Graduate Association (2012-present) 
Kentucky Thoroughbred Farm Managers Club (2005-2014, 2009 board member) 
 
Professional Positions Held 
 Graduate Research Assistant, Animal and Food Sciences Department, 
University of Kentucky, March 2012-Present. 
 Graduate Research Assistant, Veterinary Science Department, University of 
Kentucky, January 2010-March 2012. 
 Thoroughbred Farm Manager, Margaux Farm, LLC, March 2005- December 
2009. 
 Student Intern, Kentucky Equine Management Internship, Spring 2004. 
 
Peer Reviewed Publications 
KL Cerny, E Garrett, L Anderson and PJ Bridges. Steroid-dependent regulation of 
bovine oviductal epithelial cells: a transcriptomal analysis. 2015.  In Press. Biology 
and Endocrinology.  
KL Cerny, S Garbacik, C Skees, WR Burris, JC Matthews and PJ Bridges. 2015. Form 
of selenium in free-choice mineral mixes of dams affects transcriptome profiles, 
including those of steroidogenic and spermatogenic pathways, of the neonatal calf 
testis.  In Press, Biological Trace Element Research. 
 
KL Cerny, TV Little, CF Scoggin, RJ Coleman, BA Ball, MHT Troedsson, EL Squires. 
2014. Variations of potentially pathogenic bacteria found on the external genitalia of 
stallions during the breeding season. Equine Vet Science, 35(2): Pages 170-173. 
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S Hughes, KL Cerny, JR Campos, MHT Troedsson, B Ball, EL Squires. 2014. The use 
of equine follicle stimulating hormone to increase chorionic gonadotropin in the 
pregnant mare. Equine Vet Science, 34(8): Pages 1021-1024. 
 
KL Cerny, TV Little, CF Scoggin, RJ Coleman, MHT Troedsson, EL Squires. 2014. 
Presence of bacteria on the external genitalia of healthy stallions and its 
transmission to the mare at the time of breeding by live cover. Equine Vet Science, 
34(3): Pages 369-374. 
 
KL Cerny, S Hughes, JR Campos, RJ Coleman, MHT Troedsson, EL Squires. 2013. 
Fertility of mares inseminated with frozen-thawed semen processed by single layer 
centrifugation through a colloid. J Equine Vet Science, 32(5): Pages 289-291. 
Manuscripts in Preparation 
 
KL Cerny, PJ Bridges. Intraperitoneal administration of lipopolysaccharide induces 
differential expression of mRNA encoding inflammatory mediators in the oviducts of 
mice. Manuscript in Preparation. 
KL Cerny, C. Ko and PJ Bridges. Estrogen receptor alpha (ESR1) dependent 
regulation of gene expression in the mouse oviduct. Manuscript in Preparation. 
KL Cerny, L Anderson, WR Burris, M Rhoads, JC Matthews and PJ Bridges.  Effects of 
form of selenium in free-choice mineral mixes of grazing cows on ovarian dynamics.  
Manuscript in Preparation. 
Gene Expression Omnibus (publicly available datasets) 
GSE62382: Affymetrix Bovine Gene 1.0 ST array (13 microarrays).  Effect of form of 
gestational Selenium on gene expression in the neonatal calf testis.  KL Cerny, JC 
Matthews and PJ Bridges.  Record release date 10/16/2014. 
GSE62461: Qiagen Mouse Cytokines and Chemokines RT2 profiler PCR array -
PAMM-150A (36 arrays).  Differential expression of mRNA encoding cytokines and 
chemokines in the reproductive tract after infection of mice with Chlamydia 
trachomatis.  KL Cerny, M Van Fleet, A Slepenkin, EM Peterson, PJ Bridges.  Record 
release date 10/18/2014. 
GSE62570: Affymetrix WT Btau 4.0 array (16 microarrays).  Pituitary gene 
expression profiles of growing beef steers grazing high versus low endophyte-
infected tall fescue grass.  JC Matthews, R Hegge, KL Cerny, PJ Bridges.  Record 
release date 10/23/2014.  
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GSE63969: Affymetrix Bovine Gene 1.0 ST array (12 microarrays). Steroid-
dependent regulation of bovine oviductal epithelial cells: a transcriptomal analysis.  
KL Cerny, E Garrett, L Anderson and PJ Bridges.  Record release date 3/16/2015.  
Seminar Presentations 
 Mar 5, 2012: Comparison of protocols used to synchronize the Bovine 
estrous cycle.  Department Seminar Series-Animal and Food Science, 
University of Kentucky. 
 Feb 22, 2012: Presence of bacteria in the reproductive tract of healthy 
stallions and its relation to the fertility of mares. Master’s Defense Seminar-
Veterinary Science Department, University of Kentucky. 
 May 17, 2011: Fertility of frozen/thawed stallion semen centrifuged through 
a single layer density gradient.  Department Seminar Series-Veterinary 
Science Department, University of Kentucky. 
Invited Presentations 
 April 20, 2015: A transcriptomal analysis of bovine oviductal epithelial cells 
during differing phases of the estrous cycle.  Department Seminar Series- 
Animal and Food Science, University of Kentucky. 
 May 31, 2013: Equine Reproduction: What to know prior to breeding. 
Thoroughbred Owner and Breeders Association annual breeding clinic. 
Lexington, KY.  
Abstracts 
Oral Presentations 
 
KL Cerny, E Garrett, L Anderson and PJ Bridges. Steroid-dependent regulation of 
bovine oviductal epithelial cells: a transcriptomal analysis.  American Society of 
Animal Science, 2015 Southern Section meeting. Abstract #44 
 
KL Cerny, TV Little, CF Scoggin, RJ Coleman, MHT Troedsson, EL Squires. 2012. 
Presence of bacteria in the reproductive tract of healthy stallions and its relation to 
the fertility of mares. Proc of the 2012 annual conference and symposium of the 
Society for Theriogenology. P. 427. 
 
KL Cerny, S Hughes, JR Campos, MHT Troedsson, EL Squires. 2011. Fertility of 
mares inseminated with frozen-thawed semen centrifuged through a single layer 
density gradient. Proc. of the 2011 Equine Science Society Symposium. P. 316-317. 
Poster Presentations 
 
PJ Bridges, KL Cerny, M Rhoads, L Anderson, WR Burris, JC Matthews.  Form of 
selenium in free-choice mineral mixes affects ovarian production of progesterone 
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but not estradiol in cycling beef cows. American Society of Animal Science, 2015 
annual meeting.  
 
KL Cerny, PJ Bridges. Intraperitoneal administration of lipopolysaccharide induces 
differential expression of mRNA encoding inflammatory mediators in the oviducts of 
mice. American Society of Animal Science, 2015 annual meeting. 
 
KL Cerny, M Van Fleet, A Slepenkin, EM Peterson, PJ Bridges. Differential expression 
of mRNA encoding cytokines and chemokines in the reproductive tract after 
infection of mice with Chlamydia trachomatis. Biol. Reprod.  Special Issue, Proc. of 
the 46th annual meeting of the Soc. for the Study of Reproduction. Abstract #745. 
 
SR Garbacik, JC Matthews, KL Cerny, PJ Bridges. Gestational form of supplemental 
selenium (Se) affects gene expression in the newborn calf testis. I. Steroidogenesis. 
American Society of Animal Science, 2013 annual meeting.  Abstract W370. 
 
S Hughes, KL Cerny, JR Campos, MHT Troedsson, EL Squires. 2012. The use of 
equine follicle stimulating hormone to increase chorionic gonadotropin in the 
pregnant mare. Proc. of the 17th International Congress on Animal Reproduction. P. 
613. 
Awards 
 February 2015: Second place, Graduate student oral presentation 
competition, American Society of Animal Science Southern Section meeting.  
 July 2013: University of Kentucky Graduate School student travel funding 
 June 2002: American Society of Animal Science Undergraduate scholarship  
 August 2002: Intercollegiate Equestrian Foundation Undergraduate 
scholarship 
 
 
